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ABSTRACT 
Randomised controlled trials (RCTs) play a fundamental role in the development and 
marketing activities of pharmaceutical companies. They are the primary means of 
evaluating the tolerability, safety and efficacy of a drug, and for providing information 
relevant for pricing and reimbursement decisions and clinical decision 
- 
making. RCTs 
require a substantial investment by pharmaceutical companies and the financial 
consequences of poorly or sub 
- 
optimally designed trials are potentially substantial. 
Revenue does not materialise unless a licence to market a product is granted and sales 
may be restricted if a trial fails to provide evidence of sufficient strength or relevance for 
those involved in product adoption decisions. From a pharmaceutical company's 
perspective, the value of RCTs can therefore be judged on the contribution they make to 
the performance of a drug in the market and hence on their contribution to the 
performance of the firm. Consequently, the design choices made in the planning of RCTs 
are effectively investment appraisal decisions. However, the application of investment 
appraisal techniques to RCT design has not previously been proposed. 
The purpose of this thesis is to consider how private sector investment appraisal methods 
might be applied to RCT design decision-making and to explore aspects of the 
practicalities of application. A general investment appraisal model is presented and its 
application to determine profit maximising RCT designs is illustrated. Considering the 
cost side of the investment appraisal equation, it is shown how decision-makers' 
requirements for cost-effectiveness evidence derived from trials could have a significant 
i 
impact on the major determinants of cost (sample size and study duration) depending on 
their specific preferences for evidence defined over key components of RCT design. 
Considering the revenue side of the investment appraisal equation, it is shown how 
discrete choice analysis could be used to incorporate decision-makers' preferences for 
RCT designs into the planning of studies. Specifically, it is shown how the predicted 
pr-obabilities derived from the application of this technique could be used within an 
investment appraisal framework. Directions for future research into the application of 
investment appraisal to RCT design are proposed. 
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CHAPTER 1: INTRODUCTION 
MBACKGROUND 
1.1.1 The importance of randomised controlled trials in drug development and 
marketing 
Randomised controlled trials (RCTs) play a fundamental role in the development and 
marketing activities of pharmaceutical companies. 1-5 The evidence generated by 
RCTs figures prominently in the product adoption decisions taken by regulatory 
agencies, pricing and reimbursement authorities, health technology appraisal bodies 
and individual physicians. Regulatory agencies, such as the US Food and Drug 
Administration (FDA) 6 and the European Medicines Evaluation Agency (EMEA)7 are 
responsible for granting licences to companies enabling them to market their products. 
The regulatory process requires that companies perform RCTs to demonstrate a 
product's tolerability, safety and clinical efficacy. If the latter are demonstrated to the 
satisfaction of the regulatory agencies, the manufacturer is granted a licence to market 
the product. 
Clearly, the granting of a licence to market a product is a necessary condition for a 
company to obtain a return on its investment, but it is by no means sufficient. In most 
ma or markets, a manufacturer must ne otiate with national agencies (or large groups i9 
of purchasers) responsible for setting the price, reimbursement and formulary status of 
a drug. 8; 9 A company submits information dossiers according to local guidelines. 9 
Typically, they all include some requirement for evidence pertaining to unmet 
therapeutic need, clinical effectiveness, budget impact and in some jurisdictions, cost- 
effectiveness analyses. 10-13 Of particular relevance here is that the RCT evidence 
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used in the marketing approval submission is often re-appraised in the course of 
product adoption negotiations. However, the RCT evidence produced for regulatory 
purposes may not be sufficient to answer the questions of primary interest to pricing 
and reimbursement authorities or health technology assessment bodies such as the 
National Institute for Health and Clinical Excellence (NICE). 14 Most of the major 
challenges to achieving a positive pricing and reimbursement outcome are directed at 
the strength and relevance of the clinical evidence base, as illustrated by 
recommendations made by NICE' 5 and commentaries in medical journals. 16; 17 
RCTs require a substantial investment by pharmaceutical companies. It has been 
estimated that the cost of discovering and developing a new drug introduction exceeds 
US $300 millions at 1995 prices. 18-20 Most of the cost relates to the conduct of RCTs, 
in particular the major regulatory studies (known as Phase III trials). Therefore the 
financial consequences of conducting RCTs that do not meet the evidence needs of 
regulatory bodies, pricing and reimbursement authorities and other health care 
decision-makers are potentially significant since a return on the development 
investment may not materialise or be severely restricted until adequate evidence is 
generated. 
1.1.2 Economic analysis and randomised controlled trials 
The literature relating to economic analysis and RCTs consists of two broad 
components. The first component is concerned with using trials as vehicles for 
economic evaluation of health care technologies. Economic evaluation is the term 
given to a set of techniques for appraising the economic value of health programmes 
or treatments from a health care funding body or societal perspective. Many 
2 
references include good overviews of the techniqueS21 ý22 and their application 
. 
23 24-30 
It has been pointed out3l that an economic evaluation can be wholly deterministic 
(utilizing decision-analytic techniques 32-35), wholly stochastic (based on data sampled 
from studies such as trials 36-38) or a combination of the two 
. 
39 Since RCTs are the 
main scientific method for collecting patient level data for evaluating the clinical 
benefits of an intervention. 40, they have attracted research attention from economists 
exploring how they can be used for collecting data necessary for performing an 
economic evaluation. There is an extensive literature concerning the use of RCTs as 
vehicles for collecting and analyzing data for the purpose of economic evaluation (see 
for examp le23; 
3 1; 36-38; 41-68,68-129 ). 
The second (and much smaller) component of the literature relating to economic 
analysis and RCTs focuses on the economic analysis of research project selection and 
trial design. A number of researchers have examined how economic considerations 
might be used to optimise the design of RCTs. 130-142; 142-151 However, there are two 
prominent contributions in this area, each of which will be summarised briefly below. 
The first contribution is the work by Detsky, conducted in the 1980s, which considers 
how economic analysis might be used to assist government agencies with their 
decisions about awarding research grants for clinical trials. 152-154 His work was 
motivated by a concern that funds allocated to trials might not be used optimally due 
to the often arbitrary way in which key study design parameters are chosen. In 
particular, he noted that trial sample sizes are often inadequate to determine whether a 
new treatment is effective or not and that they are often calculated based on arbitrarily 
chosen clinical differences thought to be worth detecting. Using a number of 
examples based on life-saving treatments, Detsky illustrates how the cost- 
3 
effectiveness of trials can be evaluated in the planning stages and how the results can 
be used to decide whether a particular trial should be funded or not and if so how 
large the trial should be. To this end, cost-effectiveness ratios are calculated for trials 
of different sample sizes. In his model, costs are a straightforward function of sample 
size which in turn is driven by the choice of the clinically important difference a study 
aims to detect. Clearly, there is a positive relationship between the cost of conducting 
a trial and its sample size. In the model, the expected effectiveness of a trial is 
measured in terms of lives saved. It is calculated as the product of the size of the 
population who would benefit from the new treatment if adopted, the power of the 
study, the prior distribution of the true reduction in the relative risk of death and a 
proportionate implementation factor. The latter can be thought of as a crude demand 
function. In Detsky's model, the proportionate implementation factor takes on values 
which are such that a new treatment is completely adopted where a trial shows a 
statistically significant effect and is not adopted if it fails to show statistical 
significance. 
The second and more recent contribution is from Claxton, whose work was 
developing in parallel with this thesis. 155-162 He proposes the use of value of 
information analysis in order to set research priorities, determine whether further 
research is required to inform treatment adoption decisions and, if so, what the 
optimal design of that research should be. The approach is developed for a 
jurisdiction in which treatment adoption decisions are based on the results of cost- 
effectiveness analysis. Consequently, the proposed method for determining the 
optimal design of trials is also based on cost-effectiveness analysis in order to ensure 
that the criteria used for decisions about future research are consistent with those used 
4 
for treatment selection. The approach proposed by Claxton involves a number of 
elements, which are summarised briefly in non-technical terms below. 
The analysis starts from the position that if an estimate of the cost-effectiveness of a 
new treatment is acceptable to the decision-maker then it should be adopted regardless 
of whether the result is statistically significant or not. It is argued that the traditional 
paradigm of hypothesis testing is irrelevant and that it should be replaced by a method 
that minimises the societal cost of a wrong decision. Any estimate of cost- 
effectiveness will be uncertain and consequently a decision based upon it could be 
incorrect. An incorrect decision will incur costs (known as opportunity loss) and the 
approach centres on quantifying the societal cost of the uncertainty surrounding a 
decision. The costs of uncertainty can be interpreted as the expected value of perfect 
information (EVPI) because perfect information would eliminate the possibility of a 
wrong decision. So if the EVPI exceeds the cost of any future research aimed at 
acquiring additional information then further research is worthwhile i. e. it is 
potentially cost-effective. Once it is deemed that further research is potentially 
beneficial, the optimal scale (sample size) of the research needs to be determined. 
Within Claxton's approach, the optimal sample size for a trial is that which gives rise 
to an expected net benefit of sampling information (ENBS) that is positive and at its 
maximum. ENBS is the difference between the expected value of sampling 
information (EVSI) and the cost of conducting a trial at any given sample size. EVSI 
is measured as the reduction in opportunity loss which results from a trial of given 
size. 
The above works are relevant to this thesis in that they recognise the importance of 
optimising clinical trial designs and propose possible methods for doing so. 
5 
The methods proposed adopt a societal perspective based around the use of cost- 
effectiveness analysis. However, the approaches are not generally applicable because 
most major pharmaceutical markets do not currently base their technology adoption 
decisions on cost-effectiveness analysis. The works of both Detsky and Claxton 
utilise very simplistic demand functions whereby a new product is effectively 
assumed to be adopted immediately and completely if a given level of cost- 
effectiveness is achieved. The relationship between product diff-usion and cost- 
effectiveness is poorly understood and, more generally, there is an absence of research 
that explicitly explores the relationship between the adoption of a technology and the 
design of clinical trials. Whilst Claxton rejects traditional hypothesis testing as 
irrelevant, the fact is that the demonstration of statistically significant benefits of new 
products remains a key determinant of drug regulatory decisions and cannot therefore 
be ignored. This fact is recognised by Detsky whose work not only inspired the topic 
of this thesis but also provided a basis for computing the expected outcomes of 
clinical trials that will be seen in later chapters. 
In summary therefore, a notable feature of the current literature that focuses on the 
economic analysis of trial design is that none of the approaches to optimizing trial 
design adopt a private sector (pharmaceutical company) perspective. Equally notable 
is the fact that the pharmaceutical research and development project appraisal 
literature ignores the potential importance of RCT design and results on the uptake of 
a product post-approval. 163-165 
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1.2 FOCUS AND STRUCTURE OF THE THESIS 
Given the importance of RCT evidence for influencing the nature and extent of 
product adoption and the substantial cost of performing clinical trials, it seems logical 
that a privately owned pharmaceutical company should seek to optimise RCT designs 
based on economic (in particular profit) criteria. Yet a review of the literature 
pertaining to economic analysis and clinical trials reveals that a private sector 
investment appraisal approach to RCT design has not hitherto been explored. 
Therefore this thesis attempts to fill a significant gap in the literature by setting out 
how methods of investment appraisal might be applied to RCT design decision- 
making and by exploring aspects surrounding the practicalities of application. To this 
end the remainder of the thesis is made-up of four chapters (summarised below) of 
which Chapters 2-4 are presented as 'standalone' (but loosely interrelated) manuscript 
format pieces. 
Chapter 2 sets out a general investment appraisal model which shows how 
pharmaceutical companies could take profit considerations into account when making 
decisions about the design of randomised controlled trials. A general model is 
presented based on the net present value (NPV) method of investment appraisal. The 
application of investment appraisal requires an evaluation of both the costs and 
expected revenues associated with a given RCT design. Therefore a description of the 
major determinants of costs and revenues and how they might be estimated is 
presented. The importance of being able to estimate the demand for a product 
contingent upon RCT design and expected trial outcomes is emphasized. The 
approach is illustrated with a hypothetical example showing how optimal (net present 
value maximising) designs can be determined based on choices about key 
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RCT design parameters. Directions for further research are suggested and these set 
the scene for the themes that are explored in the following two chapters. 
Chapter 3 focuses on issues associated with the cost side of the investment appraisal 
equation. It takes as the starting point the special situation where it is assumed that 
decision-makers a) make product adoption decisions based on cost-effectiveness 
analyses, and b) require that those analyses be based on sampled data derived from 
RCTs (so called wholly stochastic cost-effectiveness analysis). The primary purpose 
of this chapter is to illustrate how the specific nature of decision-makers' preferences 
relating to wholly stochastic cost-effectiveness evidence could have a significant 
impact on the major determinants of RCT costs, namely sample size and trial 
duration. Data collected in a clinical evaluation are used to calculate sample sizes to 
test cost-effectiveness hypotheses for hypothetical study designs. These are compared 
with the sample sizes required to test hypotheses based only on clinical endpoints. It 
is shown that circumstances can be such that a wholly stochastic cost-effectiveness 
analysis might not be a practical proposition even though its clinical counterpart is. 
The importance of prior specification of decision-makers' preferences for different 
components of RCT study design is cmphasised. 
Chapter 4 focuses primarily on issues associated with estimating the revenue side of 
the investment appraisal equation. It considers a general situation where decision- 
makers involved with product adoption decisions will have preferences for the types 
of RCT evidence they want to see. The extent to which these preferences are satisfied 
will influence the nature and extent of a treatment's use. The primary purpose of this 
chapter is to illustrate how the technique of discrete choice analysis (DCA) could be 
used by companies to consider decision- makers' preferences for RCT designs 
8 
when planning their studies. The approach is illustrated using the design of trials of 
a uvant isp sp nates in t management o patients wi primary operable breast 
cancer as a case study. A stated preference survey is conducted to elicit clinicians' 
preferences for evidence and to model the predicted probabilities of prescribing a 
product. It is shown how the predicted probabilities of product adoption can be used 
by a company within an investment appraisal framework to identify a profit 
maximizing RCT design. Issues for consideration in future research into the 
application of DCA in this context are discussed. 
Chapter 5 presents the main conclusions and contributions of the thesis. It includes a 
brief summary of directions for future research into the application of investment 
appraisal to RCT design. 
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CHAPTER 2: AN INVESTMENT APPRAISAL APPROACH TO 
CLINICAL TRIAL DESIGN 
SUMMARY 
In this chapter, a general investment appraisal model is presented which shows how 
pharmaceutical companies could take profit considerations into account when making 
decisions about the design of randomised controlled trials. A general model is 
presented based on the net present value method of investment appraisal. The 
approach is illustrated with a hypothetical example which shows how optimal (net 
present value maximising) designs can be determined based on choices about sample 
size and endpoint measurement. The method could be extended to accommodate 
considerations about other trial design features, and could be used to determine a 
portfolio of studies which maximises the expected return on a given development or 
trial budget. Furthen-nore, the approach could be used by pharmaceutical companies 
to evaluate the incremental costs and benefits of incorporating non-clinical objectives 
into trials, such as quality of life research and economic evaluation studies. A number 
of practical difficulties would need to be overcome to utilise the approach. Directions 
for further research are therefore highlighted centred on the key components of the 
model: a trial cost function, a product demand function, innovation diffusion 
processes and Bayesian approaches to trial design. 
10 
2.1 INTRODUCTION 
Randomised controlled trials (RCTs) play a fundamental role in the development and 
marketing activities of pharmaceutical companies. They are the primary instruments 
for evaluating the tolerability of a drug, for demonstrating its efficacy, and for 
providing information relevant for clinical decision 
- 
making. 1-5 RCTs require a 
substantial investment by pharmaceutical companies in terms of the human and 
financial resources allocated to their design, execution, analysis and reporting. It has 
been estimated that the cost of discovering and developing a new drug introduction 
exceeds US $300 millions at 1995 prices. 18; 19 A significant proportion of that cost 
relates to Phase III trials which are conducted to produce evidence about a product's 
safety and efficacy to a level which at least satisfies the regulatory authorities 
responsible for granting product licences. Once approval to market has been granted, 
companies often conduct Phase IV trials designed to address the information needs of 
decision-makers involved in product utilisation decisions. The fmancial 
consequences of poorly or sub 
- 
optimally designed Phase III or Phase IV trials are 
potentially substantial: revenue is lost if a new drug fails to gain access to its intended 
market or if a trial fails to provide evidence of sufficient strength or relevance to 
secure or enhance a product's use. 
From a pharmaceutical company's perspective, the value of RCTs can therefore be 
judged on the contribution they make to the performance of a drug in the market and 
hence on their contribution to the performance of the firm. Consequently, the design 
choices made in the planning of RCTs, such as which comparators to use, which 
endpoints to evaluate and which sample size to adopt, are effectively investment 
appraisal decisions. The nature and scale of a trial will drive the size of the 
11 
investment. The return on the investment will depend upon the sensitivity of decision 
- 
makers to the different types, strengths, relevance and quality of the evidence 
provided by it. 
Although some applications of decision 
- 
analytic techniques to clinical trial design 
decisions have previously been reported, none has adopted a private sector investment 
appraisal perspective. 143; 149; 152; 154; 155 Therefore the purpose of this chapter is to 
illustrate the potential role for investment appraisal in assisting with RCT design 
decisions taken by pharmaceutical companies. The remainder of the chapter is 
divided into three sections. Firstly, the components of an investment appraisal model 
are set out in general form based on the net present value method of investment 
decision-making. Secondly, the application of the approach is illustrated with 
simulations using a hypothetical Phase IV trial design scenario facing a 
pharmaceutical company. Finally, the discussion section addresses issues 
surrounding further research that would be required to develop the approach for 
practical application. 
2.2 INVESTMENT APPRAISAL APPROACH TO TRIAL DESIGN: A 
GENERAL MODEL 
Investment appraisal is the term given to a general framework used by firms to assist 
with project investment decisions. Whilst a number of possible approaches are 
discussed in the literature, the superiority of investment decisions based on the net 
present value (NPV) discounting method is well documented. 166-168 The investment 
appraisal approach to trial design is therefore illustrated using the NPV method. With 
this method, choices about trial design would involve consideration of the differences 
12 
between the discounted revenue a trial is expected to yield and the expected 
discounted cost of conducting it i. e. trial design decisions would incorporate expected 
NPV (profit) considerations. The key components of this approach are set out below 
in general forn-L 
2.2.1 Cost function 
A pharmaceutical company will be faced with a clinical trial cost function of the 
following general form: 
C (n) = C, (Q, (n)) + C, (n) i (1) 
where C, (n) is the cost in period t associated with conducting a trial of a particular 
design and sample size, n. Any additional manufacturing and marketing costs 
incurred as a direct consequence of conducting a trial are denoted by C, (Q, (n)), 
where Q, (n) is the number of units of the product sold in time t. CT (n) is the cost in 
period t of designing and conducting a trial, and will partly depend upon the chosen 
sample size. Note that the term design refers to a trial defined over all relevant 
characteristics, such as whether it is of a parallel groups or cross 
- 
over form, study 
population, comparators, endpoints and duration of subject follow 
- 
up. 
The total cost of conducting a trial, TC(n), is given by: 
p 
H 
TC (n) C, (n) (C, (Q, (n)) + CT(n)) 
t=O t=O 
(2) 
where the costs of the investment are evaluated over the period adopted for the 
appraisal beginning at time t=0 and ending at time t=H. Costs will be 
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incurred in different time periods. For example, trial subjects may be enrolled in 
different years and the costs associated with data analysis and reporting will take 
place once data collection and processing are complete. With the NPV method of 
investment appraisal, the time distribution of costs and the risk associated with the 
project are taken into account by discounting costs to their present value: 
PTC(,, ) Cp (Q, (n)) + CT(n) 
t=O + 
(3) 
where PTC(n) is the present value of the total cost of conducting the trial and r is 
the project's risk adjusted opportunity cost of capital (see section 2.4 below). 
2.2.2 Demand function 
A demand function for a good or service specifies the relationship between the 
quantity demanded and the factors that influence it. Similarly, a prescribing 
clinicians' demand function for a drug states the relationship between the quantity of 
treatments demanded and its determinants. Demand functions therefore figure 
prominently in the estimation of revenue resulting from the conduct of a trial since 
they describe, inter 
- 
alia, the likely responsiveness of clinicians to the evidence about 
a drug's attributes provided by it. A prescribers' demand function for a drug under 
investigation will take the following general form: 
Qto = Qt* (AX, AP) (4) 
where Q is the desired demand for a treatment under investigation, say drug A. 
is expressed in terms of the number of units of A given demonstrated statistically 
significant incremental changes in the vector of product characteristics, AX, 
14 
compared with alternative treatments, say B. Note that the vector X represents 
potential trial endpoints which might include non 
- 
clinical parameters, such as non 
- 
drug treatment costs and quality of life measures. Since drug price considerations are 
becoming an increasingly important consideration in prescribing decisions, 
differential drug treatment costs are highlighted in the demand function and are 
denoted by AP. 
It is unrealistic to assume that the desired level of demand, Q, ., will be realised 
immediately the results of a trial become known. For example, factors such as the 
perceived quality of the evidence, delays in the dissemination of the information and 
the learning process associated with the adoption of a new treatment mean that it will 
take time for prescribers to switch from existing practices to drug A, and the desired 
level of use may never be realised. Further, the prescribing practices of clinicians 
might be influenced by other factors, such as the policies proposed by formulary 
committees and the promotional activities of pharmaceutical companies. Thus, the 
actual demand for drug A in any specific time period will be determined through a 
diffusion process in which the growth of actual demand, Q1, towards Q, * will be 
determined by experience gained through past consumption, Qj 
. 
and the rate of 
adoPtion, k: 
Q, (Q, * (AX, AP), Q, 
-,, 
k) (5) 
Since the results of a trial are uncertain, a decision analytic approach is required to 
estimate the expected demand for the product resulting from the conduct of a trial. 
This requires the firm to estimate the expected outcomes with respect to potential trial 
endpoints, AX, which need to be established by empirical demand research 
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to be important. Making use of the approach illustrated by Detsky, 152; 154 if only 
discrete values of AX are possible, the expected effect sizes for the product attributes, 
E,, (A. X), likely to be demonstrated by a trial of sample size n, is given by the 
following formula: 
OD 
E. (AX)= lPr(D0=AXIAX). Pr(AV). AK 
AX=--co 
(6) 
where Pr(D. 0 = AXIAX) is the conditional probability that a difference of AX will be 
established in a trial with significance level ý if that difference is in fact there, and 
where Pr(AX) is the prior probability of a true difference of AX. The expression 
Pr(D,, O 
= 
AXJAY) is otherwise known as the power of a trial. 169; 170 In the case where 
AX are continuous variables, the expected trial outcome is given by: 
Co 
E. (AX) 
=f Pr(D0 = AXIAV). Pr(AX). M dAX 
Ax. 
--00 
(7) 
where the definitions given for equation (6) apply. For convenience, the discrete case 
is used in the equations and hypothetical analyses which follow. 
By substituting the expression for E. (AX) from equation (6) for AX in the dynamic 
demand function of equation (5) we derive the following general expression for 
expected demand in time period t, Q, (n), resulting from a trial of given design, 
sample size and significance level: 
(n) Q, (Q, ( j Pr(D, 0 
= AXläV) Pr(AXýAX, k) (8) 2: 
- 
QI-l 9 AX=--m AP), 
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2.2.3 Revenue function 
The expected revenue accruing to a company from the use of drug A in each time 
period, R, (n), is determined by multiplying the expected number of units of the 
product demanded in that time period, Q, (n), by the price per unit. Let P, denote the 
exogenously determined selling price for drug A. By calculating the product 
P,. Q, (n), the following expression for the expected revenue accruing to the firm in 
time period t is derived: 
R, (n)=P,. Q, (n)=P,. Q, 
(Q, 
--(Y, Pr(D. O=A. XIAX). Pr(AX). AX, A Q,, k) P) (9) 
The total revenue accruing to the firm as a result of conducting the trial, TR(n), is 
therefore given by: 
HH 
TR(n) = 1: P,. Q, (n) = 1: P,. Q, 1: Pr(D. 0 = AXIAX). Pr(AX). AX 
1=0 t=O 
(Q 
AX= 
, 
ýo 
AP), Q, 
-., 
k) Q 0) 
Since the expected revenues occur in different time periods and are subject to 
uncertainty they must, like costs, be discounted to their present values using the 
project's risk adjusted opportunity cost of capital (see section 2.4 below): 
P'. Q, 
(Q,. 
Pr(DO, 
=, 6XIAX). Pr(AX). AX, AP), Hn 
PTR(n) AX=-. oo 
1=0 + r)' 
where PTR(n) is the present value of the total revenue resulting from the conduct of a 
trial. 
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2.2.4 Investment appraisal decision rules 
The final component of the investment appraisal approach is the calculation of the 
expected profit accruing to the firm as a consequence of conducting a trial of given 
design and sample size. With the NPV method, this is simply the difference between 
the discounted value of a trial's expected total revenue, PTR(n), and the discounted 
value of expected total cost, PTC(n): 
NPV(n) 
= 
PTR(n) 
- 
PTC(n) (12) 
where NPV(n) denotes the expected net present value resulting from a trial of given 
design, sample size and significance level. Substituting for PTR(n) and PTC(n) 
from equations (11) and (3) respectively, and substituting the expression for Q, (n) 
given in equation (8) into equation (3), we derive the following general expression for 
NPV(n): 
2: Pr(D AXIAX). Pr(A. X) 1, p AXI Ht- Q(Qt Ax=ý 
AP) I Ql- 
NPV(n) = I: 
- 
1=0 + r)' 
H 
CIP 
(Qt (Q, 
'( Z Pr(D,, O 
= AXIAX). Pr(AX). AX, AP) I Qt-j I, k)) + CT(n) Ax=-ýo 
-I- - 
1=0 + r)t 
(13) 
it should be noted that the superiority of the NPV method over alternative methods of 
making investment decisions stems primarily from the choice of H and from the use 
of discounting. 166-168 With the NPV method, H is the useful life of the 
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project (in this case the useful life of the information provided by a trial) rather than 
some arbitrarily chosen time horizon. Discounting is undertaken to allow for both the 
timing of costs and revenues and the risk associated with the project. A project's risk 
a ust iscount rate can e determined using the capital asset pricing model 
(CAPM), which states that: 167 
r= rf + vl(r. 
- 
rf ) (14) 
where r is the risk-adjusted discount rate, rf is the rate of return on risk free 
investments (e. g. Treasury Bills), r. is the rate of return on investments of similar 
risk to the project being appraised (e. g. other pharmaceutical company stock), and 
is a measure of the risk of the project relative to other similar investments. Examples 
of the application of this approach can be found in an article in which costs of capital 
are estimated for a number of pharmaceutical companies and for projects at different 
stages of development. 171 
NPV criteria can be used to assist with a number of trial planning decisions based on 
the following decision rules: 
a) A trial of given design is worth conducting if it yields a positive expected net 
present value: NPV(n) = PTR(n) 
- 
PTC(n) > 0; 
b) The optimal choice of trial design, in terms of factors such as sample size and 
primary endpoints, is that which maximises the (positive) expected net present 
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value: Max. NPV(n) = PTR(n) - PTC(n) > 0; 
c) When allocating funds to different studies competing for a limited trial budget, the 
funds should be allocated across potential trial designs so as to maximise the 
expected net present value of the overall investment. 
It should be noted that the trial design problem facing the fwm might be one of 
constrained optimisation in which the unconstrained profit maxhnising solutions 
become unattainable. For example, decision 
- 
makers within the firm may impose 
budget, sample size, study duration or other constraints on themselves. Also, the 
company might face externally imposed constraints. For example, factors such as 
regulatory requirements, ethical considerations and insufficient patient numbers could 
restrict the choice of comparators or the duration of follow 
- 
up. Such constraints do 
not invalidate the approach, although they will, if binding, inhibit the achievement of 
the unconstrained NPV maximising solution. 
The use of the NPV method of investment appraisal to determine whether an RCT is 
worth conducting and to determine the optimal strategy based on choices about 
sample size and endpoint measurement is illustrated below with a simple hypothetical 
example. 
2.3 INVESTMENT APPRAISAL APPROACH To TRIAL DESIGN: A 
HYPOTHETICAL EXAMPLE 
The investment appraisal approach is illustrated with respect to the design of a 
hypothetical Phase IV trial. It is assumed that a pharmaceutical company has 
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developed a new product, drug A, for an acute condition for which there is currently 
only one other treatment available, drug B. Drug A has been approved for marketing 
on the basis of placebo controlled trials and the national pricing authority has granted 
the company a selling price PA, = $200. Whilst prescribers of the product would be 
fully reimbursed if they were to use it, local hospital formulary committees have 
excluded drug A from their formularies on the grounds that no comparative trials have 
been conducted against druja B. It is therefore assumed that all patients needing 
treatment are currently prescribed drug B, which has been shown to produce a success 
rate of 25% on endpoint X, and 75% on endpoint X2 after 6 months of follow 
- 
up. 
It is known that the incidence of the condition will remain stable, with approximately 
200,000 patients presenting for treatment each year. No other treatment alternatives 
are expected during the next 5 years. 
The clinical development department within the company has proposed a trial of 
parallel groups design to compare drug A with drug B. It has been designed to yield 
90% power of detecting, at the 5% significance level, an arbitrarily chosen absolute 
difference of 30% based on endpoint X,. Using the sample size formula for 
comparing two binomial proportions without correction for continuity and assuming 
equal allocation, 125 patients per treatment arm are required. 169 Withdrawals from 
the trial are not anticipated. The development department has proposed not to 
evaluate endpoint X2 on the grounds that it would significantly increase the costs of 
the study. In this example, X2 might be thought of as an outcome which requires for 
its measurement a complex and costly diagnostic procedure. However, the marketing 
department is uneasy with this proposal because market research has highlighted the 
importance of endpoint X2 as a factor influencing product use. It has therefore 
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been decided to investigate the problem in more detail in order to determine an 
optimal trial strategy. 
Within an investment appraisal framework, the determination of an optimal strategy 
would involve choosing between possible trial designs so as to maximise 
expected NPV(n). In order to illustrate how this is achieved, it is necessary to impose 
specific functional forms for C, (n), Q, - and Q,. It is therefore assumed that the 
company has determined the following cost function for the trial under consideration: 
+fT+VT C, (n) 
= Vl'. Q, (n) , . n, 
where C, (n) is a linear cost function with fixed and variable components. The 
variable marketing costs per unit of the product sold, vP, will include any incremental 
costs of manufacturing, distributing and promoting the product as a direct 
consequence of conducting the trial. The trial fixed cost variables, f, ', will include 
the costs of researching, designing and planning the experiment, plus the costs of data 
analysis and reporting. Costs which vary with sample size, vT, will include 
components such as expenditures on trial monitors, payments made to investigators 
for data collection and payments made to centres for the treatments given to patients 
during the trial. 
Clearly, there may be uncertainties surrounding the estimation of some of the cost 
variables. For example, if company practice is to pay for the treatments given to 
patients during the trial as they occur, rather than as a fixed per patient payment set by 
contract in advance, it will be necessary to estimate the expected value of the payment 
per subject enrolled. This would be achieved by estimating a weighted 
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average cost per patient enrolled based on probabilities of different treatments 
occurring and their associated costs. Systems are available to assist companies in the 
production of such estimates. 172 However, the methods of estimation of the cost 
function variables are beyond the scope of this chapter. It is sufficient for the purpose 
of illustrating the approach to assume that the cost variables are either known with 
certainty, or alternatively represent expected values. 
It is assumed that company market research has been conducted which has determined 
the following desired demand function: 
Ql* 
=a+, 8AX + rAP (16) 
where 6'denotes the row vector of demand function coefficients (PI3, A) for the 
potential endpoint variables (AX,, A. X2) in the vector AX. The sign and the size of 
estimated coefficient vectors, a, 8' and y, will determine the direction and 
magnitude of the change in Q, resulting from changes in the demand function 
variables. It is further assumed that the company has determined that the expected 
diffusion process is best approximated by the following equation, which is an 
adaptation of the stock adjustment principle: 173 
k. Q, - (AX, AP) + (I 
- 
k)Q, 
-, 
(17) 
where Q, is the actual demand for drug A in time period t, and k is the coefficient of 
market adoption which takes on a value between 0 and 1. The achievement of the 
desired level of demand in the market is therefore expected to be gradual. The time 
taken to reach Q, depends upon the size of k, which in practice will be detemiined 
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by complex relationships amongst the various factors which influence prescribing 
decisions. Some of these factors will be within the control of a company and others 
will not. Substituting for Q, from equation (16) into equation (17) yields: 
k. a +, 81AX + vAP) + (I 
- 
k)Q, $-l -1 
which is the assumed hypothetical dynamic demand function for drug A. 
Substituting the above functional forms for C, (n) and Q, into equation (13) gives the 
following specific formulation of the general model that is used to simulate the 
approach: 
fo I+ 
yA. P) + (I 
- 
k)Q, 
-, 
00' 
H 
PA, k. a+, 6'f 
12: 
Pr(D. 0 
=AXIAX)Pr(AX)AX 
AX--100*/o 
NPV(n )= Z 
t=O + r)' 
H vp 
(k. 
a+ ß'l 
lf 
Pr(Do, 
= AXIAK) Pr(AX)AXI + yAP) + (1 - k)Qt-, + f, ' + v,. n, 
AX-1W/0 
t=O (1 + r)' 
(19) 
The hypothetical parameter values and assumptions for the model are summarised in 
Table 2.1 and the results are given in Table 2.2. The results are also presented 
graphically in Figures 2.1 and 2.2. All sample size results are taken to the nearest 25 
subjects per treatment arm. 
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Table 2.1 
Parameter Values and Assumptions 
Parameter values Assumptions 
Costfunction: C, (n)=vlp. Ql(n)+ftT+vtT. n, 
v, 
p 
=$ 40.00 Incremental costs of manufacturing, distributing 
and promoting the product as a direct 
consequence of conducting the trial. Assumed to 
be 20% of the selling price for product A. 
Q, (n) =variable 
f, T 
=s1,000,000 
TT $ 1,500 or vt $ 1,875 
Expected demand for product A in period t. It 
varies with trial sample size and endpoints 
measured, and is calculated by the model. 
Fixed costs of planning the trial ($ 750,000 
incurred in year t= 0) and data analysis and 
reporting ($ 250,000 incurred in year t= 1). 
Cost per patient $ 1,500 if only endpoint X, is 
evaluated and $ 1,875 if only endpoint X2 or 
both endpoints are evaluated. This cost includes 
trial monitors, payments to investigators, and the 
costs of treatment given to patients during the 
trial. The year in which costs are incurred 
depends upon the timing of subject enrolment, 
n' 
. 
Demand function: Q, = k. (a + AAxi + fl2, &x2 + yAP) + (I 
- 
k)Ql-l 
Qt = variable Expected demand for product A in period t. The 
form of the demand function needs to be 
determined by empirical research. 
k=0.30 
a 
1000 and fl2 = 4995 
Aý XIA 
- 
XIB and AX2 ý X2A 
- 
X2B 
The coefficient of market adoption which is 
assumed to have been determined by empirical 
product diffusion research. 
The assumed value implies that drug A will not 
be used in the absence of comparative evidence 
of the product's benefits in relation to product B. 
The assumed values imply that X, is a less 
important determinant of demand than X2 
. 
Coefficient values were chosen to yield 100% 
market share for product A if complete success 
was demonstrated for both endpoints. 
The expected demonstrated ifferences, EJAX), 
are calculated variables which depend upon the 
trial sample sizes and prior expectations. XIB is 
assumed to have a baseline value of 25% and 
X2B is assumed to have a baseline value of 
75%. 
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Table 2.1 (continued) 
Parameter values 
Demandfunction (continued) 
-550.00 
Ap ý PAI 
- 
PBI 
Discounting 
0.15 
to 
-t4 
Prior distributions, power and sample size 
Pr(AXI) =0.14(11%); (0.09)12%; 0.10(13%); 0.08(14%); 
0.11(15%); 0.05(16%); 0.04(17%); 0.13(18%); 
0.12(19%); 0.14(20%). 
Pr("' )=0.14(1%); 0.1l(2%); 0. O5(3%); 0.1l(4%); ýa" 2 
0.1l(5%); 0.05(6%); 0.05(7%); 0.10(8%); 
0.14(9%); 0.14(10%)]. 
P4D! 
= 
AXIAX) 
n, = variable 
Assumptions 
The assumed value implies that treatment drug 
prices have a negative impact on the quantity of 
product A demanded. 
PAt 
= 
$200 is assumed to have been 
exogenously determined by a central pricing 
authority setting prices at parity with product B. 
PAt is assumed to be constant over the 
evaluation period. 
The projects risk adjusted discount rate assumed 
to bave been determined using the capital asset 
pricing model. 
The time horizon for the investment appraisal is 
assumed to be 5 years. 
The hypothetical prior distributions for AXI and 
AX2 were produced by using Lotus Excel to 
generate 100 random numbers with a uniform 
distribution of successful outcomes for XIA in 
the range 35% 
- 
45% and for AX2A in the range 
75%-85%. 
All sample size and power calculations were 
performed using the computer programme SAS 
assuming a two - tailed test with significance 
level 0= 5% and power = 90% as appropriate. 
The formula for comparing two binomial 
proportions without continuity correction and 
assuming equal allocation was used throughout. 
Sample size is varied for the simulations. The 
trial is assumed to take two years to design and 
complete, with subjects enrolled in equal 
proportions in years t=0 and t=I- 
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2.3.1 Is the proposed trial worth conducting? 
Whether or not the hypothetical trial proposed by the clinical development department 
is worth conducting with regard to profit criteria is considered graphically in Figure 
2.1. Figure 2.1 shows how the cost, revenue and profit functions behave with respect 
to changes in sample size per treatment arm, given the assumed parameter values of 
the model. As sample size increases, PTC(n) increases at a constant rate reflecting 
the linear form of the hypothetical cost function. PTR(n) also increases, but at a 
diminishing rate. This reflects the fact that the expected additional difference in AX, 
between products A and B (and hence, through the demand function, the expected 
incremental market share and expected incremental revenue) gets smaller and smaller 
as the trial sample size is increased. It can be seen that PTR(n) is less than PTC(n) 
for sample sizes below 50 and greater than 675 subjects per arm. Conversely, 
NPV(n) is positive for any trial evaluating only endpoint X, within that sample size 
range. This profitable range is determined by the two points at which the parabolic 
NPV(n) curve intersects the sample size axis. 
In the case of the proposed trial with a sample size of 125 per arm, the present value 
of expected total revenue exceeds the present value of the total cost of conducting the 
trial, so the trial is worth conducting (NPV(n) >0). it can be seen from Table 2.2 
that a profit of $892,524 is to be expected (see Appendix 2.1 for an example 
calculation). However, the chosen sample size is sub 
- 
optimal since NPV(n) 
continues to increase as sample size increases beyond 125 subjects per arm. The 
optimal sample size is that which yields the maximum NPV(n). This can be 
determined graphically by identifying the point at which the marginal change in 
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NPV(n) for a given change in sample size is declining and equals zero 
(i. e. MNPV(n)= 0). In this example, this occurs where the trial enrols 225 subjects 
per arm and yields an expected NPV(n) of $1,093,016. A trial with this sample size 
would have 90% power to detect an absolute difference of 12% with a two-sided 
significance test conducted at the 5% level. 
2.3.2 What is the optimal trial strategy? 
Suppose that the hypothetical firm can conduct only one trial, and that, if both X, 
and X2 are evaluated, the same sample size must be used. The problem now is to 
determine the optimal trial design in terms of endpoint measurement and sample size. 
The optimal trial strategy will depend on whether or not the firm faces constraints 
imposed by factors such as the available budget or the number of potential trial 
subjects. 
If there are no constraints, there are three options available: measure only X,, only 
X2 or both endpoints simultaneously. The determination of the optimal strategy is 
shown graphically in Figure 2.2 If only X, were to be evaluated, the optimal sample 
size is 225 subjects per arm, as indicated above. However, it would be preferable to 
evaluate only X2 since this yields a maximum expected NPV(n) of $1,248,345 at the 
optimal (NPV(n) maximising ) sample size of 400 subjects per arm. Note that a 
single endpoint trial evaluating only X, is superior to a trial which measures only Xý 
for sample sizes between 50 and 250 subjects per treatment arm. Conversely, a trial 
to evaluate only X2 is preferred for sample sizes between 250 and 1000 subjects per 
treatment arnL 
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Figure 2.2 shows clearly that no single endpoint trial would be preferable to a trial 
which simultaneously evaluates both endpoints since the latter always yields an 
NPV(n) greater than the former. Such trials would produce a positive expected 
NPV(n) for sample sizes in the range 25 to 1975 subjects per arm. However, the 
optimal sample size is 425 subjects per arm, which yields an expected profit of 
$4,140,813. The firm should therefore conduct a trial which evaluates both X, and 
X2 at a sample size of 425 subjects per arm. It would have 90% power to detect a 
difference of 9% on both endpoints X, and X2 with two-sided significance tests 
conducted at the 5% level. 
2.3.3 Constrained optimisation. 
In practice, the firm might face budget or other constraints that prevent the 
achievement of the optimal trial design solution identified above. For example, 
suppose that the hypothetical trial is constrained by the availability of patients for 
enrollment and that a maximum of 300 subjects can be recruited. The optimal 
solution can be derived graphically by identifying the trial which gives the 
highestNPV(n) curve for that sample size. In this case, a trial to evaluate both X, 
and X2would be the preferred strategy and would yield an NPV(n) of $3,953,880 as 
shown in Table 2.2. 
In addition, at a macro level, a company will usually be faced with a capital rationing 
problem in which a limited investment budget needs to be allocated across competing 
trials involving different products. In this case, projects should first be ranked based 
on their profitability indices (NPV(n)IPTC(n)) and then selected for funding in 
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descending order of the index until the available budget is exhausted. Complex 
capital rationing problems can be solved using integer programming models (when 
fractional trial projects are not feasible) or linear programming models (where trial 
projects are divisible). 167 
2.4. DISCUSSION AND CONCLUSION 
The model presented in this chapter shows how a pharmaceutical company could use 
an investment appraisal framework to assist with decisions taken in the design of 
randomised controlled trials. A hypothetical scenario facing a pharmaceutical 
company has been used to illustrate how profit criteria n-fight be applied to decide 
whether a particular RCT is worth conducting, to determine an optimal (NPV 
maximising) design, and to rank RCTs in terms of their expected NPVs so as to select 
a portfolio of studies which maximises the return on a given development or trial 
budget. VVhilst the simulations conducted illustrate decisions based on choices about 
sample size and endpoint measurements, the framework could be applied to choices 
concerning other trial design parameters, such as which comparators to include, the 
duration of patient follow-up and what power to use. A number of practical 
difficulties would need to be overcome in order to utilise the approach. These are 
highlighted below, together with some directions for future research. 
Firstly, the investment appraisal approach to trial design has been illustrated using the 
NPV method of investment appraisal due to its recognised superiority over rival 
methods which can lead to incorrect SolUtionS. 166-168 Irrespective of the method used, 
the approach requires individual RCTs to be viewed as appropriate units to be 
subjected to investment appraisal. Whilst the impact of a single trial, or small 
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collection of trials, on the use of a product might be open to question, it is 
nevertheless appropriate for a firm to evaluate their likely impact at the margin of 
available evidence. This poses a number of practical difficulties including the choice 
of time horizon, the determination of a trial's opportunity cost of capital, and how to 
assign capital, production, distribution, marketing and sales costs to individual trials. 
Clearly, these issues will depend upon a company's corporate goals, attitudes towards 
risk, accounting conventions and the specific market circumstances surrounding the 
development of a product. 
Secondly, whilst the investment appraisal approach has been illustrated based on 
choices relating to the design of a hypothetical Phase IV trial, its potential value is by 
no means limited to that application. Pharmaceutical companies make their new 
product investment decisions at key milestones culminating in a decision whether or 
not to commit significant resources to the full development of a product. If full 
development proceeds, it involves deciding upon a programme of Phase III 
registration trials. These trials must demonstrate safety and efficacy only to a level 
that satisfies the regulatory authorities responsible for granting companies licences to 
market their products. However, as the debate surrounding the introduction of new 
drugs for the treatment of Alzheimer's disease highlighted, Phase III trials may fail to 
provide evidence of sufficient strength or relevance to persuade prescribing clinicians 
of the benefits of a product's use. 174-178 Thus, if only the minimum information 
required by regulatory authorities is provided at the time a product is introduced, a 
slow initial rate of diffusion (and hence low initial sales) might ensue until decision 
- 
makers' information needs have adequately been met by additional Phase IV (post 
marketing approval) trials. 
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The investment appraisal approach could therefore be used to evaluate the cost 
- 
revenue trade-offs associated with alternative late phase development strategies and to 
identify an NPV maximising portfolio of Phase III and Phase IV trial designs. Such 
an approach offers a potential improvement to the ex ante measurement of 
commercial "success" as used in a number of methods for assessing the value of 
pharmaceutical company research and development projects. 163; 164 Clearly, an 
important area for future research is the extent to which Phase III trial designs are 
constrained by the requirements of regulatory authorities. 
Thirdly, a potentially useful application for a company would be to use the approach 
to evaluate the incremental costs and benefits of incorporating non-clinical objectives 
into trials, such as quality of life research and economic evaluation studies. Such 
activities usually require significant additional resources to design and conduct. 
Within an investment appraisal framework, that additional effort can only be justified 
if the extra cost is more than offset by the incremental gain in sales revenue. A 
related important line of future research would be to compare private investment 
appraisal approaches with those which adopt a societal perspective. 143; 149; 152; 
154; 155 Of 
primary interest would be to identify the conditions under which societal and industry 
objectives and perspectives produce similar recommendations. This will hinge on the 
relative importance of cost-effectiveness considerations in drug prescribing decision- 
making about which little is currently known. Within an investment appraisal 
framework, the latter would be determined through empirical demand analysis which 
is a central component of the investment appraisal approach. 
Fourthly, whilst a dynamic form of demand function as illustrated in this chapter is 
undoubtedly more realistic than those implied in the models which have 
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adopted a societal perspective, 143; 149; 152; 154 in practice significant empirical research 
would be required to define thoroughly the properties of a product's demand function 
and the associated diffusion process. This would need to be conducted within the 
context of specific projects, and would need to address questions such as: What is the 
role of clinicians versus other decision-makers in the product adoption process? What 
is the relative importance of different types of product differentiation data to different 
decision 
- 
makers? What is the nature of the relationship between differences in 
product characteristics and prescriber take 
- 
up? What factors influencing product 
diffusion are within the control of a company and which are not? Such research 
would probably highlight the heterogeneity of decision 
- 
making criteria and 
influences, different attitudes towards risk, the role of price and other treatment cost 
parameters in the demand function, and the lack of independence of some of the 
explanatory variables. 
Conjoint analysis offers a promising way forward for investigating the properties of 
demand functions for use within an investment appraisal framework. 179; 1 80 This 
technique is often used by pharmaceutical companies, although usually for the 
purposes of product pricing and positioning once Phase III trial results are known. 
Conjoint analysis could however be applied before RCT designs are finalised in order 
to assess the relative importance of study design attributes. The results of such 
research would need to be linked to product diffusion models to produce sales 
forecasts contingent upon the evidence expected to be provided by different trial 
designs. Whilst the literature on models concerning the diffusion of innovations is 
substantial, 181-183 their application to health care technologies has been limited to 
date. 184-188 This would be a valuable area for future research. 
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Fifthly, one of the fundamental components of the investment appraisal model as 
illustrated here is the use of elements of a Bayesian approach to the planning of 
RCTs. 189 Specifically, the investment appraisal approach necessitates the derivation 
and use of prior distributions for estimating the expected endpoint outcomes. The 
results of an investment appraisal analysis will be very sensitive to the choice and 
reliability of the prior distributions, hence the importance of carefully choosing the 
method used in their derivation. A good review article describes the different possible 
approaches, their strengths and limitations, and the sources of evidence for clinical 
priors. 189 In practice, one would probably adopt a number of approaches to derive a 
so 
- 
called "community of priors", '89 and test the implications for the results of an 
investment appraisal using sensitivity analysis. 
A promising area for further research is to explore how applied demand analysis 
might be used to further advance the Bayesian approaches to trial design. For 
example, conjoint analysis could be used not only for evaluating the absolute and 
relative importance of the attributes entering a product's demand function, but also for 
eliciting the prior distributions for each of the attributes. Furthermore, such an 
approach could provide a formal framework for defining "meaningfur' effect sizes 
based on decision 
- 
maker preferences for different types and strengths of evidence 
provided by a trial. Within an investment appraisal framework, a meaningful effect 
size might be defined as the minimum size of effect required to yield a positive NPV: 
the commercially significant effect size. The extent of pharmaceutical company use 
of Bayesian approaches is not known, although there is increasing recognition by 
regulatory authorities and the scientific community of the merits of the approach. 190 
Finally, and notwithstanding the simplifications and limitations of the 
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illustrative model presented here, a strength of the investment appraisal framework 
lies in the fact that it provides a rational, transparent and health care decision 
- 
maker 
focused basis for planning and designing RCTs. The framework views trials as an 
investment in information which will contribute to the nature and extent of product 
adoption through the strength and relevance of the information they produce. Within 
this context, the efficiency of a trial or programme of trials is viewed broadly in terms 
of market adoption and profit. This contrasts with alternative, narrowly focused goals 
such as the provision of the minimum amount of information necessary to secure 
marketing approval for a product within the shortest possible time frame. Clearly, the 
approach could only be utilised effectively if there was agreement between functions 
within a company to an explicit process for generating the necessary information, 
conducting the analyses required and acting upon the results. In some companies this 
might require a fundamental shift in culture away from a largely regulatory (product 
approval) driven organisation towards an integrated managerial economics approach 
to drug development decision 
- 
making. 
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APPENDIX 2.1 
Example Calculation: NPV for Trial of Endpoint X, and Sample Size of 125 per arm 
Present value of trial cost 
PTcn=125 = $750,000 + (125 x $1500) $250,000 + (125 x $1500) 
(1+0.15)0 (1 + 0.15)' 
= $1,317,934.78 
Expected trial outcome 
En=125 (AXI) = (. 4714 x. 14 x IM) + (3367 x. 09 x 120/o) + (. 6007 x. 10 x M) + (. 6618 x 
. 
08 x N%) + 
(. 7188 x. 11 x 15%)+(. 7706 x. 05 x 1611/o)+(. 8165 x. 04 x 17%)+(. 8562 x. 13 x 18%)+ 
(. 8896 x. 12 x M) + (. 9171 x. 14 x 200/o) 
= 
11.7851% 
Expected demand (% market share) 
0 QAt = 1000 x 11.785% = 11785 (5.893%) 
QA2 ý 0.30 x 11785 + (1- 0.30) x0= 3535 (1.769%) 
QA3 ý 0.30 x 11785 + (1- 0.30) x 3535 = 6010 (3.006%) 
QA4 ý 0.30x 11785 +(1-0.30)x 6010=7743 (3.873%) 
present value of expected total revenue 
PTR, 125 =($2OOx3535)/(1+0.15)2 
* ($200 x 6010) / (I + 0.15) 3 
* ($200 x 7743) / (I + 0.15 )4 
= 
$2,210,335* 
Expected net present value 
NPvn=125 ý PTRn=125 
- 
PTCn=125 
= $2,210,335 
- 
$1,317,934.78 
= $892,400* 
* There is a small discrepancy with the result reported in Table 2.2 due to rounding. 
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CHAPTER 3: USE OF RANDOMISED CONTROLLED TRIALS 
FOR PRODUCING COST EFFECTIVENESS EVIDENCE: 
POTENTIAL IMPACT OF DESIGN CHOICES ON SAMPLE SIZE 
AND STUDY DURATION 
SUMMARY 
A number of approaches to conducting economic evaluations could be adopted. 
However, some decision-makers have a preference for wholly stochastic cost- 
effectiveness analyses, particularly if the sampled data are derived from randomised 
controlled trials (RCTs). Formal requirements for cost-effectiveness evidence have 
heightened concerns in the pharmaceutical industry that development costs and times 
might be increased if formal requirements increase the number, duration or costs of 
RCTs- Whether this proves to be the case or not will depend upon the timing, nature 
and extent of the cost-effectiveness evidence required. The purpose of this chapter is 
to illustrate how different requirements for wholly stochastic cost-effectiveness 
evidence could have a significant impact on two of the major determinants of new 
drug development costs and times, namely RCT sample size and study duration. 
Using data collected prospectively in a clinical evaluation, sample sizes were 
calculated for a number of hypothetical cost-effectiveness study design scenarios and 
the results compared with a baseline clinical trial design. The sample sizes required 
for the cost-effectiveness study scenarios were mostly larger than those for the clinical 
baseline. Circumstances can be such that a wholly stochastic cost-effectiveness 
analysis might not be a practical proposition even though its clinical counterpart is. In 
such situations, alternative research methodologies would be required. For 
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wholly stochastic cost-effectiveness analyses, the importance of prior specification of 
the different components of study design is emphasised. However, it is doubtful 
whether all the infonnation necessary for doing this will typically be available when 
product registration trials are being designed. 
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3.1 INTRODUCTION 
During the last decade or so, economic evaluation has become an increasingly 
important part of the process of developing and marketing pharmaceutical products. 
This reflects the emergence, in a number of jurisdictions, of formal requirements for 
evidence about the cost-effectiveness of a new medicine. 10 The most recent policy 
move in this area is in the UK, where the National Institute for Clinical Excellence 
(NICE) has, inter-alia, been established to appraise the clinical- and cost- 
effectiveness of selected health interventions. 191 As 013rien et al (1994) have pointed 
out, cost-effectiveness analyses can be wholly deterministic, wholly stochastic or a 
combination of the two. 31 Whilst economists accept each of these as valid approaches 
to performing economic evaluations, 39 some decision-makers may regard a wholly 
stochastic analysis as the preferred approach particularly if the sampled data are 
derived prospectively from appropriately designed randomised controlled trials 
(RCTs). For example, NICE previously indicated a preference for an RCT approach 
to producing cost-effectiveness evidence, and pointed out that pharmaceutical 
companies may therefore need to modify registration trials for this purpose. 191 More 
recent guidance from NICE still states a preference for RCTs as the means of 
generating effectiveness evidence for economic evaluation. 14 However, the current 
guidance no longer states a preference as to the source of resource use and cost data, 
probably due to the challenges faced in performing RCTs solely for cost-effectiveness 
analysis. Recent review papers and guidance to researchers highlight both the 
challenges involved as well as continued interest in using RCTs as vehicles for 
economic evaluation. 
192-194 
Formal requirements fo r cost- effectiveness evidence at the time a new 
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product is introduced have heightened concerns in the pharmaceutical industry that 
development costs and times might be increased if these requirements increase the 
number, duration or cost of RCTs. However, whether this proves to be the case or not 
will depend upon the precise nature and extent of the cost-effectiveness evidence 
required from RCTs. Specifically, it will depend upon decision-makers' preferences 
for cost-effectiveness evidence defined in terms of the choices which need to be made 
about key RCT design attributes: comparators, population, setting, endpoints, effect 
sizes worth detecting, duration of observation and acceptable probabilities of Type I 
(a) and Type 11 (, 6) errors. Clearly, choices relating to these attributes have to be 
made at the planning stages of an RCT. Indeed, prior specification of the objectives, 
design characteristics and statistical properties are essential characteristics of a well 
1-5-170 
conducted experiment. ,, The purpose of this chapter is to illustrate how different 
requirements for wholly stochastic cost-effectiveness evidence, defined in tenns of 
different choices about RCT design, could have a significant impact on two of the 
major determinants of new drug development costs and times, namely RCT sample 
size and study duration. 
In the next section, the choices which need to be made when designing an RCT are 
summarised together with an assessment of the potential impact which formal 
requirements for cost-effectiveness evidence generated in this way could have on 
study sample size and duration of observation. This is followed in section 3.3 by a 
description of the methods used to calculate sample sizes for a number of hypothetical 
cost-effectiveness analysis design scenarios. The illustrative scenarios were 
constructed using a dataset from a clinical evaluation which included the prospective 
collection of medical care resource utilisation data. The results of the sample size 
43 
calculations are presented in section 3.4. They illustrate how different formal 
requirements for cost 
- 
effectiveness evidence, expressed in the form of alternative 
research design choices, have the potential to increase the size and duration of RCTs 
significantly compared with those required for a baseline 'clinical' RCT. This in turn 
means that such requirements have the potential to increase the costs and timelines 
associated with new product development. In the final section, the implications of the 
results are discussed. 
3.2 RANDOMISED CONTROLLED TRIAL DESIGN ATTRIBUTES AND 
SAMPLE SIZE CALCULATION 
An RCT, whether conducted for the purposes of perfortning a clinical evaluation, an 
economic evaluation or both, cannot be designed adequately without explicit choices 
being made about a number of key study design attributes. The principal attributes 
requiring prior specification are summarised in the first column of Table 3.1. Choices 
made in relation to each of these attributes will have implications for both the size and 
duration of a trial. The second column of Table 3.1 shows some of the potential 
modifications to clinical trials which health care decision-makers might like to see for 
the purpose of conducting a cost-effectiveness study. The potential impact which 
such requirements might have on study sample size and duration of observation, and 
hence on development costs and timelines, are also shown in the third column of 
Table 3.1. 
The prunary concem in this chapter is to illustrate how different requirements for 
cost-effectiveness evidence might impact the size and duration of an RCT compared 
with the size and duration of a study conducted solely for the purpose of perfomiing a 
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clinical evaluation. Given this objective, approaches to sample size determination for 
both clinical and economic evaluations are considered briefly in turn below. 
3.2.1 Sample size calculation for clinical evaluation 
in the design of a clinical RCT, it is usual to select one 'primary' endpoint which is 
used as the principal criterion for comparing the relative merits of the alternative 
treatments under evaluation. The primary endpoint usually serves as the basis for all 
subsequent sample size calculations. In order to calculate the required sample size, 
researchers must choose both the magnitude of the endpoint difference which is 
deemed to be worth detecting and the acceptable probabilities of Type I (a) and Type 
11 (, B) errors. The magnitude of endpoint difference worth detecting requires a 
decision to be taken about what constitutes a 'clinically meaningful' treatment effect. 
Typically, the significance level a is set by convention at 5% i. e. a clinical trial is 
usually designed such that there is a small probability of concluding that there is a 
difference between the treatments being compared when in fact there is no difference. 
Sin-fflarly, a clinical trial is usually designed with 8 (the probability of wrongly 
concluding that there is a difference between treatments) set by convention at either 
10%or20%. The latter is equivalent to setting the statistical power (1-, 8) of the test 
of a trial at 90% or 80% respectively. The precise sample size formula which is 
appropriate for a given RCT will depend primarily on how the endpoints of interest 
are to be measured and the methods of statistical inference which are relevant for the 
data. There is an extensive literature relating to sample size calculations for clinical 
experiments. Formulae are available for a wide variety of clinical trial designs, types 
of data and methods of statistical analysis. 
170,195; 196 
45 
Table 3.1 
Trial Design Attributes: Potential Impact on Sample Size, Study Duration and 
Costs of Modifications for Economic Evaluation 
Trial Design Attributes* Example Modifications to Potential Implications for 
RCTs for Cost- Study Sample Size, 
effectiveness Analysis Duration and Cost 
1. Comparators 
Can be chosen from one or more 0 Replacing a placebo 0 Sample sizes will be larger 
broad types, including: comparator with standard hence costs will increase 
i) Placebo 
ii) Most commonly used 
practice 
9 Adding a standard practice 0 Adding a third treatment arm 
iii) Most effective arm as well as placebo to a trial would increase total 
iv) Least cost sample size, hence costs will 
V) Most cost-effective. increase 0 In both cases, enrolment Specification usually involves the times might be extended 
choice of specific product depending upon the 
formulations and modes of availability of trial subjects 
administration. hence development timelines 
Most studies compare two will be longer 
treatments although more are 
possible. 
2. Population 
Specification usually involves Relaxing trial entry criteria 0 Sample sizes will be larger 
choices about: to generate a more typical hence costs will increase 
i) Age group study population e. g. 0 The trial could be more 
ii) Sex allowing entry to patients complex to manage hence 
iii) Ethnic origin with co-morbidities costs will increase 
iv) Disease stage 0 Enrolment times might be 
V) Co-morbidities extended depending upon the 
vi) Previous treatments availability of trial subjects 
vii) Concomitant treatments hence development timelines 
viii) De novo or refractory will be longer 
patients. 
ix) Sub-group comparisons 
3. Setting 
Specification usually involves Single setting, centre or Enrolment times might be 
choices about: country data required extended depending upon the 
i) Single country, single availability of trial subjects 
centre 
hence timelines are longer 
ii) Single country, multi- 
centre 
iii) Multinational, single 
centre 
iv) Multinational, multi- 
centre 
V) Inpatient 
vi) Outpatient 
vii) Specialist centre 
viii) Routine practice centre 
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Table 3.1 (continued) 
4. Endpoints 
Specification usually involves 
choices about: 
i) Efficacy 
ii) Effectiveness 
iii) Side effects 
iv) Adverse events 
V) Quality of life 
vi) Direct costs (NB 
includes product prices) 
vii) Indirect costs 
viii) Resource use 
Adding endpoints for 
economic analysis 
Increases the amount of data 
to be collected and analysed 
which increases costs for a 
trial of a given sample size 
5. Effect sizes 
Specification usually involves 
choices about: 
Clinical significance 
Statistical significance 
Primary endpoints 
6. Duration of 
observation 
Specification usually involves 
choices about: 
Fixed period of 
observation 
Variable (e. g. in 
sequential designs). 
Choices are linked closely to the 
choice of endpoints and the 
statistical properties of the study. 
7. Acceptable error rates: 
a and 0 
Choices are linked closely to the 
choice of endpoints and the 
duration of follow-up. 
Often chosen according to 
convention and based on the 
primary endpoint(s) i. e. a= 5%, 
P= 10% 
Do not have to be the same for 
each endpoint (and usually 
arenI). 
Used in conjunction with the 
statistical properties of endpoints, 
the desired effect sizes and 
withdrawal rates to determine 
sample size. 
Testing cost-effectiveness 
hypotheses based on 
predefined levels of 
willingness to pay for a unit 
increase in effectiveness 
Longer periods of follow-up 
required to evaluate final 
economic outcomes 
Conventional probabilities of 
Type I and Type II error 
applied to additional (economic) parameters 
Increasing the number of 
endpoints for hypothesis 
testing increases sample sizes 
and hence costs 
Sample sizes will be larger to 
ensure sufficient patients 
complete the study hence 
costs will increase 
Increases the amount of data 
to be collected and analysed 
which increases costs for a 
trial of any sample size 
Period of evaluation is longer 
hence development timelines 
will be lonRer 
Increasing the number of 
endpoints for hypothesis 
testing increases sample sizes 
and hence costs 
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Table 3.1 (continued) 
8. Statistical methods 
Specification usually involves 
choices relating to: 
Objectives of the trial 
Nature of other trial 
parameters, most 
notablY the disease area 
and endpoints (type of 
data) 
Method of 
randomisation. 
Hypothesis tests to be 
performed on all variables 
and sub-groups of interest at 
conventional levels of 
statistical significance 
Sample sizes will be larger 
hence costs will increase 
Enrolment times might be 
extended depending upon the 
availability of trial subjects 
hence timelines will be 
longer 
* Decisions pertaining to these attributes are made by those designing the trial 
although the choices may be constrained by factors such as regulatory requirements, 
ethical considerations, patient availability and budget. 
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3.2.2 Sample size calculation for economic evaluation 
In contrast to the design of an RCT conducted for the purpose of perfonning clinical 
evaluations, the primary endpoint of interest in an economic evaluation is a ratio. 
Specifically, economists are interested in estimating the incremental cost- 
effectiveness ratio (ICER), which is given by: 
ICERAB ý- 
CA 
- 
CB 
- 
ACAB 
EA-EB AEAB (1) 
where AC,,, and AEAB denote, respectively, the differences in the average cost 
(CA-C,, ) and the average effectiveness (EA- EB) between two treatments, A and 
B. The economic evaluation analogue to a clinically meaningful difference is a 
critical threshold value of the ICER (denoted Rc) below which a treatment is deemed 
to be cost-cffective. In other words, treatment A is cost-effective compared against 
treatment B and should therefore be implemented if. 
ICERAB < Rc 
, 
for AEAB ýý'O or ICERAB > Rc 
, 
for AE,,, <0 (2) 
Whereas the literature pertaining to sample size calculations for clinical experiments 
is substantial, it is only relatively recently that methods for determining the sample 
sizes required fo r performing cost-effectiveness analyses have been 
propoSed. 49; 54; 65; 68.70 Al et al (1998) have used a simulation approachO 
, 
Briggs and 
Gray (1998) present a parametric formula which ignores covariance", and the work of 
Laska et al (1999) includes formulae based on non-parametric teStS. 49 The method 
used to perforni the illustrative sample size calculations reported in this chapter is a 
parametric approach developed independently by Briggs and Tambour 
49 
(1998,2001,2002) 70; 197; 198 Laska et al (1999)49 and Gardiner et al (2000) 54 (see 
formula in the methods section below). Essentially, these authors base their approach 
on the net benefit (NB) formulation of the cost-effectiveness decision rule set out in 
equation (2) above due to the advantageous properties of the NB statistic for the 
66; 199 
analysis of sampled cost-effectiveness data. Specifically, the NB approach states 
that a new treatment is cost-effective and should be implemented if- 
NBCAB= Rc (AEAB)-ACAB ýý' 
or, equivalently, 
NBEAB AEAB - 
Rc 
ACAB >0 (4) 
where NBCAB and NBEAB are the net benefits associated with treatment A expressed 
in units of money and effectiveness respectively. Using the NB approach, Briggs and 
Tambour (1998,2001,2002), Laska et al. (1999) and Gardiner et al (2000) develop a 
sample size formula for detecting whether the NB associated with an intervention is 
positive given acceptable probabilities of Type I (a) and Type 11 ('8) 
errors. 
49; 54; 70; 197; 198 It should be noted at this juncture that, unlike clinical evaluations, 
there is currently no consensus amongst economists about the levels of acceptable 
errors for use in cost-effectiveness analysis. For the purpose of the analysis presented 
here, it is assumed that the conventions for clinical RCTs apply. 
3.3 METHODS 
The primary concern in this chapter is with how different requirements for cost- 
effectiveness evidence might impact the size and duration of an RCT compared 
50 
with the size and duration of a study conducted solely for the purposes of a clinical 
evaluation. To illustrate these differences, the methods used to calculate sample sizes 
for a number of hypothetical cost-effectiveness analysis design scenarios are 
described in this section. 
3.3.1 Sources of data 
The dataset used for the illustrative analyses presented in this chapter comes from a 
clinical evaluation which included the Prospective collection of medical care resource 
utilisation data. This dataset has previously been used in other economic evaluation 
methodology researCh. 
69; 86; 91; 94 The data come from a study which compared the 
effectiveness of a new drug against placebo for the treatment of a cbronic condition 
for which there is currently no known cure. The primary endpoint was survival, and 
subjects were followed for four years ie. long-term survival and medical care 
resource utilisation histories are available. The medical care resource utilisation 
variables for which data were collected include: number of days spent in hospital, 
number of outpatient consultations and number of attendances at a day hospital. For 
the purpose of this illustrative analysis, the resource use variables have been valued 
using unit cost data taken from the UK NHS Management Executive database. 200 The 
actual cost values used are shown in the footnotes to the tables which follow. In 
addition, data were collected on a clinical variable which is now used as the primary 
basis for classifying patients in terms of the severity of their disease at diagnosis. The 
salient descriptive statistics pertaining to the clinical evaluation dataset are presented 
in Table 3.2. These are presented to highlight the fact that the nature of the dataset 
permits alternative hypothetical cost-effectiveness study scenarios to be constructed 
based on the RCT design attributes summarised in Table 3.1. The 
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construction of the scenarios is discussed below. 
3.3.2 RCT design scenarios 
To date, researchers investigating the methods for the analysis of sampled economic 
data and the methods for determining sample sizes for cost-effectiveness studies have 
ignored the potential importance of a number of key attributes pertaining to the design 
of an RCT. In order to emphasise the importance of this omission, equation (3) can 
be re-written as follows: 
H (HE 
'Lý'ASI-EBst 
Pi XUSt 
- 
PixiBSt 
NBCABs, = Rc. ýý (5) 
" 
('+rE)t 
t=l i=l + rc), 
where NBCABs, is the net-benefit, expressed in monetary terms, of treatment A 
compared with treatment B in population S evaluated over a time-period of t years. 
In the illustrative calculations presented in this chapter, the effectiveness of the 
alternative treatments being compared (EAs, Eqs, ) is measured in terms of the average 
years of survival. The cost part of the net-benefit equation has been broken into its 
two principal components, namely the average quantities of different types of medical 
resources (denoted by X, ) and their associated unit costs (denoted by P, ). The 
subscripts E, C on the discount rate r indicate the fact that the effectiveness and cost 
outcomes can be discounted at different rates. However, whilst differential 
discounting of costs and effects appears to be favoured in the UK, 191 use of the same 
rate QE = rc) seems to be the most commonly recommended approach. 201 
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Table 3.2 
Key Features of the Clinical Evaluation Dataset 
Variable All Subject A. Advanced Disease B. Early isease 
A B A B A B 
n= 81 n= 67 n=52 n=46 n= 29 n=21 
Costs (L) 
Year 1 16,557 17,288 16,494 19,298 16,671 12,887 
(14,725) 1 (13,763) (13,693) (14,454) (16,671) (11,197) 
Year 2 24,035 20,654 24,754 22,316 22,746 17,012 
___ý16,049) (15,170) (16,109) (16,298) (16,141) (11,895 Year 3 27,398 21,182 27,525 22,586 27,170 18,105 
(18,297) (15,192) (19,427) (16,110) (16,402) (12,776) 
Lifetime 27,640 21,252 27,583 22,667 27,741 18,152 
(18,318) (15,186) (19,41ý1 (16,085) (1 6,495) (12,813) 
Survival (Year ) _ _ 
Year 1 0.95 0.72 0.94 0.71 0.97 0.74 
(0.17) (0.34) (0.20) (0.34) (0.10) 0.33 
Year 2 1.58 1.06 1.52 1.01 1.70 1.16 
(0-50) (0.71) (0.52) (0.69) (0.47) (0.76) 
Year 3 1.91 1.27 1.76 1.21 2.18 1.41 
(0.85) (1.03) (0.82) (1.01) (0.85) (1.09) 
Year 4 1.98 1.34 1.80 1.26 2.29 1.51 
(0.94) (1.15) (0.88) (1.11) (0.97) (1.24) 
Inpatient days 
Year 1 86.60 96.85 85.87 108.35 87.93 71.67 
(85.30) (77.85) (79.55) (81.64) (96.21) (63.53) 
Year 2 123.69 115.36 127.60 125.15 116.69 93.90 
(89.03)_ (85.15) (86.42) (91.47) (94.68) (66.34) 
Year 3 140.88 118.10 142.10 126.59 138.69 99.52 
(100.31) (85.15) (104.45) (90.47) (94.18) (70.61) 
Year 4 141.98 118.39 142.31 127.00 141.38 99.52 
(100-06) (85.10) (104.41) (90.35) (93.52) (70.61) 
Day patient 
attendances 
Year 1 1.44 0.30 1.54 0.22 1.28 0.48 
(3.17) (1.02) (3.29) (0.87) (2.99) (1.29) 
Year 2 3.60 0.45 3.71 0.30 3.41 0.76 
(9.33) (1.50) (10.45) (1.03) (7.04) (2.21) 
Year 3 4.12 0.48 4.00 0.30 4.34 0.86 
(10.31) (1.68) (10.80) (1.03) (9.54) (2.59) 
Year 4 4.22 0.49 4.02 0.30 4.59 0.90 
(10.55) (1.68) (10.81) (1.03) (10.25) (2.59) 
Outpatient 
attendances 
Year 1 11.19 2.51 11.92 2.50 9.86 2.52 
(11.07) (3.70) (11.59) (3.40) (10.11) (4.38) 
Year 2 16.78 3.61 17.17 3.11 16.07 4.71 
(15.16) (5.83) (15.52) (4.37) (14.73) (8.21) 
Year 3 19.02 4.15 18.63 3.35 19.72 5.90 
- 
17.11 6.75 (17.05) (4.42) (17.50) 
-(10.08) Year 4 19.22 9 4.3  18.73 3.46 20.10 6.43 
- 
17.42 7.50 (17.18) (4.49) 18.12) (11.57) 
Values are sample means with standard deviations shown in parentheses. Mean cost figures are 
derived using the following unit costs: drug cost = E250 per annum; Inpatient = E176.07 per day, 
Outpatient = E73.06 per consultation; Day case = E176.07 per attendance. 
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It should be noted that although the calculations which follow are based on the 
arithmetic means of effectiveness and costs for each of the time periods for which 
analyses are performed, the sample averages are not necessarily the appropriate 
estimators to use in the presence of censored data. 
48; 76; 86; 87 However, the use of 
arithmetic means does not invalidate the main arguments or conclusions in this 
chapter. 
It can be seen from equation (5) that the net benefit demonstrated for a given 
intervention depends upon the choices made about the various study design attributes 
summarised in Table 3.1. Consequently, the sample size detemlined by applying any 
formula based on the net benefit statistic will also be a function of the choices about 
RCT design attributes. Despite the existence of a large number of methodological 
guidelines, these tend to be at a general level. 10 Consequently, there is currently 
considerable discretion in the choice of design parameters, although arguably the 
choices would reflect the preferences of the ultimate consumers of the information. 
In order to illustrate the impact which different design preferences can have on study 
sample size and duration, hypothetical RCT design scenarios were constructed based 
on different assumed choices regarding the following components of equation (5): 
- 
duration of observation, t years 
- 
medical care resource components measured in the RCT, X, 
- 
medical care resource unit costs, P, 
- 
discount rates applied to costs (rc) and effectiveness (r, ) 
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- 
study population based on sub-groups of patients with different disease 
severity at diagnosis, S. 
The sample sizes for each of the design scenarios defined on the above variables are 
compared against the sample size calculated for a hypothetical baseline clinical study 
of I year duration (see below). The impact on sample size of different design choices 
is evaluated across a range of critical threshold values of the ICER (Rc). 
3.3.3 Sample size formulae 
The parametric method of sample size determination set out by Briggs & Tambour 
(1998,2001,2002)70; 197; 198 
, 
Laska et al (1999)49 and Gardiner et al (2000)54 was used 
to calculate the sample sizes required for the different RCT design scenarios that were 
created in the manner described above. Based on the decision rule that a treatment 
should be implemented if NB is significantly positive, the above authors report 
formulae for testing the statistical hypothesis that 
HO: NBCAB :: ý 0 
versus the altemative hypothesis 
HI: NBCAB > 0* 
Following the notation used by Briggs & Tambour (1998,2001,2002), it can be shown 
that the sample size required to test the above hypothesis is given by: 
(Za [R2 (aE2A 
+ CE2B 
) 
+(a 2+ Cr 2 )- 2RCPV(car2 2B 2 2; )] +Zc+ aE (aTCA + (ac 
n> 
CA 
_ 
CB (6) (RCAEAB 
- 
"-ýCAB 
55 
where n is the number of subjects required per arm of the triaL Za and Z. denote the 
critical values from the standard normal distribution corresponding to the required 
22 
significance level and power respectively, C; -EAIUEB'aCAICFCB are the variances of 
effects (E) and costs (C) for treatments A and B, and p is the correlation between 
ACAB and AEAB. Note that equation (6) could be rewritten using the notation 
introduced in equation (5) in order to emphasise the point that sample size is a 
function of various RCT design attributes. However, this has not been done here in 
order to simplify the presentation. The formula for estimating p from the pilot data 
(which has unequal sample sizes) is given by: 
PCEA 
-CCA'aEA + 
PCEB'CCB 
nA nB 
f22 
CA CB ! ICL 
+ ý 
2+ CE2 
X 
aEA B 
n A nB nA nB 
(7) 
where pcFA and pcEB are the correlation coefficients between costs and effects for 
treatment groups A and B respectively, and nA and nBare, the corresponding sample 
sizes. Readers interested in seeing a detailed derivation of the sample size formula 
should see Briggs & Tambour (1998,2001,2002), Laska et al (1999) or Gardiner et al 
(2000). 49; 54; 70; 197; 198 A particularly useful aspect of the paper by Gardiner et al (2000) 
is that they present a formula for determining the ratio of the sample size requirements 
for tests of hypotheses on the ICER to the requirements for testing differences in 
effectiveness. 
54 
To calculate the sample size required for the baseline clinical study of I year duration, 
the formula for a two sample test of the equality of means given by Rosner (2000) 
56 
was used 
196: 
2 +a 2 /rXz. /2 +Z 
(OrEA 
EB 
'0 
y 
nA =. 
EA 
-EB 
and nB = rnA (8) 
where r=1 for a trial with equal allocation to each arm This formula yields the same 
results as that cited in Gardiner et al (2000). 
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No allowance is made for withdrawals in any of the sample size calculations although 
it is common practice to make adjustments for this eventuality. 195 This does not affect 
the conclusions of the analysis, although it does mean that all sample sizes are 
probably lower than would be used in practice. All calculations utilise levels of 
acceptable errors typically used in RCTs, namely a= 5%,, 6 = 10%. 
3.4 RESULTS 
In order to illustrate how different requirements for wholly stochastic cost- 
effectiveness evidence might impact the size and duration of an RCT, it is necessary 
to choose a baseline RCT design where the sample size has been determined based on 
a 'clinical' primary endpoint. Clearly, any statements about incremental sample sizes 
and development times attributable to requirements for cost-effectiveness analysis 
will depend upon the choice of baseline design. For this analysis, the data from the 
original clinical evaluation are viewed as pilot data assumed to be available for 
designing an RCT. These were used to calculate the sample size required to compare 
the two treatments in terms of average survival times after I year of follow up for a 
trial in a population of subjects with mixed disease severity. Using the formula given 
in equation (8) and assuming equal allocation, 29 subjects per arm would be required 
57 
making no allowance for withdrawals from the study. 196 The formula presented by 
Gardiner et al (2000) yields the same sample size. 54 Thus, a total of 58 subjects and a 
trial of I year duration is used as the baseline design for the comparisons which 
follow. The sample sizes required for a similar trial of 2,3 or 4 years duration would 
be 60,92 and 114 subjects respectively. Using the formulae presented in equations (6) 
and (7), sample size calculations were performed for the cost-effectiveness RCT 
design scenarios described above. The results of these calculations are presented in 
Tables 3.3 to 3.7, which shows the total sample sizes compared with the clinical 
baseline. The results are presented in terms of each of the design attributes and are 
discussed in tum below. 
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3.4.1 Choice of duration of observation 
Rows numbered 2 to 4 of Table 3.3 show the sample size implications of testing 
economic hypotheses based on different periods of follow-up (I to 3 years) and for 
different assumed critical values of the ICER (F. 5,000, E10,000J15,000, F. 20,000 and 
E25,000). These calculations are based on the study population which includes a mix 
of patients with both advanced and early disease i. e the same population as for the 
baseline clinical design. It can be seen that for each economic analysis scenario (1,2 
and 3- years follow-up), sample sizes are higher than those which would be required 
for the clinical baseline design (row 1). For the critical ICER values used in Table 
3.3, the sample sizes required for economic analysis are a decreasing function of the 
critical value of the ICEF, and the ICER (and hence net benefit) is an increasing 
function of the duration of subject follow-up. For example, based on an analysis at 1 
year and a critical ICER of ; E10,000 a trial which enrolled a total of 760 subjects 
(compared with 58 for the baseline clinical analysis) would be required to test the 
hypothesis that net benefits are statistically significantly positive. In contrast, a 3-year 
study would require a sample size of 344,229 subjects to test the hypothesis that net 
benefits are statistically significantly positive. 
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Table 3.3 
Sample Sizes for an RCT when different economic follow-up periods are used 
RCT Design Attribute lCW Total Sample Size for Critical ICER of : ed 
Pa L5,000 L10,000 L15,000 L20,000 L25,000 
1. Clinical baseline 
- 
E3,193 58 58 58 58 58 
2. Economic: I year 0.104 
- 
E3,193 1958 760 410 262 188 
3. Economic: 2 years 0.077 E6,447 2634 522 248 160 
4. Economic: 3 years 0.087 L9,711 344229 1322 462 276 
ap= the correlation between the difference in costs and effects of treatments A and B 
b Incremental cost-effectiveness ratio calculated from the data. "Ihese values are the hypothesised ICERs for 
the sample size calculations. 
c Probablities of Type I error = 0.05 and Type II error = 0.10 throughout. All sample size calculations take 
into account the correlation between cost and effectiveness differences using the formula cited in the text. 
d All calculations are based on undiscounted costs and effects 
Denotes the fact that the sponsor of a technology under investigation would probably not conduct a study 
to test economic hypotheses if the postulated ICER was greater than the critical value. 
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The impact on sample size of choosing alternative periods of observation and 
alternative critical values of the ICER for the purposes of evaluating cost- 
effectiveness is also illustrated graphically in Figure 3.1. Figure 3.1 shows sample 
sizes (logarithmic scale) plotted against different critical values of the ICER (EO to 
E30000) for the clinical baseline RCT design, and for trial designs which evaluate 
economic outcomes after 1,2 and 3 years of observation. The results presented in 
Figure 3.1 show clearly that sample sizes are larger for each possible economic design 
scenario (combination of duration and critical values of the ICER) compared with the 
clinical baseline design, although they converge as the critical value of the ICER 
increases. 
Figure 3.1 shows clearly that study designs which bring the hypothesised ICER and 
the critical value into close proximity with one another will render a standard 
frequentist stochastic cost-effectiveness analysis unattainable although in the 
examples shown here, a standard clinical evaluation would still be a practical 
proposition. From the pilot data, the hypothesised values for the studies of 2 and 3 
years duration are E6,447 and E9,711 respectively. In these cases, the sample sizes 
required for the cost-effectiveness analyses can be seen to tend to infinity as the 
critical value of the ICER approaches the hypothesised value. 
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3.4.2 Choice of medical care resource use endpoints 
Table 3.4 shows the impact on sample size of performing an economic analysis which 
includes the measurement of different components of resource use in an RCT. 
Specifically, the sample sizes required for evaluating cost-effectiveness based only on 
measuring days spent in hospital as an inpatient (rows numbered 2-4), only outpatient 
consultations (rows numbered 5-7) or only daypatient attendances (rows numbered 8- 
10) are shown for different periods of observation and for different critical values of 
the ICER. Rows 11-13 show the sample size requirements if inpatient resource use is 
excluded from the analysis. 
It can be seen that, in instances where only inpatient or outpatient resource use is 
measured, the required sample sizes are mostly larger than for the baseline clinical 
analysis although they are very close for the higher critical values of the ICER. 
Economic evaluations which measured only daypatient attendances or which excluded 
inpatient stays would require larger sample sizes irrespective of the duration of 
observation or the critical values of the ICER. 
3.4.3 Choice of medical care resource use unit costs 
The results presented in Table 3.5 show that the sample sizes required for trials 
performed to test hypotheses about the cost-effectiveness of an intervention are 
influenced not only by which components of medical care resource use are measured, 
but also by how they are valued. The results shown in rows numbered 2 to 4 of Table 
3.3 are based on the assumption that the price of the medication under study equates 
to a cost of E250 per patient per year. 
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Table 3.4 
Sample Sizes for an RCT when different medical care resources are evaluated 
RCT Design Attribute ICERb Total Sample Size for Critical ICER of : ', d 
Pa L5,000 00,000 U5,000 E20,000 L25,000 
1. Clinical baseline E3,193 58 58 58 58 58 
2. Inpatient only* I year 0.094 E1,919 128 72 60 56 54 
3. Inpatient only. 2 years 0.128 fl, 815 122 70 60 56 54 
4. Inpatient only* 3 years 0.143 fl, 750 176 108 94 88 86 
5. Outpatient only* I year 0.226 0,807 820 116 80 68 62 
6. Outpatient only. 2 years 0.327 E2,589 182 82 66 60 58 
7. Outpatient only. 3 years 0.349 E2,445 256 122 102 94 90 
8. Daypatient only. I year 0.093 L6,844 956 476 290 200 150 
9. Daypatient only- 2 years 0.057 E3,553 14238 786 290 168 120 
10. Daypatient onl)r 3 years 0.067 L7,010 3158 574 290 200 
11. Excluding inpatient costs: I year 0.102 L4,074 1600 670 374 244 176 
12. Excluding inpatient costs: 2 years 0.072 L5,387 1516 404 210 142 
13. Excluding inpatient costs: 3 years 0.082 L8,708 16794 918 378 242 
ap= the correlation between the difference in costs and effects of treatments A and B 
b Incremental cost-effectiveness ratio calculated from the data. These values are the hypothesised ICERs for 
the sample size calculations. 
c Probablities of Type I error = 0.05 and Type II error = 0.10 throughout. All sample size calculations take 
into account the correlation between cost and effectiveness differences using the formula cited in the text. 
d All calculations are based on undiscounted costs and effects 
Denotes the fact that the sponsor of a technology under investigation would probably not conduct a study 
to test economic hypotheses if the postulated ICER was greater than the critical value. 
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Rows numbered 2 to 4 of Table 3.5 show the impact on sample size of doubling the 
assumed price of the treatment under investigation and rows numbered 5 to 7 show 
the impact of quadrupling the price. It can be seen that in this case study sample sizes 
are generally an increasing function of the price of the product under investigation. 
An identical pattem is observed when the unit costs for inpatient, daypatient and 
outpatient attendances are simultaneously increased by 50 per cent (rows numbered 8- 
10) or 100 per cent (rows numbered 11-13) compared with the baseline unit costs 
assumed for the other calculations. Large increases in sample size requirements are 
observed in the instances where changing the unit costs brings the hypothesised ICER 
into very close proximity to the highlighted critical values. For example, when the 
critical ICER is assumed to be E10,000, the total sample size required for a2 year 
cost-effectiveness study increases from 2634 (row number 3 of Table 3.3) to 140408 
when unit costs are increased by 50% (row 9 of Table 3.5). Conversely, large sample 
size reductions are observed when the hypothesised ICER diverges from the critical 
value as a result of changes in unit costs. 
The sensitivity of sample size requirements to the choice of unit costs used to value 
medical care resource utilisation data is illustrated graphically in Figure 3.2. Figure 
3.2 shows sample sizes (logarithmic scale) as a function of critical values of the ICER 
for the clinical baseline RCT design scenario, and for cost-effectiveness studies 
performed over a1 
-year period using different assumptions about drug price (100% 
increase) and other resource use (100% increase). 
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Table 3.5 
Sample Sizes for an RCT when different medical care resource costs are used 
RCT Design Attribute 
Pa 
1. Clinical baseline 
2. Drug price x 2: 1 year 0.105 
3. Drug price x 2: 2 years 0.080 
4. Drug price x 2: 3 years 0.092 
5. Drug price x 4: 1 year 0.107 
6. Drug price x 4: 2 years 0.086 
7. Drug price x 4: 3 years 0.101 
8. Resource prices x 1.5: 1 year 0.104 
9. Resource prices x 1.5: 2 years 0.076 
10. Resource prices x 1.5: 3 year 0.085 
11. Resource prices x 2: 1 year 0.104 
12. Resource prices x 2: 2 years 0.075 
13. Resource prices x 2: 3 years 0.084 
ICERý Total Sample Size for Critical ICER of : "d 
; E5,000 L10,000 E15,000 L20,000 L25,000 
- 
E3,193 58 58 58 58 58 
- 
E2,155 2566 896 460 288 202 
E7,202 4242 628 278 174 
E10,458 1786 534 304 
- 
E80 5092 1302 596 350 236 
L8,712 19962 962 356 206 
El 1,951 3942 746 374 
- 
L5,308 2786 1262 722 472 336 
E9,292 140408 2298 714 370 
E14,193 99512 2262 782 
- 
L7,423 3416 1732 1046 704 508 
L12,138 15468 2154 858 
E18,674 65676 3248 
ap= the correlation between the difference in costs and effects of treatments A and B 
b Incremental cost-effectiveness ratio calculated from the data. These values are the hypothesised ICERs for 
the sample size calculations. 
c Probablities of Type I error = 0.05 and Type II error = 0.10 throughout. All sample size calculations take 
into account the correlation between cost and effectiveness differences using the formula cited in the text. 
d All calculations are based on undiscounted costs and effects 
Denotes the fact that the sponsor of a technology under investigation would probably not conduct a study 
to test economic hypotheses if the postulated ICER was greater than the critical value. 
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3.4.4 Choice of discount rate 
It is common practice in economic evaluation to discount both cost and effectiveness 
outcomes to reflect social time preferences and social opportunity costs of resources. 
Whilst there is consensus about the need to perform discounting, there is no consensus 
regarding the rates that should be used 
. 
20 1 The results presented in Table 3.6 show 
that the choice of discount rate and whether it is applied to both costs and effects or 
not will have an impact on the sample sizes required to perform hypothesis tests about 
cost-effectiveness. For the range of scenarios presented here, sample size 
requirements are a decreasing function of the discount rate. Whilst most reductions in 
sample size are relatively small (compared with rows 3 and 4 of Table 3.3 as 
appropriate) a substantial impact can be seen when the hypothesised ICER is in close 
proximity to the assumed critical value. This can be seen, for example, in the case of 
the scenario in which a 3-year study is planned around a critical ICER of E10,000. 
Sample size requirements reduce from 344,106 subjects (0% discount rate, row 4 of 
Table 3.3) to 58,596 when both costs and effectiveness are discounted at 6% (row 3 of 
Table 3.6) and to 31,670 when a 10% discount rate is used (row 5 of Table 3.6). 
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Table 3.6 
Sample Sizes for an RCT when different discount rates are used 
RCT Design Attribute ICERý Total Sample Size for Critical ICER of: cýd 
Pa L5,000 00,000 U5,000 L20,000 L25,000 
1. Clinical baseline 
- 
E3,193 58 58 58 58 58 
2. Discount rate: 6% 2 years 0.070 E6,201 2394 510 246 160 
3. Discount rate: 6% 3 years 0.075 L9,287 58596 1156 430 260 
4. Discount rate: 10% 2 years 0.066 L6,044 2262 504 246 160 
5. Discount rate: 10% 3 years 0.068 E9,020 31670 1070 412 252 
6. Discount costs only. 6% 2 years 0.065 E6,003 2052 468 232 154 
7. Discount costs only: 6% 3 years 0.068 E8,860 21614 970 392 248 
ap= the correlation between the difference in costs and effects of treatments A and B 
b Incremental cost-effectiveness ratio calculated from the data. These values are the hypothesised ICERS for 
the sample size calculations. 
c Probablities of Type I error = 0.05 and Type II error = 0.10 throughout. All sample size calculations take 
into account the correlation between cost and effectiveness differences using the formula cited in the text. 
d All calculations are based on discounted costs and effects using the rates shown in column 1. 
Denotes the fact that the sponsor of a technology under investigation would probably not conduct a study 
to test economic hypotheses if the postulated ICER was greater than the critical value. 
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3.4.5 Choice of study population 
The results presented so far pertain to a study population which contains patients with 
different levels of disease severity at diagnosis. However, it is likely that the cost- 
effectiveness of an intervention will vary amongst sub-groups within a population of 
people with a disease. Therefore a diagnostic variable was used to partition the 
dataset into two groups of patients. For illustrative purposes, these are referred to as 
sub-group A (advanced disease at diagnosis) and sub-group B (early disease at 
diagnosis). Table 3.7 shows the sample size requirements for performing separate 
trials to test the hypothesis that the net benefit of the intervention is statistically 
significantly positive for sub-groups A and B. In both cases, the sample sizes 
required are much larger than those necessary for the baseline clinical trial design 
involving a mix of patients (row 1). Whilst the sample sizes for sub-group A (rows 2- 
4 of Table 3.7) are mostly lower than the corresponding requirements for an economic 
study involving a mix of patient types (rows 2-4 of Table 3.3), the sample size 
requirements for sub-group B are predominantly larger (rows 5-7 of Table 3.7). Once 
again, the largest changes in sample sizes occur when the hypothesised ICER is in 
close proximity to the assumed critical value. 
The sensitivity of sample size requirements to the choice of study population is 
illustrated graphically in Figure 3.3. Figure 3.3 shows sample sizes (logarithmic 
scale) as a function of critical values of the ICER for the clinical baseline RCT design 
scenario, and for cost-effectiveness studies performed over a1 -year period using the 
three different study populations. 
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Table 3.7 
Sample Sizes for an RCT when different study populations are used 
RCT Design Attribute ICW 
Pa 
1. Clinical baseline 
-0,193 
2. Sub 
- 
group A: I year 0.134 - L12,429 
3. Sub 
- 
group A: 2 years 0.092 E4,800 
4. Sub 
- 
group A: 3 years 0.060 L8,893 
5. Sub 
- 
group B: I year 0.052 L16,390 
6. Sub 
- 
group B: 2 years 0.115 f. 10,710 
7. Sub 
- 
group B: 3 years 0.208 E 11,827 
Total Sample Size for Critical ICER of:,, d 
E5,000 00,000 115,000 L20,000 L25,000 
58 58 58 58 58 
432 262 180 134 106 
875920 1384 408 216 146 
34794 1430 556 342 
10764 1994 
1690 444 234 
1974 416 222 
ap= the correlation between the difference in costs and effects of treatments A and B 
b Incremental cost-effectiveness ratio calculated from the data. These values are the hypothesised ICERs for 
the sample size calculations. 
c Probablities of Type I error = 0.05 and Type II error = 0.10 throughout. All sample size calculations take 
into account the correlation between cost and effectiveness differences using the formula cited in the text. 
d All calculations are based on discounted costs and effects using the rates shown in column 1. 
Denotes the fact that the sponsor of a technology under investigation would probably not conduct a study 
to test economic hypotheses if the postulated ICER was greater than the critical value. 
A Sub-group A= advanced disease at diagnosis. 
B Sub-group B= early disease at diagnosis. 
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3.5 DISCUSSION AND CONCLUSION 
The results presented in this chapter illustrate how the modification of a clinical trial 
design to accommodate an appraisal of the cost-effectiveness of an intervention could 
have a significant impact on two of the major deten-ninants of drug development times 
and costs, namely the size and duration of an RCT. Specifically, the results show that 
sample size is sensitive to different requirements for cost-effectiveness evidence 
defined by the choices made in relation to key study design attributes. Different 
preferences for cost-effectiveness study designs affect sample sizes through their 
impact on the parameters of equations (6) and (7). The preferred duration of 
evaluation will clearly have a direct impact on development times. In addition, larger 
sample sizes could lead to longer development times if the period required to enrol 
subjects is extended. 
The sample sizes required for the majority of the hypothetical cost-effectiveness 
analysis scenarios considered in this chapter were larger than those for the baseline 
clinical evaluation around which they were constructed. This finding is consistent 
with the conclusions of other researchers who have suggested that the sample sizes 
required for economic analysis are likely to be larger than those required for the 
underlying clinical evaluation. 54; 65; 69 However, the ratio of the economic and clinical 
sample sizes will not always exceed unity as demonstrated by the presence of ratios 
less than unity in the results. 
The results presented in this chapter show that sample sizes tend to infinity as changes 
to any of the study design parameters bring the hypothesised. ICER into close 
proximity to the critical value (from above or below). In such circumstances, the 
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required sample sizes would likely prohibit a conventional frequentist stochastic 
approach to cost-effectiveness analysis e. g. one can envisage extreme situations where 
the epidemiology of a disease is such that it could take hundreds of years to enrol a 
sufficient number of patients into a trial. Therefore one of the practical implications 
of this finding is that alternative approaches to the evaluation of the cost-effectiveness 
of an intervention will be necessary in such situations. Moreover, during the planning 
stages of an RCT, researchers would be unable to identify the potential for such a 
situation unless, at that time, the critical value of the ICER was known and unless 
pilot data were available to formulate a hypothesis about the cost-effectiveness of a 
new treatment. Typically, such data are unavailable to the sponsor of a new 
technology prior to its introduction to the market. This has led some researchers to 
question the practical value of being able to perform sample size calculations for an 
cconon-dc evaluation even though methods for doing so are available. 65 
This chapter illustrates the potential impact of a requirement to produce wholly 
stochastic cost-effectiveness evidence within the framework of an RCT in which the 
statistical hypothesis tested is that the net-benefit associated with an intervention is 
positive at conventional probabilities of Type I (a) and Type 11 (, 8) errors. Clearly, 
this is not to suggest that this is the only research approach which could be adopted 
for producing cost-effectiveness evidence. Rather the goal of the chapter is to shed 
some light on the potential implications if such an approach were to be implemented 
in practice. Indeed, alternative modelling approaches (deterministic analysis) are 
frequently app lied, 3 1 and some researchers have argued that modelling may be a 
39; 12 
necessary complement to RCT based evidence (partially stochastic analysis). 
From a practical standpoint, the need for such alternative research approaches seems 
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inevitable for the extreme situations referred to above. 
Another way of avoiding the potential sample size problems of stochastic cost- 
effectiveness analysis would be to accept the probabilities of Type I and Type Il 
errors resulting from the sample sizes required for the clinical evaluation, rather than 
insisting that the conventions used in medical research be applied to economic 
evaluation. Emphasis would then be placed on reporting confidence intervals or cost- 
effectiveness acceptability curves rather than on fonnal hypothesis testing. With this 
approach, any additional costs associated with a requirement for RCT based cost- 
effectiveness evidence would then be driven by the administrative consequences of 
collecting additional data and by any requirement to extend the duration of a trial. 
Alternatively, it has recently been argued that decisions about cost-effectiveness based 
on statistical inference are irrelevant and that a Bayesian decision theoretic approach 
to the stochastic evaluation of health care technologies should be used. 157 Whether 
this alternative approach will have more or less of an impact on pharmaceutical 
company development costs and timelines is unknown. This will depend upon a 
number of factors, such as whether and how the costs borne by the sponsor of the 
technology are incorporated into the analysis. 
The results of this study highlight that the sample size requirements for cost- 
effectiveness analyses can be sensitive to the choices made about a number of RCT 
design attributes. The degree of uncertainty surrounding the results of any Cost- 
effectiveness analysis will also be sensitive to these choices. One of the practical 
implications of this study, therefore, is that it is difficult to see how sponsors of 
technologies could conduct adequately designed trials without a clear prior 
specification of the key RCT design attributes referred to in this chapter, 
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namely: comparators, study population, endpoint measurements, unit costs, duration 
of observation, discount rates, critical value of the ICEP, and acceptable probabilities 
of Type I and Type Il errors. Failure to be explicit about each of these factors prior to 
the conduct of an RCT would be tantamount to bad scientific practice. Moreover, 
being clear on these design issues is a necessary condition for evaluating the 
practicality and feasibility of conducting a wholly stochastic cost-effectiveness 
analysis, as referred to above. 
A primary concern amongst companies developing new health care technologies is 
how a requirement to produce evidence of cost-effectiveness based on RCTs will 
impact development costs and development times. Clearly, the direction and 
magnitude of the impact will depend upon the precise nature and extent of the cost- 
effectiveness evidence required by decision-makers. With respect to development 
times, the impact of cost-effectiveness evidence requirements will depend upon the 
desired duration of the evaluation of cost and effectiveness outcomes compared with 
the period of follow-up required purely for the purpose of conducting a clinical 
evaluation. For example, a requirement to follow subjects for 3 years as opposed to 
I 
-year will extend product development times by at least 2 years. Development times 
can be extended indirectly if larger sample sizes affect enrolment rates. Sponsors of 
technologies will also be concerned about the revenue implications of extended 
development times. Studies of longer duration will erode the effective patent life of a 
product and could therefore have a negative effect on cumulative revenue. On the 
other hand, stronger cost-effectiveness evidence might lead to wider diffilsion once 
the product is introduced Le. the gains in revenue associated with a delayed 
introduction with stronger evidence might exceed the losses incurred as a result of that 
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delay. 202 The potential gains and losses associated with different strategies for 
producing cost-effectiveness evidence would be a worthwhile area for future research. 
The impact of cost-effectiveness evidence requirements on the scale of investment 
required for product development will depend primarily upon the relationship 
between trial sample size and the cost of conducting an RCT. This relationship will 
be known by a company, who will be able to convert the sample size calculations into 
cost functions. 172 It for example, the total cost of conducting a trial was simply a 
function of sample size based on a fixed cost per subject enrolled, then Figures 3.1 to 
3.3 could be interpreted as cost functions with an appropriate adjustment made to the 
sample size scale representing the fixed cost per subject. The figures would currently 
equate to a cost function where the cost per subject enrolled is fl. 00. A cost per 
subject enrolled of E1,000 would require the sample sizes in Figures 3.1 to 3.3 to be 
multiplied by 1,000 in order to transform the figures into cost functions. Little is 
published about the behaviour of RCT cost functions. This would be a necessary area 
for future research if the economic consequences of alternative requirements for cost- 
effectiveness evidence are to be assessed. Clearly, the cost implications will be 
sensitive to choices made about study design attributes in the same way as sample 
sizes are. Sponsors of technologies will therefore have to decide whether the 
investment in the production of wholly stochastic cost-effectiveness evidence is worth 
making. This will require companies to compare the costs of alternative requirements 
with the expected revenue associated with meeting them. An approach for doing this 
203 has previously been proposed 
. 
In conclusion, formal requirements for wholly stochastic cost-effectiveness evidence 
based on the standard frequentist paradigm have the potential to increase 
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the size, duration and number of RCTs significantly and hence the costs and timelines 
associated with new product development. Moreover, it is possible to envisage 
situations where such an approach would be impossible to adopt. Clearly, further 
research is required into the issue of how to appraise the economic consequences of 
alternative economic evaluation research strategies. Ultimately, the results of such 
research could be used to inform the development of economic evaluation guidelines, 
specifically relating to the choice of research method appropriate to different product 
circumstances. In situations where wholly stochastic cost-effectiveness evidence is 
required from RCTs, the importance of prior specification of the key economic 
evaluation design attributes should not be underestimated. 
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CHAPTER 4: THE USE OF DISCRETE CHOICE ANALYSIS IN 
THE DESIGN OF RANDOMISED CONTROLLED TRIALS 
SUMMARY 
Randomised controlled trials (RCTs) are the primary means by which pharmaceutical 
companies evaluate the therapeutic benefits of their products. The strength and 
relevance of the evidence provided from RCTs will determine whether a product can 
be marketed or not and the subsequent extent of its use. In order to gain access to a 
market, pharmaceutical companies must perform RCTs to produce safety and efficacy 
evidence to a level which satisfies the regulatory bodies responsible for granting 
product licences. However, the safety and efficacy evidence produced for that 
purpose may not be sufficient to ensure that a product is reimbursed and actually used 
in clinical practice. Health technology assessment and appraisal bodies, such as the 
National Institute for Clinical Excellence (NICE) and Hospital Drugs and Therapeutic 
Committees, critically appraise the nature and relevance of RCT evidence in order to 
make recommendations about the extent to which a product should be used. 
individual clinicians will make treatment decisions based on their own assessment of 
the evidence, as well as taking into account the reviews performed by advisory bodies. 
Thus, those involved with product adoption decisions will have preferences for the 
types of evidence they want to see and, consequently, the extent to which these 
preferences are satisfied will influence the nature and extent of a treatment's use. It is 
therefore important for sponsors of drugs to consider decision-makers' preferences for 
RCT designs when planning their studies. The primary objective of this chapter is to 
illustrate how discrete choice analysis (DCA) could be used for that purpose. The 
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approach is illustrated using, as a case study, the design of trials to evaluate adjuvant 
bisphosphonates in the management of patients with primary operable breast cancer. 
Clinicians' preferences for evidence are determined and then used to identify a trial 
design likely to lead to the highest probability of prescribing the product (market 
share). However, evidence generation has a cost attached to it. Therefore the chapter 
goes on to look at how physician preferences for evidence and the resulting predicted 
impact on product use can be combined with trial design costs in an overall 
investment appraisal framework. Within such a framework, it is shown how a 
company producing a technology could identify the profit maximising RCT strategy. 
Finally, a number of issues for consideration in future research are briefly discussed, 
including the circumstances under which private and public sector perspectives are 
likely to be aligned. 
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4.1 EVrRODUCTION 
Discrete choice analysis (DCA) is the name given to a set of multivariate data analysis 
techniques which can be used to predict decision-makers' choices between alternative 
products or services. 204-206 The techniques have been widely applied to assist with 
product design and marketing decisions in a number of industries. 1K207; 208 In the 
commercial context, the primary interest has been to use DCA to estimate the 
probability that a decision-maker will choose a given product or service from the set 
of available alternatives. Since the probability of choosing a given product is 
assumed to depend upon the utility derived from its attributes compared with that of 
its alternatives, it is possible to use DCA to estimate the demand for both new and 
existing products given different defining characteristics. 
In contrast to the commercial applications of DCA, where the primary interest is in 
modelling product demand, health economists have recently begun to use the 
technique for estimating the value of treatment processes and outcomes in preference, 
utility or monetary terms. The literature on health applications of DCA is now 
extensive. 209-228; 228-260 But, to date, DCA has not been applied to assist with the 
design of randomised controlled trials (RCTs). However, the purpose of RCTs is 
such that DCA is likely to be of value in the RCT planning and design context 
because there is a relationship between the decision to adopt a health care intervention 
(demand for the intervention) and the design characteristics of the RCTs used to 
evaluate its benefits. 
Randon-ýised controlled trials (RCTs) are the primary means by which pharmaceutical 
companies evaluate the therapeutic benefits of their products. 1-5 The strength and 
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relevance of the evidence provided from RCTs will determine whether a product can 
be marketed or not and the subsequent extent of its use. In order to gain access to a 
market, pharmaceutical companies must perform RCTs to produce safety and efficacy 
evidence to a level which satisfies the regulatory bodies responsible for granting 
product licences. However, the safety and efficacy evidence produced for that 
purpose may not be sufficient to ensure that a product is reimbursed and actually used 
in clinical practice. Health technology assessment and appraisal bodies, such as the 
National Institute for Clinical Excellence (NICE) and Hospital Drugs and Therapeutic 
Committees, critically appraise the nature and relevance of RCT evidence in order to 
make recommendations about the extent to which a product should be used. 191 
individual clinicians will make treatment decisions based on their own assessment of 
the evidence, as well as taking into account the reviews performed by advisory bodies. 
Thus, those involved with product adoption decisions will have preferences for the 
types of evidence they want to see and, consequently, the extent to which these 
preferences are satisfied will influence the nature and extent of a treatment's use. It is 
therefore important for sponsors of drugs to consider decision-makers' preferences for 
RCT designs when planning their studies. The primary objective of this chapter is to 
illustrate how discrete choice analysis (DCA) could be used for that purpose. The 
approach is illustrated using a discrete choice stated preference (SP) survey concerned 
with the design of trials to evaluate adjuvant bisphosphonates in the management of 
patients with primary operable breast cancer. 
The remainder of the chapter is divided into seven sections. In the following section, 
a discrete choice modelling approach to drug prescribing behaviour is set out in 
general form. This is followed in section 4.3 by an overview of the key components 
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of a discrete choice SP survey. In section 4.4, the design of the adjuvant 
bisphosphonates case-study survey is presented. The results for the non-choice 
question components of the survey are presented in section 4.5. The results pertaining 
to the estimation of the parameters of a binary discrete choice model are presented in 
section 4.6 where consideration is given to the qualitative and quantitative effects. 
Section 4.7 focuses on using the discrete choice model results for the design of RCTs. 
Specifically, the use of the results to determine designs which optimise the probability 
of product adoption and to operationalise an investment appraisal approach to RCT 
design are illustrated. The final section includes a discussion of the results and the 
implications for future research. 
4.2 A DISCRETE CHOICE MODEL OF DRUG DEMAND 
In this section, a discrete choice model of drug demand is set out in general form. A 
specific binary choice formulation of this model is used in the applied example which 
follows later in the chapter. 
4.2.1 Random utility theory of drug choice behaviour 
Discrete choice models derive from random utility theory of choice behaviour. 204; 206 
Under this theory, the probability that a clinician will choose drug i from the set of 
alternative treatments available, J, is given by: 
Pr(iii)=Pr(ui>ui) VjEj, j;, i (1) 
where U, and U, denote the utility which a clinician derives from using the different 
products, iand j. A clinician is assumed to choose the treatment option which 
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maximises his or her utility. Assuming that the clinician is behaving as a perfect 
agent, this should also be the choice which maximises the utility of the patient 
receiving the treatment. Since the utility of a treatment is assumed to be derived from 
the characteristics that define it, equation (1) can be re-written as: 
Pr(iii)=Pr(u, (z, )>u, (z, )) vjc=i, j: p, 
-i (2) 
where Z, and Zj denote vectors of characteristics the levels of which define the 
treatment alternatives, iand j. Note that the vectors of attributes can include 
characteristics of the clinician e. g. the preferences of primary care physicians might 
differ from those of hospital specialists. 
If a clinician's utility function was known and if all the relevant characteristics were 
observed, then pcrfcct predictions could be made about a clinician's choice of 
treatment. Since this is not the case in practice, a discrete choice model of behaviour 
can be constructed based on the following identity. 
Pr(ilj)=Pr(Ui(Zi)>Uj(Zj))=Pr(Vi(Xi)+c, >Vj(Xj)+ej) VjEJ, j#i (3) 
where V, and Vj denote the observable components of utility, X, and X, are vectors 
of observable treatment characteristics and r, and e. are the unobserved random 
components of utility for products i and i respectively. The latter takes into account 
the difference between the true, U, and observed, V, utility. The right hand side of 
equation (3) can be re-arranged to give the following general (multinomial) 
expression for a random utility model of drug prescribing behaviour: 
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Pr(jjj)=Pr(C, 
-C, <Vj(Xj)-Vj(Xj)) VjEJ, j#i (4) 
4.2.2 Discrete choice model formulations 
In order to operationalise the above model, it is necessary to specify functional forms 
for both the observable and unobservable components of utility. For the deterministic 
component of utility, it is common practice in discrete choice models to specify V as 
a function which is linear in the vector of unknown parameters, 8', such that: 
vi = fl'xi = Axi, . ........... +, 8, Xli 
Vj = j6'Xj = Axii . ........... +j6lXU VjEJ, j#i 
where A 
........ 
01 are the coefficients to be estimated for each of the I attributes 
included in the model. In practice it has been observed that the linear additive model 
of equation (5) works well in most applied situations204 and is a fonnulation that has 
been used frequently in recent health economics applications. This functional form 
for the observable component of utility will therefore be used in the analyses which 
follow. 
For the unobservable component of utility, the disturbances ( el, ej ) are assumed to be 
distributed randomly (hence the name random utility model). A number of alternative 
distributions can be assumed which give rise to different discrete choice model 
2K205 formulations. The most frequently used approaches are the logit and probit 
models. It has been noted that in practice there is little difference between the results 
derived from those two approaches. 205 Since the probit model is used in the case- 
study which follows, it is described in more detail here. In the case of probit 
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models, the unobserved components of utility are assumed to be distributed jointly 
normal. Using the probit discrete choice model formulation, the probability that a 
prescribing clinician will choose drug i from the set of alternative treatments 
available, J, is given by: 
co e, +V-Ve+V-V c +V-V 
P, (i I J) 
fIIf2....... 
.f 'O(C)de, 
... 
de2dede,, 
ei=-"o Aý-"o 
-2-'*o Cj---. OD 
(6) 
where (D(. ) denotes the standardised. cumulative normal distribution, e is a vector 
composed of each disturbance e, for all i in J and there are j alternatives in J. The 
probit model is estimated using maximum likelihood techniques. This gives rise to 
estimates for 8, 
........ 
fl, and consequently, through equation (6), the probabilities of 
choosing alternative products can be derived. 
4.3 DISCRETE CHOICE STATED PREFERENCE SURVEYS 
The parameters of a discrete choice modeL such as that set out in equation (6), can be 
estimated using data pertaining to observed choice behaviour (revealed preference 
data), simulated choice behaviour (stated preference data) or a combination of the 
tWO. 201ý206 Regardless of the source of data, the dataset needs to contain, for each 
alternative in the choice set, an indicator of the choice made together with the defining 
characteristics of the alternatives (the Xs in the above equations). 
To date, the approach typically adopted by health economists has been to use 
simulated choice data obtained from discrete choice stated preference surveys (often 
referred to as conjoint analysis). 179; 250 Since the required data on actual drug choice 
behaviour would be difficult to obtain and, by definition, is not available for 
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new products in development, the approach adopted in this chapter is to use data 
generated from a discrete choice stated preference (SP) survey. The design stages of 
such surveys have been enumerated in detail elsewhere, 179; 206 but generally they 
include the following components: 
1) Determination of attributes, levels and scenarios 
2) Elicitation of preferences 
3) Data analysis and interpretation 
These stages are discussed briefly in tum below. 
4.3.1 Determination of attributes, levels and scenarios 
When designing an SP survey, the attributes (characteristics) of interest need to be 
defined and levels (values) need to be assigned to them. A number of approaches to 
doing this have been identified, including the use of literature reviews, interviews and 
selection based on a specific research question. 179; 206 The various approaches are not 
mutually exclusive and, in practice, a combination of them is often used. At a general 
level, it is postulated here that the probability of choosing a given health care 
intervention is a function not only of the demonstrated benefits, but also of the 
'design' characteristics of the RCTs from which the evidence of product benefit is 
derived. Consequently, the design problem in the current context involves selecting 
attributes and levels from the set of RCT design characteristics enumerated in Table 
4.1. In order to ensure that an SP survey is realistic, the literature suggests that 
attribute levels should be plausible and capable of being traded. 179 
Once the attributes and their levels have been determined, they are combined into 
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scenarios or profiles to present to survey participants for evaluation. A scenario is a 
combination of attributes and levels that characterize the choice object of interest in 
the study, in this case RCTs. The number of possible scenarios (the full factorial 
design) defined by the chosen number of attributes and levels can be very large and is 
given by-. 
S=flL 
where S denotes all possible combinations of attribute levels and A, denotes the 
number of attributes possessing the number of levels L,. An SP survey with a very 
large number of scenarios would be impractical due to the cognitive burden which the 
presentation of a large number of scenarios would place on survey participants. 
Therefore a practical problem to overcome is how to reduce the number of scenarios 
whilst ensuring that the parameters of the model can be reliably estimated. A 
common approach to reducing the number of scenarios is to identify an orthogonal 
fraction using experimental design catalogues such as those available in computer 
programmes like SPEED. 261 Orthogonal arrays of scenarios are such that each 
attribute level appears an equal number of times and the attributes are uncorrelated. 206 
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Table 4.1 
Trial Design Attributes 
1. Comparators 
Can be chosen from one or more broad types, including: 
i) Placebo 
ii) Most commonly used 
iii) Most effective 
iv) Least cost 
V) Most cost-effective. 
Specification usually involves the choice of specific product formulations and modes of administration. 
Most studies compare two treatments although more are possible. 
2. Population 
Specification usually involves choices about: 
i) Age group 
ii) Sex 
iii) Ethnic origin 
iv) Disease stage 
V) Co-morbidities 
vi) Previous treatments 
vii) Concomitant treatments 
viii) De novo or refractory patients. 
ix) Sub-group comparisons 
3. Setting 
Specification usually involves choices about: 
Single country, single centre 
Single country, multi-centre 
iii) Multinational, single centre 
iv) Multinational, multi-centre 
V) Inpatient 
vi) Outpatient 
vii) Specialist centre 
viii) Routine practice centre 
4. Endpoints 
Specification usually involves choices about: 
i) Efficacy 
ii) Effectiveness 
iii) Side effects 
iv) Adverse events 
V) Quality of life 
vi) Direct costs (NB includes product prices) 
vii) Indirect costs 
viii) Resource use 
ix) Surrogate endpoints 
5. Effect sizes 
Specification usually involves choices about: 
i) Clinical significance 
ii) Statistical significance 
iii) Primary endpoints 
iv) Secondary endpoints 
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Table 4.1 (continued) 
6. Duration of observation 
Specification usually involves choices about: 
i) Fixed period of observation 
ii) Variable (e. g. in sequential designs). 
Choices are linked closely to the choice of endpoints and the statistical properties of the study. 
7. Acceptable error rates: cL and P 
Choices are linked closely to the choice of endpoints and the duration of follow-up. 
Often chosen according to convention and based on the primary endpoint(s) i. e. a= 5%, 10% 
Do not have to be the same for each endpoint (and usually aren't). 
Used in conjunction with the statistical properties of endpoints, the desired effect sizes and withdrawal 
rates to determine sample size. 
8. Statistical methods 
Specification usually involves choices relating to: 
i) Objectives of the trial 
ii) Nature of other trial parameters, most notably the disease area and endpoints (type of data) 
iii) Method of randomisation. 
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4.3.2 Elicitation of preferences 
Preferences are elicited by presenting the scenarios to respondents who are asked to 
rank or rate each of them, or to indicate their preference (choice) from sets of two or 
more profiles presented alongside each other (the discrete choice format). The 
preference elicitation approach preferred by health economists to date has been the 
discrete choice format since it reflects the random utility theory of choice behaviour 
(see above). 179; 204; 206 Further, health economists have tended to elicit preferences 
using binary (pairwise) choice tasks in which respondents select their preferred 
scenario from each of a number of pairs (the choice set). Typically, choice sets have 
been generated by randomly pairing (without replacement) the scenarios in the 
orthogonal array, although alternative approaches could be employed. 
The choice sets usually incorporate some pairwise comparisons that form the basis of 
tests to identify inconsistent respondents. Inconsistent respondents are traditionally 
defined as those who do not make the choices one would expect them to make given 
the researcher's prior expectations about a positive or negative relationship between 
the attribute values and utility. Thus, to test for inconsistency defined in this way, the 
design needs to contain some pairwise combinations of scenarios for which the 
preferred scenario might be predicted a priori. These can fall naturally from the 
random generation of the choice sets or be generated manually. Using such tests, 
inconsistent respondents can then be identified at the analysis stage and dropped from 
the analysis along with non-trading subjects (see below). 
As far as the author is aware, there is no formula for estimating the sample sizes 
required for binary choice SP surveys. Consequently, there is no firm statistical basis 
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for the sample sizes used in previously reported studies. However, a notable feature 
of discrete choice surveys is that each respondent can provide as many as n 
observations to the dataset, where n is the number of choice sets included in the 
survey. Thus, a relatively small number of respondents can provide a sufficiently 
large number of observations for valid statistical analyses to be performed. Finally, 
preference elicitation surveys have been administered to respondents in a variety of 
ways including the use of mail, phone, web and interactive computer elicitation 
techniques with adequate responses having been reported for each. 179 
4.3.3 Data analysis and interpretation 
The statistical method used to analyse SP data depends upon the approach used to 
elicit preferences. For the discrete choice approach, which is of primary interest here, 
probit regression has been widely used by health economists for estimating the 
parameters of discrete choice models. A number of probit estimators are available in 
262 
statistics programmes such as Stata Version 7.0 (Stata). However, in previously 
published studies, researchers have tended not to specify the statistics progranunes or 
the precise estimation commands they have used. 
A standard probit estimator relies on the assumption that the explanatory variables 
and the error term are independently and identically distributed and that they are 
uncorrelated. These assumptions are likely to be inappropriate in the case of discrete 
choice data obtained from SP surveys since multiple observations are obtained from 
each respondent. Stata provides two alternative probit estimation commands which 
are appropriate for such repeated measurement panel data: probit (cluster) and 
xtprobit (pa, robust) 
. 
262 Both estimators, which are essentially equivalent, take into 
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account the potential for a respondent's responses to be correlated. Both approaches 
also generate robust standard errors. 
An estimation issue which arises in the literature is whether or not discrete choice 
regression models should be specified with a constant term. Examples of both 
approaches can be found. The answer to this issue appears to lie in the way in which 
the choice exercise is framed. For example, in a study which looked at preferences 
for miscarriage management, the scenarios presented to respondents were labeled 
, 9245 66surgical treatment" and "medical treatment 
. 
Since these labels convey 
information which might be used by respondents to decide which option was 
preferred, the authors estimated a model with a constant term. The authors interpreted 
the negative constant as indicating a general preference for surgical over medical 
management when all the attributes for the two interventions are the same. 
In contrast, models have been estimated without constants where the labeling of the 
choices conveys no properties of the alternatives. For example, in a study looking at 
preferences for in vitro fertilization services, the choice alternatives were labeled 
f6clinic N' and "clinic B" and the authors estimated a model without a constant 
term. 263 Thus, contemporary practice is to omit constants when the choice task 
involves generically labeled alternatives and vice-versa. 
A linear additive form of the utility function has typically been assumed by health 
economists on the grounds that research has shown that alternative models seldom 
result in a better fit than the linear additive model. 264 It has recently been pointed out 
that a simple regression error specification test (RESET) could be applied to 
determine whether there are problems associated with the linear functional form of 
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discrete choice models. 265 However, in health economics applications, only one study 
could be found that reports a test for model mis-specification. 238 
In the health economics literature, it has become common practice to estimate models 
based only on a subset of respondents who are deemed to be consistent traders. 
Inconsistent respondents (as defined above) and non-trading respondents are typically 
dropped from the analysis and the results obtained from the full sample are not 
usually reported. A non-trading respondent is defined as one who always selects a 
choice scenario with a higher level of a particular (don-ýinant) attribute irrespective of 
the levels of the remaining attributes. Such respondents are identified at the analysis 
stage by looking for choice patterns consistent with this behaviour. However, it has 
been noted that whether or not analyses should be performed on the full sample or 
only on consistent traders depends upon the objectives of the study. 210 In this study, 
analyses are reported for both the full sample as well as subsets of consistent traders. 
Finally, health economics researchers have primarily been interested in using the 
regression coefficients for deriving utility scores and, where a cost attribute is 
included, estimates of willingness-to-pay (WTp). 179 This has enabled, for example, 
alternative service configurations to be ranked in terms of their utility scores. To date, 
health economists applying discrete choice stated preference surveys have not derived 
predicted choice probabilities from their models, although these are the primary 
interest here. 
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4.4 CASE STUDY OF ADJUVANT BISPHOSPHONATES 
4.4.1 Adjuvant bisphosphonates in the management of breast cancer 
Breast cancer is the most common form of female cancer in England and Wales 
where, in 1998, there were 34,822 newly diagnosed cases representing an incidence 
rate of 130.83 per 100,000 females. The incidence of breast cancer increases sharply 
with age and, overall, has been rising since the early 1970s. During the same period, 
mortality from breast cancer has fallen. Currently, the survival rate at 5 years post- 
diagnosis is 75.9%. In 2000, there were 11,340 deaths from breast cancer in England 
and Wales. 266 
National guidance exists for the management of patients with breast cancer. 266 
Management is centred on multidisciplinary teams composed of breast surgeons, 
oncologists (clinical and medical), radiologists, pathologists and breast care nurses. 
The precise nature of initial treatment depends upon the clinical staging of the disease 
at diagnosis, but typically involves a combination of surgery, chemotherapy, 
radiotherapy and hormone replacement therapy. After completion of initial treatment, 
patients are monitored on an ongoing basis to ensure early detection of disease 
recurrence (relapse). In patients who relapse, most have metastatic (distant) disease 
which often affects both organs (visceral metastases) and bone (osseous metastases). 
The prognosis for patients with metastatic disease is poor, with the aim of treatment 
being palliative rather than curative. 
The case study presented here is concerned with the preventive use of a class of drugs 
known as bisphosphonates which inhibit bone resorption (destruction). Clinical 
research has shown that bisphosphonates reduce the incidence of hypercalcaemia 
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and pathological bone fractures in patients with established bone metastases from 
breast cancer. Moreover, bisphosphonates have been shown to reduce the risk of bone 
metastases in patients with relapsed breast cancer without obvious bone involvement. 
In view of these proven benefits, the National Institute for Clinical Excellence in 
England and Wales (NICE) has recently reconunended that bisphosphonates be used 
in the management of patients with bone metastases. 266 It has been estimated that 
currently about one third of patients with bone metastases receive bisphosphonate 
treatment at an approximate annual cost in England and Wales of; C3.9 million. The 
annual cost could rise to as much as E25.6 million per annum if there is adherence to 
the recent guidance. The annual cost per patient for one of the more researched oral 
bisphosphonates (sodium clodronate) is about E2,200 and, once initiated, is 
recommended to be continued as long as skeletal disease remains an important 
problem 
267 
Whilst bisphosphonates have been recommended by NICE as a treatment for patients 
with bone metastaseS266, the benefits of adjuvant bisphosphonates as a therapeutic 
strategy for the prevention of metastatic bone disease in patients with primary 
operable breast cancer has yet to be definitively established. A trial performed by 
Diel et al (1998) showed that, after 2 years treatment and 3 years of follow-up, the 
incidence of both osseous and visceral metastases was significantly lower for patients 
treated with the oral bisphosphonate clodronate compared with the control group. 268 
Moreover, a statistically significant reduction in all cause mortality was observed. 
More recently, a larger and more representative prevention trial has demonstrated 
similar benefits. 269 Specifically, patients treated with clodronate experienced a 
statistically significantly lower rate of bone metastases compared with the placebo 
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controls during a2 year treatment period. This trend was observed at the end of a 5.5 
years follow-up period although the difference was not statistically significant. A 
significant reduction in all cause mortality was observed at the end of the long-term 
follow-up period. Whilst the evidence is suggestive of benefits associated with early 
bisphosphonate use, the indication remains under investigation and a further large trial 
of adjuvant clodronate is currently being conducted. 270 
Given that the early (preventive) use of bisphosphonates is a new indication, it was 
felt that it would make a practical case study for assessing the potential use of discrete 
choice analysis in the design of RCTs. This is primarily because it permits the use of 
a binary choice model formulation (see below). Consequently, a stated preference 
experiment has been designed to generate choice data taking the potential preventive 
use of adjuvant bisphosphonate therapy in primary operable breast cancer as an 
applied case study. However, it is important to note that the analyses which follow 
are exploratory and illustrative i. e. they are not intended as a definitive application of 
the method in this disease area. 
4.4.2 Binary choice model formulation 
in the case study which follows, a clinician is assumed to be faced with a binary 
choice situation in which he or she has to decide between two alternative 
bisphosphonate prevention regimens, i or j. Such binary choice behaviour is a 
special case of the multinomial choice situation described above since decision 
makers are assumed to be faced with exactly two alternative courses of action: 
i= ji, j). Thus, for the binary choice probit model, equation (6) becomes: 
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Pr(i 1 j) = O(V, - Vj) = (Dý'(X, - Xj) (7) 
which is estimated using maximum Uelihood techniques. 
Thus, in this case study we are interested in predicting the probability of product 
adoption given different product benefit and trial design characteristics, X, 
, 
Xj 
associated with the use of adjuvant bisphosphonates. The approach uses stated 
preference data generated from a discrete choice experiment the key design 
components of which are described below. 
4.4.3 Determination of attributes and attribute levels 
The design problem involves selecting, from the generic RCT design characteristics 
previously enumerated in Table 4.1, attributes and levels of specific relevance to the 
bisphosphonates case-study. These were determined by reviewing adjuvant 
bisphosphonate RCT publicationS268-270 and discussing a preliminary (pilot) survey 
design with physicians with specialist knowledge of breast cancer management. The 
specific attributes and levels chosen for the analysis and how they rclate to the generic 
characteristics in Table 4.1 are discussed in turn below and are summarised in Table 
4.2. 
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Table 4.2 
Attributes and Levels for the Stated Preference Survey 
ATTRIBUTES X, 
Endpoint 
The primary measure of 
effectiveness used in the trial 
Effectiveness 
Difference in % of patients achieving 
primary endpoint at the end of the 
trial: (bisphosphonate minus current 
practice) 
Uncertainty 
Width of 95% confidence interval 
for the effectiveness outcome 
Duration 
The duration of observation of 
patients enrolled in the trial 
Population 
Disease stage at diagnosis for 
patients enrolled in the trial 
Cost 
Additional cost of using adjuvant 
bisphosphonate prevention 
(compared with current practice) per 
100 patients treated 
Notes. 
1. Binary variable coded 0 for analysis. 
2. Binary variable coded I for analysis. 
LEVELS 
Patients without metastatic bone disease' 
Patients alive without disease recurrence? 
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1% 
10% 
25% 
40% 
Level I: ±0.01 x% Effectiveness 
Level 2: ±0.25 x% Effectiveness 
Level 3: ±0.75 x% Effectiveness 
Level 4: ± 0.99 x% Effectiveness 
2 years 
4 years 
8 years 
10 years 
Stage III only' 
Stages I, II and 1112 
£0 
£450,000 
£900,000 
£19800,000 
Endpoint. A large number of outcome measurements (endpoints) are usually made in 
RCTs. However, it is usual practice to select one outcome measure (the primary 
endpoint) which is used as the primary basis for discriminating between treatments 
under investigation and for determining the sample sizes required for the study. In 
order to explore the impact of the choice of primary endpoint on the decision to use 
adi vant bisphosphonates, a categorical attribute with two levels was used. The first ju 
level, 'patients without metastatic bone disease', was chosen to reflect a primary 
hypothesis relating to adjuvant bisphosphonates, namely that the incidence of bone 
metastases is reduced as a result of their use. 268; 269 The second level, 'patients alive 
without disease recurrence' was chosen to reflect the fact that disease free survival is 
arguably a more relevant primary endpoint, as reflected in the protocol of a recently 
designed and ongoing trial. 270 The first level was coded '0' for analYSis and the 
second level was coded 'I' for analysis. 
Effectivenes& A challenge in designing this survey was to choose levels for the I- 
effectiveness attribute that would be plausible when combined with the levels of the 
endpoint, study population and duration attributes. It was also necessary to ensure 
that trading would take place (by not choosing attribute levels too close together) and 
that predictions of product adoption could encompass possible improved effectiveness 
of future treatments (by not restricting the levels to previously observed ranges). The 
effectiveness attribute was included as a continuous variable representing the absolute 
difference in the percentage of patients achieving the primary endpoint at the end of 
the trial (% effectiveness for bisphosphonate minus % effectiveness for current 
treatment practice). Four positive levels were chosen (1%, 10%, 25% and 40%) 
which means that only statistically significant improvements in effectiveness in 
100 
favour of bisphosphonate prevention are considered in the analysis. 
Allowing for the considerations mentioned above, the choice of attribute levels was 
informed by interpolating, for different annual time points, effectiveness outcomes 
from results reported for two recent triaIS2W269 (see Appendix 4.1). From this 
interpolation, the smallest statistically significant difference observed was 2% (95% 
confidence interval: 0.33% to 3.67%) and the largest was 18% (95% confidence 
interval: 11.75% to 24.25%). The highest upper limit of the 95% confidence interval 
was 27.05% and the smallest was 0.23%. In order to facilitate respondents' 
interpretation, the effectiveness attribute values were also presented as 'number 
needed to treat' (NNT). 
Uncertainty. A continuous variable attribute was included to assess the impact, on 
the adoption decision, of the degree of precision surrounding the point estimate of 
effectiveness for the primary endpoint. This was achieved by presenting 95% 
confidence intervals for the effectiveness outcomes which were calculated using the 
fonnula: 
95% CI =±P (Effectiveness 
where P, which denotes 'proportion', took on four values: 0.01,0.25,0.75 and 0.99. 
These levels of precision were the values used for the uncertainty variable at the 
analysis stage. The upper value was chosen to ensure that a high degree of 
uncertainty could be accommodated in the design without violating the assumption 
about the statistical significance of the results (see below). In otherwords, the 
constraint that P could not exceed unity ensured that the 95% confidence intervals 
did not straddle zero. The lower limit was chosen to accommodate a very low 
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degree of uncertainty. The selection of the intermediate values was arbitrary, being 
equidistant from the upper and lower values. In addition to presenting respondents 
with the 95% confidence intervals expressed as percentages, they were also presented 
in terms of NNT for the reasons stated for the effectiveness attribute above. 
Duration. In order to assess the impact of duration of subject follow-up on the 
decision to use adjuvant bisphosphonates, duration of observation was included in the 
design as a continuous variable attribute with four levels: 2,4,8 and 10 years. These 
values were chosen to ensure that the range encompassed the periods of observation in 
two reported trials. Diel et al reported a median period of follow-up of 3 years, 
although some subjects were observed for as long as 7 years. 268 In the Powles et al 
trial, the median period of follow-up was 5 years with a maximum of 9.5 years. 269 
The lowest level was chosen because it represents the duration of bisphosphonate 
prevention medication given in both trials. 
Population. Patients with primary operable breast cancer can be classified into three 
stages of disease at diagnosis (Stages 1, Il and III) which reflect how advanced the 
disease is at presentation. Recent studies permitted the enrolment of patients from 
each of these three stages, although one study enrolled only subjects who were 
deemed to be at high risk of developing bone metastases. 268 In order to explore the 
impact of choice of study population on the decision to use adjuvant bisphosphonates, 
a categorical attribute with two levels was included in the survey design. The first 
level represented contemporary trial design practice of enrolling any patient with 
primary operable breast cancer i. e. with Stages 1,11 or III disease at diagnosis. The 
second level was chosen to depict an arguably less representative trial in which only 
patients with Stage III disease at diagnosis were enrolled. Since this 
102 
population has more advanced disease, such a trial would depict a desire on the part of 
a study sponsor to demonstrate a therapeutic benefit in a shorter period of time. A 
priori, one would expect respondents to prefer a trial which is more representative of 
the actual population being treated hence the first level was coded 'I' for analysis and 
the second level was coded '0'. 
Cost. In order to assess the impact of the cost of using bisphosphonates on the 
decision to use them, cost was included in the design as a continuous variable 
attribute with four levels: EO, E450,000, E900,000 and E1,800,000. For consistency 
with the measurement of effectiveness, the levels were defined as the additional cost 
of using adjuvant bisphosphonate prevention (compared with current practice) per 100 
patients treated. Moreover, in the introduction to the discrete choice task, it was 
pointed out that the cost related to the period of the trial and that the value could 
reflect different product formulations and durations of medication. The level 
E450,000 reflects the approximate UK price for the oral clodronate dosing regimen 
used in the Powles et al trial. 
267; 269 The other levels were chosen to provide a wide 
range of cost possibilities which could reflect, for example, different pricing policies, 
dosing regimens or duration of bisphosphonate prevention medication. 
Other RCT design attribute consideration& Not all the RCT design characteristics 
presented in Table 4.1 appeared explicitly as attributes in the case-study survey design 
although all but study setting were covered in the survey questionnaire in some way. 
Those that were not included as attributes are considered briefly in turn below. 
Comparator& The choice of Comparator is an important aspect of RCT design. Since 
adjuvant bisphosphonate prevention is not currently standard practice, the issue of 
103 
comparing explicitly against an alternative prevention regimen does not arise. The 
choice of comparator was not therefore included as an attribute in the discrete choice 
survey. Instead, in the introduction to the discrete choice tasks, respondents were 
asked to assume that the evidence presented came from trials where standard practice 
was permitted in both arms of the trial, including the use of bisphosphonates, as 
appropriate, in the event of relapse (see questionnaire in Appendix 4.2). These 
assumptions reflect the practice actually adopted in recent trials. Thus, the 
comparators were assumed to be standard practice plus placebo versus standard 
practice plus bisphosphonate prevention. 
Statistical propertie& The survey did not include any attributes pertaining to the 
statistical properties of the hypothetical RCT designs, such as sample sizes, 
probabilities of type I and type II errors or the statistical methods used to analyse the 
data. However, in the introduction to the discrete choice tasks, respondents were 
asked to assume that the results presented to them were statistically significant at the 
conventional 5% level and, more generally, that the trials were well conducted (see 
survey questionnaire in Appendix 4.2). 
Setting. No reference was made to the setting of the study, such as whether the trial 
was conducted in a number of centres or in a number of countries. Since the 
respondents are likely to be fan-ffliar with RCTs conducted in this context, it is 
reasonable to suppose that they would expect such studies to be multinational, 
multicentre trials. 
Thus, the final design was based on the six attributes as decribed above. These were 
used to produce hypothetical RCT design scenarios using the method described 
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below. 
4.4.4 Generation of the discrete choice RCT design scenarios 
The number of RCT design scenarios which can be defined given the attributes and 
2 levels shown in Table 4.2 is 44 x2= 1024 (the full factorial). In order to construct a 
cognitively manageable number of binary choice questions, an orthogonal fraction 
was obtained using SPEED experimental design software. "' This resulted in a set of 
16 RCT profiles as shown in Table 4.3. A key property of this fraction of profiles is 
that the attributes are not correlated, and that the levels appear the same number of 
times. 
In order to generate the binary choice questions to present to respondents, a method 
described by Louviere, Hensher and Swait (2000) was used. 206 This involves pairing 
each of the 16 RCT profiles shown in Table 4.3 with a different RCT profile 
randomly selected from a duplicate set. This process resulted in 16 choice sets. The 
differences between the attribute levels for each choice set are shown in Table 4.4. In 
order to minimise the problem of multicollinearity, the differences in attribute levels 
must not be significantly correlated. The absence of statistically significant 
correlations at conventional levels confmns that the resulting experimental design is 
reasonably orthogonal. 
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Figure 4.1 
Example Binary Choice Question 
Trial Design Characteristics Bisphosphonate 
Prevention A 
Primary endpoint Patients alive without 
disease recurrence 
Difference in % of patients achieving primary 10% 
endpoint at the end of the trial 
(bisphosphonate minus placebo) NNT = 10 
95% confidence interval on the primary 2.50% to 17.50% 
endpoint 
NNT = 5.71 to 40.00 
Duration of observation 10 years 
Disease stage at diagnosis for patients Stage III only 
enrolled in the trial 
Additional cost of using adjuvant E 1,800,000 
bisphosphonates Per 100 Patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention B 
Patients without 
metastatic bone 
disease 
1% 
NNT = 100 
0.75% to 1.25% 
NNT = 80.00 to 133.331 
8 years 
Stages 1,11 and III 
E 1,800,000 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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In the study questionnaire presented to respondents, the choice sets were formed into 
16 binary choice questions. Respondents were asked to consider each choice and then 
indicate which alternative they would prefer based on the profile descriptions 
presented. Figure 4.1 provides an example of one of the choice questions presented to 
physicians in the stated preference survey. The study questionnaire is presented in 
full in Appendix 4.2. 
4.4.5 Formulation of non-choice questions 
A number of additional (non-choice) questions were included in the survey 
instrument. These covered a number of factors including: 
i) Characteristics of the respondent: specialty, grade and budget 
responsibilities 
ii) Patient caseload by stage of disease at diagnosis 
iii) Respondent views on the relative importance of different decision- 
makers in the product adoption decision (to assess the extent to which 
the sample covered the important decision-makers) 
iv) The importance of different trial design characteristics (to assess 
whether or not important attnibutes were omitted from the design) 
V) The importance of different endpoints (to assess whether or not 
important endpoints were omitted from the design) 
vi) The difficulty of completing the questionnaire and the time taken by 
both the respondent and interviewer (to assess the practicality of the 
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survey). 
In addition to the above, respondents were invited to make comments on any aspect of 
the survey. The format of the non-choice questions can be seen in the full survey 
instrument which is presented as Appendix 4.2. 
4.4.6 Sample selection and survey administration 
A pfio? i, a number of decision-makers and other influences can be hypothesized to 
affect the product adoption decision. One issue is whether to sample individuals or a 
collective decision-making unit. In this study, it was decided to focus on a sample of 
senior physicians selected primarily from the specialties which, a priori, are the most 
actively involved in the management of patients with this condition and, 
consequently, the choice of adopting the new treatment regimen or not. 
The population from which the sample was selected was identified from a proprietary 
database containing details of UK physicians including their specialty and contact 
detailS27 1A search of the database was performed in order to identify clinicians 
involved in the management of breast cancer. The results of the search are 
summarised in Table 4.5. 
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Table 4.5 
Stated Preference Survey Sample 
Specialty' Population 2 Invited to Agreed to Completed the 
participate participate questionnaire 
Medical 32 21 18 14 
oncologist (85.71%) (66.67%) 
Clinical 284 58 18 16 
oncologist (31.03%) (27.59%) 
Surgical 28 22 19 17 
oncologist (86.36%) (77.27%) 
Radiologist 33 9 5 2 
(55.56%) (22.22%) 
Other 17 15 10 5 
(66.67%) (33.33%) 
Total 394 125 70 54 
(56.00%) (43.20%) 
Notes. 
1. Specialists were senior registrar grade or higher and actively involved in breast 
cancer management. 
2. Identified from The Medical Directory, FT Business Ltd, 1999.271 
3. Percentages are the response rates relative to the number invited to participate. 
III 
In this survey, the questionnaire was administered using a telephone-mail-telephone 
technique which involved the following three steps: 
i) Calling potential respondents to enlist involvement and, if willing to 
participate, to arrange a telephone follow-up interview 
ii) Mailing the questionnaire to participants to review the materials and 
complete the responses, and 
iii) Follow-up telephone interviews to record responses on paper. 
A professional market research agency was commissioned to implement the survey, 
although they were not involved with the design of the questionnaire, the processing 
of the data, the statistical analysis or the interpretation of the results. All completed 
questionnaires were mailed to the author who processed and analysed the data. 
Prior to the implementation of the full survey, simulations based on pilot data (4 
completed questionnaires) were used to assess the results with different sample sizes. 
In this way, a sample in excess of 25 respondents was deemed necessary although a 
target of 100 was set within the data collection budget available. Afmalsampleof54 
was achieved (see Table 4.5 and the results section below). 
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4.4.7 Model specification and estimation 
In order to estimate a binary choice probit model of the demand for bisphosphonates 
as postulated in equation (7) above, the following linear additive utility function was 
assumed: 
AV=AAENDPOINT +, 62 AEFFECTIVENESS + P3AUNCERTAINTY + 
, 
84 AD URA TION + fls APOP ULA TION +, 86 A COST +c 
(8) 
where AVis the difference in utility between the two bisphosphonate prevention 
regimens, AEATDPOINT is the difference in the primary endpoint, 
AEFFECTIVENESS is the difference in the effect size demonstrated, 
AUNCERTAIN7T is the difference in the degree of uncertainty surrounding the 
demonstrated effectiveness, ADURATIONis the difference in the duration of 
observation, APOPULATION is the difference in study population and ACOST is 
the difference between the incremental cost associated with bisphosphonate use. 
, 
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- 
fl6 are the parameters to be estimated, and c is the unobservable error term for 
the model which reflects the unobservable factors in the utility function. Given that 
the choice alternatives presented to respondents are couched in 'generic' terms (i. e. 
Prevention A and Prevention B), models were estimated without a constant. 
The explanatory variables are measured as the differences between the levels of the 
attributes appearing in the 16 choice questions (prevention A minus prevention B) as 
shown in Table 4.4. AV is measured as a binary variable which takes on the value 
11, if prevention A is chosen (the left hand side of the choice sets) and '0' if 
prevention B is chosen (the right hand side choice). 
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Models were estimated using the probit (cluster) command in Stata version 7 
(Stata). 262 A regression error specification test (RESET) was applied to each model in 
order to determine whether there were problems associated with the functional form 
of the model. 265 Any model failing the RESET test at conventional levels of 
significance (p < 0.05) would be regarded as being inis-specified. 
Models were estimated for the full sample of respondents and for two sub-groups of 
'consistent traders' identified using the definitions of inconsistent and non-trading 
respondents given below. 
Consistent traders sub-group A. In this survey, a test for consistency fell naturally 
from the random pairing of the choice scenarios since two choice sets contained the 
same profiles (see choice sets 10 and 12 in Table 4.4 and Appendix 4.2). One would 
expect a respondent who is consistent with their answers to select the same scenario 
for both of these choices. An advantage of this definition over the conventional 
approach described below is that it is not necessary to have prior expectations about 
the qualitative effects to perform this test. In this study it is therefore regarded as the 
primary test of consistency. Respondents who failed to choose the same scenario for 
choice sets 10 and 12 were dropped for this sub-group analysis together with non- 
trading respondents. Non-trading respondents were identified at the analysis stage by 
examining those individuals who exhibited any one of the choice patterns shown in 
Table 4.6. 
Consistent traders sub-group AA sub-group analysis was also performed based on 
a conventional test of consistency. Table 4.4 shows four choice sets for which the 
preferred scenarios might be predicted given the expected signs of the coefficients. 
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Respondents who failed to make choices in line with those that might be expected for 
choice sets 8,9,13 or 14 were dropped for this sub-group analysis together with non- 
trading respondents who were identified in the same way as for sub-group A above. 
No other sub-group analyses were performed (e. g. separate analyses by specialty) due 
to the relatively small sample sizes to which such analyses would give rise. 
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Table 4.6 
Choice patterns used to define non-trading respondents 
Choice set Endpoint Effectiveness Uncertainty Duration Population 
1 1 1 1 1 0 
2 0 0 0 0 
3 1 0 0 
4 0 1 1 0 
5 1 1 
6 0 0 1 
7 1 0 0 
8 0 1 0 
9 1 0 
10 0 0 
11 0 1 1 0 
12 1 1 0 
13 0 1 0 0 
14 1 0 1 
15 0 0 1 
16 1 0 1 1 1 
Cost 
I 
0 
0 
0 
0 
1 
1. Non-trading respondents were deemed to be those who exhibited the choice 
patterns specified in the columns of Table 4.6. A '1' in a column indicates that 
bisphosphonate prevention option A was chosen and '0' indicates the choice of option 
B. 
116 
4.5 RESULTS: NON-CHOICE QUESTIONS 
In this section, the results of the non-choice question components of the stated 
preference survey are presented. Many of the results tables referred to in this section 
can be found in Appendix 4.3. Such tables are denoted Table A4.3.1, A4.3.2 etc. 
4.5.1 Study population and sample 
The survey response rate, by specialty, is shown in Table 4.5. A total of 394 
specialists were identified of which 125 (31.73%) were invited to participate in the 
survey. Of those invited to participate, 55 (44.00%) refused and 70 (56%) accepted. 
Of those agreeing to participate, questionnaires were obtained from 54 providing an 
overall response rate of 43.20%. Therefore a sample of 54 questionnaires was 
obtained within the budget constraint and the completion rate for those who 
responded was 100%. 
4.5.2 Respondent characteristics 
The composition of the 54 respondents in terms of their specialty and title are shown 
in Table A4.3.1. The sample included 17 surgical oncologists (31.48%), 14 medical 
oncologists (25.93%) and 16 clinical oncologists (29.63%). Forty respondents 
(74.07%) were senior registrar grade or higher. At the time the survey was conducted, 
only one of the respondents was not involved in the day-to-day management of 
patients with breast cancer. The annual number of new cases of breast cancer seen by 
the respondents is summarised, by specialty, in Table A4.3.2. For the sample as a 
whole, the average number of new cases seen each year is 176.37 (SD = 142.42). The 
estimated distribution of new cases by stage of disease at diagnosis is shown in Table 
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A4.3.3. Only 14 respondents (25.93%) indicated having any involvement with the 
management of budgets related to the treatment of patients with breast cancer (Table 
A4.3.4). The nature of that responsibility, exactly as articulated by the respondents, 
can be found in Table A4.3.15. 
4.5.3 Survey completion 
Apart from the optional open-ended questions, there were no missing responses. It 
can be seen from Table A4.3.5 that only 2 respondents found the questionnaire "very 
difficult" to complete. 22 respondents (40.74%) found the questionnaire "moderately 
difficult" to complete, 18 (33.33%) found it "slightly difficult" to complete and 12 
(22.22%) found it "not difficult" to complete. Respondents spent an average of 26.76 
minutes (SD = 13.11) reviewing the materials and preparing their responses for the 
telephone interview (Table A4.3-6). The telephone interviews lasted an average of 
11.41 minutes (SD = 4.56). Therefore in total respondents spent an average of 38.17 
minutes (SD = 13.32 ) participating in this survey. 
Of the 54 respondents, 48 (88.89%) indicated a willingness to participate in future 
research. This required their personal details to be disclosed (Table A4.3.7). The 
same number indicated that they would like to see the results of the study (Table 
A4.3.8). Finally, 30 respondents (55.56%) provided comments on the questionnaire 
(Table A4.3.9). The comments, exactly as articulated by the respondents, can be 
found in Table A4.3-16. 
4.5.4 Influences on the decision to use adjuvant bisphosphonates 
Respondents were asked to rate the importance of a predetermined list of specialties 
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on a3 point ordinal scale: 
i) High degree of influence on the decision to adopt bisphosphonates 
(coded I for analysis) 
Some influence on the decision to adopt bisphosphonates (coded 2 for 
analysis) 
No influence on the decision to adopt bisphosphonates (coded 3 for 
analysis). 
The results of the analysis of the responses to this question using the above coding are 
shown in Table A4.3.10. Medical oncologists (mean rating 1.15, SD = 0.41), 
radiotherapists (1.35, SD = 0.55) and surgical oncologists (1.80, SD = 0.59) were 
viewed as the specialties with the highest degree of influence on the decision to use 
bisphosphonates. 
36 respondents (66.67%) indicated that important influences on the decision to use 
bisphosphonates were missing from the list of specialties provided (Table A4.3.1 1). 
These are shown, exactly as articulated by the respondents, in Table A4.3.17. The 
missing influences cited were other specialties (16 citations, 33.33% of all citations), 
nurses (14,29.17%), patients / relatives / patient support groups (11,22.92%), 
managers / policy makers (6,12.50%) and the media (1,2.08%). 
4.5.5 Importance of adjuvant bisphosphonate trial design characteristics 
Respondents were asked to rate the importance of a predetermined list of trial design 
characteristics on a4 point ordinal scale: 
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i) Very important characteristic (coded I for analysis) 
ii) Quite important characteristic (coded 2 for analysis) 
iii) Characteristic of little importance (coded 3 for analysis) 
iv) Characteristic not important (coded 4 for analYSis). 
The results of responses to this question using the above coding are shown in Table 
A4.3.12. The results confim the importance of the six trial design characteristics 
included in the discrete choice exercise. Four of these characteristics (primary 
endpoint, statistical significance, effect size and study population) had a mean rating 
close to I (very important) and two (duration of observation and comparators) had a 
mean rating between 1 (very important) and 2 (quite important). The other 
characteristics included in this question (lead investigators, countries in which the trial 
is conducted and organisation sponsoring the trial) had mean ratings tending towards 
3 (of little importance). The choice of primary endpoint (mean rating 1.15, SD = 
0.49), statistical significance (1.22, SD = 0.46) and effect size (1.26, SD = 0.44) were 
the three most important design characteristics. 
4.5.6 Importance of bisphosphonate trial endpoints 
Respondents were asked to rank a predetermined list of bisphosphonate trial primary 
endpoints in order of importance with I being the most important endpoint and 8 
being the least important. The results of responses to this question using the above 
coding are shown in Table A4.3.13. The two endpoints used in the discrete choice 
exercise, percentage of patients alive without disease recurrence and percentage of 
patients without metastatic bone disease, were ranked as the most important and 
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third most important endpoints respectively. The former had a mean ranking of 2.43 
(SD = 1.80) and the latter 3.91 (SD = 1.94). The additional cost associated with the 
use of adjuvant bisphosphonates was ranked as the least important endpoint (mean 
6.81, SD = 1.59). 
Six respondents (12.97%) indicated that important endpoints were missing from the 
list provided (Table A4.3.14). These are shown, exactly as articulated by the 
respondents, in Table A4.3.18. It can be seen that 5 of the II ornissions cited could 
be referred to as 'clinical' endpoints (e. g. serum calcium levels) and the remainder as 
6economic' endpoints (e. g. cost per QALY). 
4.6 RESULTS: DISCRETE CHOICE MODEL ESTIMATION 
In this section, the results of the discrete choice model probit regression analysis are 
presented in terms of the qualitative and quantitative effects. 
4.6.1 Qualitative effects 
For each of the three models estimated, the signs on the attribute coefficients suggest 
identical qualitative effects (see Table 4.7). These are surnmarised below. 
1) Choice ofprimary endpoint The coefficient for this attribute (Endpoint) 
has a positive sign which implies a preference for disease free survival 
over the incidence of metastatic bone disease as the primary endpoint in 
adjuvant bisphosphonate trials. Consequently, this suggests that a product 
is more likely to be chosen if a trial demonstrates an improvement in the 
proportion of patients alive without disease recuff ence compared with one 
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that shows an improvement in the incidence of metastatic bone disease. 
2) Effectiveness. For the effectiveness attribute (Effectiveness), the 
coefficient has a positive sign suggesting that the probability of adopting a 
product is an increasing function of the level of effectiveness 
demonstrated, regardless of the choice of primary endpoint. 
3) Degree of uncertainty surrounding the point estimate of effectiveness. 
The sign on the coefficient of the uncertainty variable (Uncertainty) is 
negative which indicates that the preference for a product decreases as the 
degree of uncertainty surrounding the point estimate of effectiveness 
increases. 
4) Duration of observation. The positive sign on the coefficient for this 
attribute (Duration) suggests a preference for trials of longer durations. In 
other words, the probability of adopting a product is an increasing function 
of the duration of evaluation of its benefits. 
5) Study population. A product whose benefits are demonstrated in a trial 
which enrolls patients with all stages of primary operable breast cancer is 
more likely to be chosen than one whose enrohnent is restricted to subjects 
with Stage III disease at diagnosis. This is indicated by the positive sign 
on the study population coefficient (Population). 
6) Incremental cost of adjuvant hisphosphonate use. The negative 
coefficient for the cost attribute (Cost) suggests that the lower the 
incremental cost of using a bisphosphonate prevention strategy the more 
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likely it is to be chosen. 
To summarise the above findings, the qualitative effects (signs for the attribute 
coefficients) are in line with the author's prior expectations which provides evidence 
of the theoretical validity (internal consistency) of the estimated models. 
4.6.2 Quantitative effects 
Table 4.7 shows the primary results of this analysis. A Ramsey regression error 
specification test (RESET) suggests there is no problem with the functional form of 
any of the three models. The null hypothesis that all of the coefficients are 
simultaneously zero can be rejected on the basis of the Wald test (p < 0.01 in each 
case). Independently, attnibutes are statistically significantly different from zero at the 
5% level or better with the exception of the duration variable which is borderline 
significant in both the 'full sample model' and the 'consistent traders sub-group A' 
model (p = 0.06 in both cases). These results indicate that each of the RCT design 
attributes included in the analysis is important in the decision to adopt adjuvant 
bisphosphonate treatments and that most respondents were willing to trade off 
different RCT design characteristics. 
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Table 4.7 
Probit Regression Results' 2 
(1) (2) (3) 
RCT Design Attributes Full Sample Consistent Consistent 
Traders: Sub- Traders: Sub- 
group A3 group B4 
Endpoint 0.2787*** 0.2700*** 0.3185*** 
[0.0522] [0.0630] [0.0625] 
Effectiveness 0.0457*** 0.0390*** 0.0464*** 
[0.0061] [0.0068] [0.0068] 
Uncertainty 
-0.6210*** -0.6653*** -0.7844*** [0.0746] [0.09871 [0.0725) 
Duration 0.0255* 0.0301 * 0.0482*** 
[0.0134] (0.0159] [0.0136] 
Population 0.2419*** 0.2675*** 0.3292*** 
[0.0563] [0.06511 [0.0704] 
Cost 
-5.43e-07*** -5.86e-07*** -5.95e-07*** [5.97e-08] [7.36e-08] [6.97e-08] 
Observations 864 608 656 
Respondents 54 38 41 
Log likelihood 
-399.35 -285.18 -290.39 
Wald chi2 (6) 238.95 163.01 241.27 
Prob > chi2 0.0000*** 0.0000*** 0.0000*** 
Ramsey chi2(l) 0.30 0.10 0.01 
Prob > chi2 0.5861 0.7485 0.9060 
Correct predictions 79.28% 79.93% 81.10% 
Notes. 
1. Models were estimated using the probit (cluster) option available in Stata 
Version 7 
. 
0.262 This estimator takes into account the potential non-independence 
of the observations and generates robust standard errors (shown in brackets). 
2. Significance levels are denoted as follows: * significant at 10%; ** significant at 
5%; *** significant at 1% 
3. Inconsistent respondents were defined as those who did not choose the same 
scenario for choices 10 and 12 (n=10). Non-trading respondents were defined as 
those who exhibited dominant preferences for any attribute (n--7). Dropping 
these respondents left a sample of 38 consistent traders (one respondent was both 
inconsistent and a non-trader). 
4. Inconsistent respondents were defined as those who did not choose the options 
expected for choices 8,9,13 or 14 (n=6). Non-trading respondents were defined 
as those who exhibited dominant preferences for any attribute (n=7). Dropping 
these respondents left a sample of 41 consistent traders. 
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The primary interest in this analysis is with using the regression results to compare the 
predicted probabilities of product adoption contingent upon alternative RCT designs. 
These can be computed using the regression results from Table 4.7 and Equations (7) 
and (8). Therefore sponsors of RCTs could use the regression results from product- 
specific stated preference surveys in a number of ways, including to: 
1) Evaluate the impact of different RCT designs on the probability of product 
adoption; 
2) Determine a technically feasible design which maximises the expected 
predicted probability of product adoption, and 
3) Operationalise an investment appraisal approach to RCT design. 203 
Each of these uses is illustrated briefly in section 4.7 below. 
4.7 USING DISCRETE CHOICE MODEL RESULTS IN RCT DESIGN 
A number of potential uses of discrete choice modelling results in the context of RCT 
design are considered below. It must be emphasised that although this analysis is 
based around a case study of adjuvant bisphosphonate trials, the material presented 
below is purely illustrative. The main body of the text focuses on the results. The 
forinulae, working assumptions and example calculations are presented in Appendix 
4.4. 
4.7.1 Impact of RCT designs on the probability of product adoption 
One potential use of DCM results is to compare and rank alternative RCT designs in 
terms of the predicted probabilities of product adoption to which they give rise. 
125 
Specifically, given a set of candidate designs, sponsors of RCTs could use the results 
to select the design which gives the highest predicted probability of product adoption, 
Pr(A I J). This is equivalent to choosing the design with the highest decision-maker 
preference or utility score, A VAB 
- 
Table 4.8 and Figure 4.2 illustrate this application of the results by comparing the 
predicted probabilities of each of seven hypothetical candidate designs against a 
hypothetical baseline (existing) treatment. The differences in utility, AVAB 
, 
are 
calculated by substituting the regression coefficients from the full sample model 
(Table 4.7) and the differences in the values of the RCT design attributes into 
Equation (8). The predicted probabilities are calculated by substituting the resulting 
utility values into Equation (7). An example calculation is provided in Appendix 4.4. 
in Table 4.8, designs I to 6 differ from the baseline design only in terms of the level 
(value) of one RCT design attribute. This is done in order to illustrate how the impact 
on Pr(A I J) of changing the value of only one RCT design characteristic can be 
evaluated. For example, Design I differs from the baseline in ten-ns of the choice of 
primary endpoint. This gives rise to a predicted probability of adoption of 
approximately 0.61. With a design identical to the baseline, the predicted probability 
would be 0.50. In contrast, hypothetical RCT Design 7 is defined as having the "best" 
attribute values shown in Table 4.2. This means that this design has "bettee' design 
characteristics than the baseline for all attributes except study population (which is the 
same). Consequently, Design 7 has the highest predicted probability amongst the 
RCT designs compared in Table 4.8. The ranking of the designs in descending order 
of their predicted probabilities is shown in the last row of Table 4.8. 
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Whilst it is informative to compare selected candidate RCT designs in this way, this 
approach does not identify an optimal (predicted probability maximising) design 
because all possible combinations of attribute values are not considered. Moreover, 
the calculations do not allow for the fact that the 'Effectiveness' and 'Uncertainty' 
attribute values are, prior to the conduct of a trial, uncertain. Thus, of more practical 
value is to identify a trial design which maximises the expected predicted probability 
of product adoption. How this can be done is illustrated in section 4.7.2 below. 
4.7.2 Identifying a design that maximises the expected probability of product 
adoption 
At the planning stages of an RCT, the predicted probability of product adoption given 
by Equation (7) is uncertain since the results of a trial are unknown. Specifically, for 
the case study presented in this chapter, the uncertainty surrounding the predicted 
probabilities stems from the uncertainty surrounding the results of trials with respect 
to the 'Effectiveness' and 'Uncertainty' attributes. Since it is desirable to consider 
alternative RCT designs in a way which allows for this uncertainty (i. e. in terms of 
expected predicted probabilities), it is necessary to calculate the expected values for 
the 'Effectiveness' and 'Uncertainty' outcomes for any trial design under 
consideration. The expected values are then used for the calculation of predicted 
probabilities using Equation (7). 
Making use of an approach previously described by Backhouse (1998)203 and Detsky 
(1985; 1 990), 152; 154 expected 'Effectiveness' and 'Uncertainty' outcomes have been 
calculated to produce the illustrative results presented in Figure 4.3 (see Appendix 4.4 
for formulae, working assumptions and example calculations). Figure 4.3 shows 
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expected predicted probabilities, over a range of trial sample sizes, for six 
hypothetical RCT designs when compared against the baseline treatment presented in 
Table 4.8. In order to simplify the exposition, the six designs differ from the baseline 
only in terms of i) the choice of primary endpoint (patients without metastatic bone 
disease (MBD)) or patients alive without disease recurrence (DFS)) and / or ii) the 
duration of the trial (2,5 or 8 years). It can be seen that, upto a total sample size of 
approximately 440 subjects (220 per arm), a trial of 2 years duration with MBD as the 
primary endpoint gives rise to the highest expected predicted probability. Thereafter, 
a trial with 8 years of follow-up and DFS as the primary cndpoint has the highest 
expected predicted probability of adoption. This is the design which maximises the 
expected predicted probabilities given the working assumptions. It should be 
emphasised that these results are purely illustrative and are sensitive to the 
assumptions made in their derivation, particularly the distributions of the prior 
expected outcomes (see Appendix 4.4). 
A problem with this approach to RCT design is that, whilst an expected predicted 
probability maximising design can be identified, it may not be optimal from a 
commercial (profit maximising) perspective. This is because it does not take account 
of costs and time to market and hence the timing of revenues. It is therefore necessary 
to extend this analysis to consider the cost and revenue implications of alternative 
RCT designs. 
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4.7.3 Using DCM results within an investment appraisal framework 
Backhouse (1998) has shown how pharmaceutical companies could take profit 
considerations into account when making decisions about the design of their RCTs. 203 
In this section, the hypothetical trial designs considered in section 4.7.2 above are 
used, together with the same assumptions, as a basis for illustrating how a 
commercially optimal (expected net present value maximising) design can be 
identified. In order to do this, a number of additional simplifying assumptions are 
made about the costs of perfonrdng the bisphosphonate trials, market size, product 
uptake and the time horizon for the commercial appraisal. The assumptions made can 
be found in Appendix 4.4 together with the formulae used and example calculations. 
Figure 4.4 shows the expected net present values (NPV), as a function of sample size, 
for each of the six hypothetical RCT designs considered in section 4.7.2 above. For 
each individual trial, the optimal sample size is that for which the expected NPV 
curve is at its maximum. It can be seen that, for all sample sizes up to at least 5000 
subjects in total, a trial of 2 years duration with MBD as the primary endpoint gives 
rise to the highest expected NPV. The expected NPV maximising design occurs at a 
total sample size of approximately 3200 subjects (1600 per arm) and has an NPV of 
about El 15 millions. A notable feature of this finding is that it serves to illustrate that 
a design which maximises expected NPV is not necessarily the design which 
maximises the expected predicted probability of product adoption. 
once again, it is important to emphasise that the calculations presented in this chapter 
are for illustrative purposes only and that the findings are sensitive to the various 
assumptions that need to be made for this type of analysis. 
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4.8 DISCUSSION AND CONCLUSION 
The results from this exploratory study suggest that the application of discrete choice 
modelling to stated preference data provides a promising method for incorporating the 
preferences of decision-makers into the design of RCTs. Specifically, this chapter 
illustrates how such empirical analyses of decision-makers' preferences for RCT 
design characteristics can be used to estimate the probabilities of product adoption 
contingent upon different designs. It has been shown how the probabilities can be 
used to determine preference maximising and profit maximising RCTs. The findings 
also suggest that the approach is both practical and theoretically valid in this context. 
Few respondents had difficulty understanding and completing the questionnaire, there 
was no missing data and the total time respondents spent on the survey was less than 
one hour. All but six participants expressed both a willingness to participate in any 
further stages of the research and an interest in seeing the results. The qualitative 
effects for the RCT design attributes included in the analysis are in line with prior 
expectations, each was found to be a statistically significant determinant of the 
decision to adopt a new product and most respondents were prepared to make trade- 
offs between them 
Despite the promising results, a number of issues need to be considered in future 
research and practical applications. Firstly, this analysis utilised preferences elicited 
from clinicians from different specialties involved in the management of patients with 
I 
breast cancer. This implies that other decision-makers are not involved in the product 
adoption decision and that each specialty represented in the sample carries equal 
weight. If these assumptions do not hold, then the predicted probabilities of product 
adoption will be unreliable. Respondents in this survey confirmed 
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the importance to the product adoption decision of the specialties that made-up most 
of the sample. But they also indicated that the influence of other parties should be 
considered, notably patients and other specialties involved in the management of 
breast cancer. If the preferences of physicians and patients are aligned, then the 
results which focus on the former will be robust. There would be practical challenges 
in applying this type of survey to patients because they may not be familiar with the 
tenninology and practices of RCT design. This would be a valuable area for future 
researclL 
It is notable that very few respondents indicated that the influence of decision-making 
and advisory bodies such as formulary committees and NICE were important. 
Nevertheless, how such groups formulate their decisions and the preferences 
underlying them is both a fundamental and topical issue 
. 
272X3 Therefore the potential 
for applying discrete choice analysis to members of such bodies would be a 
worthwhile line of future investigation since it offers a feasible means of explicitly 
quantifying the preferences of key stakeholder groups. 
Secondly, the example application chosen for this study lent itself readily to the use of 
a simple binary choice model of drug prescribing. This is because adjuvant 
bisphosphonates are not currently established as a therapeutic strategy for the 
prevention of metastatic bone disease and so the choice problem could be simplified 
to the decision to use them or not contingent upon the RCT designs and results. 
Clearly, many treatment choice situations will be less straightforward as physicians 
are often presented with more than two possible courses of action. In such situations, 
it may be necessary to construct more complex multinomial modeW04 of drug 
prescribing behaviour which would in turn require more complex stated 
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preference choice surveys for their application. 206 Moreover, the results from a 
survey conducted for one product indication will not be generalisable to another 
which could, for example, lead to a large number of studies required for a sponsor of 
multiple technologies. So the number, size and complexity of stated preference 
surveys would necessitate consideration being given to the potential benefits and costs 
associated with the research effort. 
Thirdly, the stated preference survey presented respondents with a series of binary 
choices for which they were required to indicate a preference for one of the two 
adjuvant bisphosphonate prevention options. Respondents were not given the 
opportunity to indicate that they would prefer an alternative other than the two 
presented in any given choice set. In other words, they were not given the 
opportunity to 'opt-out'. A review of applications of discrete choice experiments to 
health care programmes confirms that this approach is consistent with previous 
practice. 274 However, it has recently been pointed out that the inclusion of an opt-out 
option may better mimic the circumstances under which actual choices are made and 
may therefore give rise to more reliable estimates of product or service adoption. 275 
But there are also disadvantages of including opt-out alternatives. Subjects may 
choose the opt-out alternative simply to avoid making difficult trade-offs and it may 
not be possible to derive the attribute levels (characteristics) of the opt-out option. 275 
Both of these factors could significantly reduce the number of observations available 
for analysis. Furthermore, research conducted outside the health field suggests that 
estimates of attribute weights and demand can be sensitive to the format of the opt-out 
alternative presented to respondentS. 276 Clearly, further research is required into the 
issue of obtaining reliable predictions of actual choice behaviour from discrete choice 
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stated preference surveys. In this respect whether and how to include an opt-out 
alternative is one of a number of aspects to address. 
Fourthly, the model parameters were estimated using discrete choice stated preference 
survey data which is currently the most common approach used in health economics 
applications. An alternative would be to use revealed preference dat2 73 i. e. data 
pertaining to actual rather than simulated choices. However, it may not be practical to 
obtain or construct a dataset containing the necessary RCT and product adoption 
variables and such data will clearly not be available for new products. It should also 
be noted that it may not be practical to conduct stated preference surveys amongst 
some decision-makers e. g. NICE appraisal committee members. 
Finally, although aspects of this chapter have illustrated the potential use of DCA 
within a private sector investment appraisal framework, this should not detract from 
the potential value, in other contexts, of modelling product adoption decisions as a 
function of RCT design. For example, a useful line of future research would be to 
explore the conditions under which the private sector perspective on optimal RCT 
designs would be aligned with the societal perspective adopted by NICE. NICE 
considers both clinical effectiveness and cost in formulating its advice and its 
preferred measure for gauging value is the cost per quality adjusted life-year (QALY) 
(the incremental cost-cffectiveness ratio). 272 Approaches to producing optimal trial 
designs from the societal perspective using cost-effectiveness criteria have been 
proposed. 155; 159 The extent to which the private and societal perspectives will yield 
equivalent optimal designs will depend upon the importance of the cost-effectiveness 
ratio in product adoption decisions. Little is known about this relationship and 
although a recent paper used discrete choice modelling to produce insights 
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from recommendations made by NICE, the extent of the impact of the 
273 
recommendations on actual product usage was not explored 
. 
In this study, 
measures of both clinical effectiveness and cost were considered as separate variables 
but the cost per quality adjusted life year gained was not explicitly evaluated by 
respondents. However, in considering whether important endpoints were missing 
from the analysis, only two respondents mentioned the absence of cost per QALY 
information which raises questions about the alignment of physician and NICE 
decision-making criteria. Further research into how cost per QALY data could be 
presented in stated preference surveys would be a beneficial area for further research 
because it is not a measure that is widely understood amongst many stakeholders. 
In conclusion, more sophisticated survey designs and statistical analysis methods may 
be required in future applications in order to correctly model the treatment decision- 
making situation of interest. Nevertheless, the results from this analysis suggest that 
DCA offers a practical and valid method by which sponsors of RCTs could take the 
preferences of decision-makers into account when planning their studies. Therefore 
further research into the application of the technique in this context would seem to be 
worthwhile. 
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Appendix 4.1 
Effectiveness Outcomes Interpolated From Clinical Trials 
Clodronatel Placebo' Difference 2 Lower Upper 
95%CI3 95%CI3 
% Patients without 
metastatic bone disease 
From Powles et al (2002) 
Year 1 99.00 97.00 2.00 0.33 3.67 
Year 2 96.20 93.30 2.90 0.23 5.57 
Year 3 94.00 89.00 5.00 1.67 8.33 
Year 4 91.00 87.50 3.50 
-0.21 7.21 
Year 5 89.00 84.50 4.50 0.45 8.55 
Year 6 86.00 83.50 2.50 
-1.81 6.81 
Year 7 84.50 82.00 2.50 
-1.97 6.97 
Year 8 83.00 80.00 3.00 
-1.65 7.65 
From Diel et al (1998) 
Year 1 100.00 92.00 8.00 3.58 12.42 
Year 2 98.00 88.00 10.00 4.28 15.72 
Year 3 97.00 82.00 15.00 8.20 21.80 
Year 4 92.00 78.00 14.00 6.03 21.97 
Year 5 88.00 75.00 13.00 4.31 21.69 
Year 6 78.00 75.00 3.00 
-6.57 12.57 
Year 7 78.00 75.00 3.00 
-6.57 12.57 
Patients alive 
From Powles et al (2002) 
Year 1 98.00 98.00 0.00 
-1.68 1.68 
Year 2 92.70 92.40 0.30 
-2.85 3.45 
Year 3 90.00 87.00 3.00 
-0.82 6.82 
Year 4 86.50 84.00 2.50 
-1.75 6.75 
Year 5 82.90 79.30 3.60 
-1.09 8.29 
Year 6 81.00 76.50 4.50 
-0.40 9.40 
Year 7 78.50 73.00 5.50 0.37 10.63 
Year 8 78.00 72.00 6.00 0.82 11.18 
Year 9 74.00 65.50 8.50 3.02 13.98 
Year 10 74.00 60.00 14.00 8.43 19.57 
From Diel et al (1998) 
Year 1 100.00 82.00 18.00 11.75 24.25 
Year 2 95.00 78.00 17.00 9.44 24.56 
Year 3 90.00 72.00 18.00 9.31 26.69 
Year 4 80.00 65.00 15.00 5.03 24-97 
Year 5 80.00 63.00 17.00 6.95 27.05 
Year 6 75.00 60.00 15.00 4.54 25.46 
Year 7 75.00 60.00 15.00 4.54 25.46 
1. Data points were interpolated from the survival curves reported in Powles et al (2002)269 and Diel et al (1998 ). 269 
2. Clodronate % minus placebo %. 
3. Confidence intervals for the differences in % effectiveness were calculated using the formula provided by Armitage & 
Berry (1995) pp 128-130.170 
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APPENDIX 4.2 
THE STATED PREFERENCE SURVEY QUESTIONNAIRE 
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Our reference 
Your retercm c 
Direct linc c-nmil 
--A. - VI 
AN 
Nottingham University 
Business School 
8 March 2002 
Dear [Doctor] 
The Use of Conjoint Analysis in the Design of Clinical Trials 
Thank you very much for agreeing to take part in this research. 
jubilce Caillpus 
Wollaton Road 
Nottinghain 
NG8 IBB 
Tel: +44 (0) 115 846 6602 
Fax: +4-4 (0) 115 8-10 6667 
I am a part-time PhD student at the University of Nottingham. As part of 
my research I am conducting a survey to assess how a technique known 
as conjoint analysis might be used to take into account the views of 
health care professionals when designing clinical trials. The work is not 
being conducted on behalf of any sponsoring organisation or company. 
The research will include interviews with specialists like you and I have 
asked Accent Marketing and Research to conduct these interviews on my 
behalf 
I should be gratetbl if you would assist rne with this research by 
spending about 10 minutes reading the enclosed material. Then on the 
(insert date), one of Accent's researchers will telephone you to collect 
your responses to each of the questions. Hence, this material does not 
need to be returned to me. 
The questionnaire does not require you to provide any personal or patient 
information. Furthermore, Accent will not pass on the narnes of those 
who participate in this research to me unless you give your consent for 
this to happen. 
A copy of the results of this survey will be available for all those who 
have taken part in this research. 
if you have any questions relating to the enclosed, please do not hesitate 
to contact me. 
Thank you in advance for your help with this research. 
Yours sincerely. 
Martin E Backhouse 
Enc. 
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INTRODUCTION 
Clinical research has shown that bisphosphonates reduce the incidence of 
hypercalcaernia and pathological bone fractures in patients with established bone 
metastases from breast cancer. Moreover, bisphosphonates have been shown to 
reduce the risk of bone metastases in patients with relapsed breast cancer without 
obvious bone involvement. However, the effectiveness of adjuvant bisphosphonates 
as a preventive therapeutic strategy for patients with primary operable breast cancer 
has yet to be definitively established. 
In the choices which follow, you are asked to imagine that you alone are deciding 
which adjuvant bisphosphonate therapy to use based on the trial evidence which is 
presented. For each choice, you will be asked to compare two alternatives (labelled 
Bisphosphonate Prevention A'andBisphosphonate Prevention B), which differ only 
in terms of the following trial design characteristics and results: 
Primary endpoint: the main measure chosen to compare the effectiveness of 
adjuvant bisphosphonate therapy against no such therapy (placebo) in patients 
with primary operable breast cancer. 
Difference in % of patients achieving the primary endpoint: the effectiveness 
of adjuvant bisphosphonate therapy measured as the difference between the % of 
patients experiencing the primary endpoint in the 'bisphosphonate' and 'no 
bisphosphonate' arms of the trial i. e. adjuvant bisphosphonate % minus no 
adjuvant bisphosphonate %. The results are also shown in the form of the number 
of patients that would need to be treated with bisphosphonates in order for one 
patient to benefit from treatment i. e. number needed to treat (NNT). 
95% confldence interval on the primary endpoint: a measure of the uncertainty 
surrounding the point estimate of the primary endpoint outcome. A range of % 
difference values is presented within which there is a 95% chance that the true 
difference will lie. The 95% confidence interval is also shown in the form of the 
number of patients that would need to be treated with bisphosphonates in order for 
one patient to benefit from treatment i. e. number needed to treat (NNT). 
Duration of observation: the duration of the trial in years (not the duration of 
adjuvant bisphosphonate therapy). It is assumed that all subjects are followed for 
this period of time. The primary endpoint results are those observed at the end of 
this follow-up period. 
Disease stage at diagnosis: the eligible study population defined in terms of the 
stage of primary operable breast cancer at diagnosis (Stages I to III). 
Additional cost of using adjuvant bisphosphonates: the additional cost of using 
adjuvant bisphosphonates compared with not using them i. e. adjuvant 
bisphosphonate cost minus no adjuvant bisphosphonate cost. The cost figure 
presented is the difference per 100 patients for the period of the trial. In the 
choices which follow, no information is provided about the duration of adjuvant 
bisphosphonate therapy i. e. the cost information can reflect different agents and 
different durations of bisphosphonate treatment. 
In making your choices you should assume that: 
1) The efficacy results presented are statistically significant at the 5% level. 
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2) The evidence comes from well-designed, randomised, double-blind 
placebo controlled trials in patients with primary operable breast cancer. 
3) The evidence is the only evidence that is available to make your decision. 
4) The alternatives differ only in terms of the characteristics which are 
presented. 
5) Subjects in both arms of the trial received surgery, chemotherapy, 
hormonal therapy and radiotherapy as required. 
6) In the event of relapse, appropriate local or systemic therapies (including, 
bisphosphonates) were administered as required to subjects in both arrns of' 
the trial. 
7) The adjuvant bisphosphonates were well tolerated i. e. no significant side 
effects were observed. 
PART A 
In this part of the questionnaire you are presented with 16 choices. In each case, 
you are asked to choose only one of the two adjuvant bisphosphonate treatment 
strategies for patients with primary operable breast cancer. Please indicate your 
choice by marking a v"in the appropriate box as shown in the following example: 
Example: 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients alive without 
disease recurrence 
10% 
NNT = 10 
2.50% to 17.50% 
NNT = 5.71 to 40.00 
10 years 
Stage III only 
E 1,800,000 
Bisphosphonate 
Prevention B 
Patients without 
metastatic bone 
disease 
1% 
NNT = 100 
0,75% to 1.25% 
NNT = 80.00 to 133.331 
8 years 
Stages 1,11 and III 
F 1,800,000 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
Now please complete the following choice questions making sure that you choose one 
option for each of the 16 choices. 
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CHOICE 1 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
b1sphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients alive without 
disease recurrence 
10% 
NNT = 10 
2.50% to 17.50% 
NNT = 5.71 to 40.00 
10 years 
Stage III only 
E 1,800,000 
Bisphosphonate 
Prevention B 
Patients without 
metastatic bone 
disease 
1% 
NNT = 100 
0.75% to 1.25% 
NNT = 80.00 to 133.33 
8 years 
Stages 1,11 and III 
f 1,800,000 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Pre ention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
1 
CHOICE 2 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates, Per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients without 
metastatic bone 
disease 
10% 
NNT = 10 
9.90% to 10.10% 
NNT = 9.90 to 10.10 1 
8 years 
Stage III only 
f 900,000 
Bisphosphonate 
Prevention B 
Patients alive without 
disease recurrence 
25% 
NNT = 41 
6.25% to 43.75% 
NNT = 2.29 to 16.00 1 
8 years 
Stages 1,11 and III 
E0 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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CHOICE 3 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients alive without 
disease recurrence 
10% 
NNT = 10 
7.50% to 12.50% 
NNT = 8.00 to 13.33 
4 years 
Stages 1,11 and III 
E 450,000 
Bisphosphonate 
Prevention B 
Patients alive without 
disease recurrence 
1% 
NNT = 100 
0.01 % to 1.99% 
NNT = 50.25 to 
10000.00) 
10 years 
Stages 1,11 and III 
f: 900,000 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
CHOICE 4 
Trial Design Characteristics Bisphosphonate Bisphosphonate 
Prevention A Prevention B 
Primary endpoint Patients without Patients alive without 
metastatic bone disease recurrence 
disease 
Difference in % of patients achieving primary 10% 1% 
endpoint at the end of the trial 
(bisphosphonate minus placebo) NNT = 10) NNT = 100 
95% confidence interval on the primary 0.10% to 19.90% 0.99% to 1.01% 
endpoint 
NNT = 5.03 to 1000.00 NNT = 99.01 to 10 1.01 
Duration of observation 2 years 4 years 
Disease stage at diagnosis for patients Stages 1,11 and III Stage III only 
enrolled in the trial 
Additional cost of using adjuvant E0 f: 0 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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CHOICE 5 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate_m/nus PlacebOL_ 
Bisphosphonate 
Prevention A 
Patients alive without 
disease recurrence 
25% 
ININT = 41 
6.25% to 43.75% 
I NNT = 2.29 to 16.00 
8 years 
Stages 1,11 and III 
E0 
Bisphosphonate 
Prevention B 
Patients alive without 
disease recurrence 
25% 
NINIT = 41 
18.75% to 31.25% 
NINIT = 3.20 to 5.331 
2 years 
Stage III only 
E 900,000 
Which adjuvant bisphosphonate prevention re er Prevention A re r Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
CHOICE 6 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients without 
metastatic bone 
disease 
25% 
NNT =4 
24.75% to 25.25% 
NNT = 3.96 to 4.04 
10 years 
Stages 1,11 and III 
f 450,000 
Bisphosphonate 
Prevention B 
Patients without 
metastatic bone 
disease 
40% 
NNT = 2.51 
10.00% to 70.00% 
NNT = 1.43 to 10.00 
4 years 
Stages 1,11 and III 
E 900,000 
Which adjuvant bisphosphonate prevention Prefer Prevention Ar Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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CHOICE 7 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates; per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients alive without 
disease recurrence 
25% 
NNT = 41 
18.75% to 31.25% 
NNT = 3.20 to 5.33 
2 years 
Stage III only 
E 900,000 
Bisphosphonate 
Prevention B 
Patients alive without 
disease recurrence 
10% 
[NNT= 10] 
2.50% to 17.50% 
NNT = 5.71 to 40.00 
10 years 
Stage III only 
E 1,800,000 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
CHOICE 8 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients without 
metastatic bone 
disease 
25% 
NNT = 41 
0.25% to 49.75% 
NNT = 2.01 to 400.00 
4 years 
Stage III only 
E 1,800,000 
Bisphosphonate 
Prevention B 
Patients without 
metastatic bone 
disease 
40% 
NNT = 2.51 
30.00% to 50.00% 
NNT = 2.00 to 3.33 
10 years 
Stage III only 
f: 0 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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CHOICE 9 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients without 
metastatic bone 
disease 
40% 
NNT = 2.5 
10.00% to 70.00% 
[ NNT = 1.43 to 10.00 1 
4 years 
Stages 1,11 and III 
E 900,000 
Bisphosp onate 
Prevention B 
Patients without 
metastatic bone 
disease 
25% 
NNT = 41 
0.25% to 49.75% 
NNT = 2.01 to 400.00 
4 years 
Stage III only 
f: 1,800,000 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage I 11)? 
CHOICE 10 
Trial Design Characteristics 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients alive without 
disease recurrence 
40% 
NNT = 2.51 
39.60% to 40.40% 
NNT = 2.48 to 2.53 
2 years 
Stages 1,11 and III 
E 1,800,000 
Bisphosphonate 
Prevention 8 
Patients alive without 
disease recurrence 
40% 
NNT = 2.51 
0.40% to 79.60% 
NNT = 1.26 to 250.00 
8 years 
Stage III only 
E 450,000 
Which adjuvant bisphosphonate prevention Prefer Prevention Ar Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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CHOICE 11 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients without 
metastatic bone 
disease 
40% 
NNT = 2.51 
30.00% to 50.00% 
NNT = ZOO to 3-33 
10 years 
Stage III only 
E0 
Bisphosp onate 
Prevention B 
Patients alive without 
disease recurrence 
10% 
NNT = 10 1 
7.50% to 12.50% 
NNT = 8.00 to 13.33 
4 years 
Stages 1,11 and III 
E 450,000 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
CHOICE 12 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients alive without 
disease recurrence 
40% 
NNT = 2.51 
0.40% to 79.60% 
NNT = 1.26 to 250.001 
8 years 
Stage III only 
f 450,000 
Bisphosphonate 
Prevention B 
Patients alive without 
disease recurrence 
40% 
NNT = 2.5 
39.60% to 40.40% 
NNT = 2.48 to 2.53 1 
2 years 
Stages 1,11 and III 
f 1,800,000 
Which adjuvant bisphosphonate preventio Pref r Prevention Ar Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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CHOICE 13 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates Per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients without 
metastatic bone 
disease 
1% 
NNT = 100 
0.25% to 1.75% 
NNT = 57.14 to 400.00 
2 years 
Stage III only 
E 450,000 
Bisphosphonate 
Prevention B 
Patients without 
metastatic bone 
disease 
25% 
NNT = 41 
24.75% to 25.25% 
NNT = 3.96 to 4.041 
10 years 
Stages 1,11 and III 
E 450,000 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Prevention IS 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
CHOICE 14 
Trial Design Characteristics Bisphosphonate Bis-phosphonate 
Prevention A Prevention B 
Primary endpoint Patients alive without Patients without 
disease recurrence metastatic bone 
disease 
Difference in % of patients achieving primary 1% 1% 
endpoint at the end of the trial 
(bisphosphonate minus placebo) NNT = 100 NNT = 100 
95% confidence interval on the primary 0.99% to 1.01 % 0.25% to 1.75% 
endpoint 
NNT = 99.01 to 101.01 NNT = 57.14 to 400.00 
Duration of observation 4 years 2 years 
Disease stage at diagnosis for patients Stage III only Stage III only 
enrolled in the trial 
Additional cost of using adjuvant E0 E 450,000 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prevention B Pr-- 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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CHOICE 15 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisphosphonate minus placebo) 
Bisphosphonate 
Prevention A 
Patients without 
metastatic bone 
disease 
1% 
NNT = 100 
0.75% to 1.25% 
NNT = 80.00 to 133.33 
8 years 
Stages 1,11 and III 
C 1,800,000 
Bisphosphonate 
Prevention B 
Patients without 
metastatic bone 
disease 
10% 
NNT = 10 1 
0.10 % to 19.90% 
NNT = 5.03 to 1000.00 
2 years 
Stages 1,11 and III 
f: 0 
Which adjuvant bisphosphonate prevention Prefer Prevention A Prefer Pro ention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
CHOICE 16 
Trial Design Characteristics 
Primary endpoint 
Difference in % of patients achieving primary 
endpoint at the end of the trial 
(bisphosphonate minus placebo) 
95% confidence interval on the primary 
endpoint 
Duration of observation 
Disease stage at diagnosis for patients 
enrolled in the trial 
Additional cost of using adjuvant 
bisphosphonates per 100 patients treated 
(bisph phonate minus plac bo 
Bisphosphonate 
Prevention A 
Patients alive without 
disease recurrence 
1% 
NNT = 100 1 
0.0 1% to 1.99% 
NNT = 50.25 to 
10000.001 
10 years 
Stages 1,11 and III 
f 900,000 
Bisphosphonate 
Prevention B 
Patients without 
metastatic bone 
disease 
10% 
I NNT = 10 1 
9.90% to 10.10% 
NNT = 9.90 to 10.10 
8 years 
Stage III only 
C 900,000 
Which adjuvant bisphosphonate prevention Prefer Prevention Ar Prevention B 
option would you prefer for patients 
presenting with primary operable breast 
cancer (Stage I to Stage 111)? 
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PART B 
1. What is your area ot'spccialisation (please tick one of the following): 
Medical Oncologist Radiologist El 
Surgical Oncologist Radiotherapist El 
General Practitioner F-I Pharmacist El 
Other F-I Please specify: 
............................ 
2. Approximately hmv many new cases of breast cancer do you see each year? 
Of the neii cases of breast cancer that you see each year, approximately what 
pcrccnta&, c have the following stages of disease at diagnosis: 
Per cent of ncý, v cases with Stage I disease at diagnosis = 1: 11: 1ý% 
Per cent of new cases with Stage 11 disease at diagnosis = DEIF] % 
Per cent of new cases with Stage III disease at diagnosis = 0[: ][: ]% 
Per cent of new cases with Stage IV disease at diagnosis = 1: 10171% 
Please check that the total adds to 100% = EIFIF% 
4. In deciding whcther to start using adjuvant bisphosphonates in patients with 
primary operable breast cancer, please indicate with a I/ the degree of influence 
that you think each of the following specialties would have on the decision: 
Specialty High degree of 
influence 
Some influence No influence 
Radiologist 
Medical Oncologist 
Radiotherapist 
Surgical Oncologist 
Pharmacist 
General Practitioner 
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5. Are there awy important decision-makers or influences missing from the list 
provided in Question 4'. ' (please tick Yes or No) 
Yes 
N, 
If Yes. please specify: 
................................................................... 
............................................................................................... 
6. When considering the evidence trorn a clinical trial relating to the use of adjuvant 
bisphosphonates in patients with primary operable breast cancer, please indicate 
with aV the importance to you of the following trial design characteristics: 
Trial NI cry Quite Of little Not important 
characteristic important important importance 
Primary 
endpoint 
Comparator 
Study 
population 
Duration of 
-follow-UP SiZe of effect 
demonstrated 
- - I ist ica ýtat 
significance of 
results 
Organisation 
sponsoring the 
_tnal Countries in 
which the trial 
is conducted 
- 
ead E 
investiýators 
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7. If you were designing a clinical trial to inform you whether to use adjuvant 
bisphosphonates in patients with primary operable breast cancer, please rank the 
following endpoints in order of importance from 1 (the most important cndpoint to 
you) to 8 (the least important endpoint to you): 
Side cffects 0 
% patients alive without disease recurrence n 
Quality of life experienced by patients m 
patients alive 0 
Cost of patient management with bisphosphonates; 
% patients without metastatic bone disease 
% patients without non-skeletal metastases 
% patients not experiencing skeletal morbidity El 
8. Are there any important endpoints missing from the list provided in Question 7? 
(please tick Yes or No) : 
Yes 
No 
If Yes, please specify: 
................................................................... 
............................................................................................... 
............................................................................................... 
............................................................................................... 
............................................................................................... 
9. Do you have any responsibility for managing budgcts rclated to the trcatmcnt of 
patients with breast cancer? (please tick Yes or No): 
Yes 
No El 
If Yes, please provide a brief description of your responsibilities: 
............................................................................................... 
............................................................................................... 
............................................................................................... 
............................................................................................... 
............................................................................................... 
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10. Did you find this questionnaire: 
Very difficult to complete El 
Moderately difficult to complete F] 
Slightly difficult to complete F1 
Not difficult to complete F1 
11. Please provide any comments you would like to make about this questionnaire 
below: 
................................................................................................... 
................................................................................................... 
................................................................................................... 
................................................................................................... 
................................................................................................... 
................................................................................................... 
................................................................................................... 
................................................................................................... 
................................................................................................... 
12. How long has it taken you to complete this questionnaire? E][][] minutes 
Please check that you have answered all the questions and then return this 
questionnaire in the envelope provided. 
Thank you for completing this questionnaire. 
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APPENDIX 4.3 
RESULTS OF THE NON-CHOICE COMPONENTS OF THE STATED 
PREFERENCE SURVEY 
(QUESTIONNAIRE PART B) 
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Table A4.3.1 
Question 1: What is your area of specialisation? 
Specialty Title 
Professor Consultant Senior 
Registrar 
Registrar Other TotaF 
Medical 
oncologist 
1 5 3 3 2 14 
Surgical 
oncologist 
1 15 0 1 0 17 
Clinical 
oncologist 
0 11 0 4 1 16 
Other 0 4 0 0 3 7 
Total 21 35 1 TI 81 61 54 1 
Table A4.3.2 
Question 2: Approximately how many new cases of breast cancer do you see 
each year? 
Specialty S mmary of new cases 
Mean Standard 
deviation 
Frequency 
Medical 
oncologist 
156.86 112.25 14 
Surgical 
oncologist 
144.29 65.36 17 
Clinical 
oncologist 
224.38 188.82 16 
Other 183.57 203.32 7 
Total 176.37 
. 
142.42 54 
Table A4.3.3 
Question 3: Approximately what percentage of new cases have the following 
stages of disease at diagnosis? 
Stage Observations Mean Standard 
deviation 
Min Max 
% Stage 1 54 38.24 22.63 0 90 
% Stage Il 54 30.19 15.42 0 60 
% Stage 111 54 15.83 11.89 0 50 
% Stage IV 54 12.04 14.84 0 80 
Stage 1 54 69.66 65.54 0 360 
Stage 11 54 55.04 44.59 0 213 
_ Stage 111 54 30.24 50.02 0 340 
: Stage IV 54 21.43 29.12 0 1 *7 -;l 
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Table A4.3.4 
Question 9: Do you have any responsibility for managing budgets related to the 
treatment of patients with breast cancer? 
Specialty udget responsibi ty? 
Yes No Total 
Medical 
oncologist 
5 9 14 
Surgical 
oncologist 
5 12 17 
Clinical 
oncologist 
4 12 16 
Other 0 7 7 
Total 14 40 54 
Table A4.3.5 
Question 10: How difficult was this questionnaire to complete? 
Specialty ifficulty of que tionnaire t complete 
Very 
difficult 
Moderately 
difficult 
Slightly 
difficult 
Not at all 
difficult 
Total 
Medical 
oncologist 
0 4 6 4 14 
Surgical 
oncologist 
1 6 9 1 17 
Clinical 
oncologist 
0 7 3 6 16 
Other 1 5 0 1 7 
Total 2 22 18 12 -5-41 
Table A4.3.6 
Question 12: How long have you spent on this questionnaire? * 
Variable Observations Mean Standard 
deviation 
Min Max 
Reviewing 
time 
54 26.76 13.11 60 
Interview time 54 11.41 4.56 -0" 2632 
Total time F- 54 38.17 1 13.32 1 191 801 
* Times are in minutes. 
1. The minfinum of zero was caused by one respondent reporting no preparation prior to interview. 
2. Ile minimum of zero was caused by one respondent mailing responses but not participating in the 
interview. 
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Table A4.3.7 
Are you happy to have your personal details disclosed? 
Specialty Disclosure of persona details 
Yes No Total 
Medical 
oncologist 
12 2 14 
Surgical 
oncologist 
15 2 17 
Clinical 
oncologist 
14 2 16 
Other 7 0 7 
Total 48 6 54 
Table A4.3.8 
Would you like to be sent a copy of the results of this survey? 
Specialty Receive copv of the s rvey? 
Yes No Total 
Medical 
oncologist 
9 5 14 
Surgical 
oncologist 
17 0 17 
Clinical 
oncologist 
15 1 16 
Other 7 0 7 
Total 48 6 54 
Table A4.3.9 
Question 11: Do you have any comments on the questionnaire? 
Specialty Comments on questio naire? 
Yes No Total 
Medical 
oncologist 
5 9 14 
Surgical 
oncologist 
13 4 17 
Clinical 
oncologist 
8 8 16 
Other 4 3 7 
Total 30 24 54 
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Table A4.3.10 
Question 4: Degree of influence of different specialties on the decision to use 
adjuvant bisphosphonates? 
Specialty Observations Mean Standard 
deviation 
Min Max 
Medical 
oncologist 
54 1.15 0.41 1 3 
Radiotherapist 54 1.35, 0.55 1 3 
Surgical 
oncologist 
54 1.80 0.59 1 3 
Pharmacist 54 2.57 0.57 1 3 
Radiologist 54 2.63 0.56 1 3 
GP 0.52 1 3 
Table A4.3.11 
Question 5: Are there any important decision makers or influences missing from 
the list in Question 4? 
Specialty Missing influences? 
Yes No Total 
Medical 
oncologist 
7 7 14 
Surgical 
oncologist 
11 6 17 
Clinical 
oncologist 
11 5 16 
Other 7 0 7 
Total 36 18 54 
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Table A4.3.12 
Question 6: Importance to you of the following design characteristics of an 
adjuvant bisphosphonates trial 
Variable Observations Mean Standard 
deviation 
Min Max 
Primary 
endpoint 
54 1.15 0.49 1 4 
Statistical 
significance 
54 1.22 0.46 1 3 
Effect size 54 1.26 0.44 1 2 
Study 
populatim 
54 1.44 0.57 1 3 
Duration 54 1.50 0.50 1 2 
Comparator 54 1.57 0.57 1 3 
Lead 
investigator 
54 2.57 0.69 1 4 
Countries 54 2.59 0.69 1 4 
Sponsor 54 2.80 0.68 1 4 
Table A4.3.13 
Question 7: Ranking of importance of adjuvant bisphosphonate trial endpoints 
Variable Observations Mean Standard 
deviation 
Min Max 
Disease free 
survival 
54 2.43 1.80 1 8 
Alive 54 3.78 2.45 1 8 
No metastatic 
bone disease 
54 3.91 1.94 1 7 
Quality of life 54 4.11 2.09 1 8 
Side effects 54 4.63 1.88 1 8 
No skeletal 
morbidity 
54 4.98 2.05 1 8 
No other 
metastases 
54 5.35 1.82 2 8 
Cost 54 6.81 1.59 3 
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Table A4.3.14 
Question 8: Are there any important endpoints missing from the list in Question 
7? 
Special! y Missing endpoln ? 
Yes No Total 
Medical 
oncologist 
1 13 14 
Surgical 
oncologist 
1 16 17" 
Clinical 
oncologist 
4 12 16 
Other 1 6 7 
Total 7 47 54 
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Table A4.3.15 
Budget responsibility as articulated by respondents 
Respondent Comment 
13 For the surgical side of things but not for the drugs. 
14 As lead clinician I have some input into where our significant 
expenditure should be. 
15 1 start the treatment and see the patient through to when they die. 
16 Not directly but we all have some influence. We have the North Trent 
Breast Care Group which we all have input in and decisions taken 
through this. 
19 I'm the lead clinician for cancer. Separately responsible for prioritising 
money for the cancer agenda trust. 
20 I'm Director of Surgery with a budget of fl5n-ffllions. Also I'm the 
lead Cancer Clinician for the hospital. The hospitals overall budget is 
El 15millions. 
27 Indirectly in an advisory capacity re drugs and radiation therapy. 
31 1 sit on the Network Committee and we make decisions about where 
the money will go. 
35 1 was Head of Department and made some decisions regarding drugs 
to be used. Otherwise decisions are joint with other consultants. 
36 I'm Clinical Director of Royal Free University College. I Chair the 
Breast Tumour Board for North London Network. 
40 Answered no but made the comment: "Only priority setting at 
consultant meetings. " 
42 1 sit on the Joint Hospital Board. Decide which drugs we will use. 
43 Formulary sub-committee. Chairman of Cancer Network Systems, 
Network Therapeutics Group: dealing with all new cancer drugs. 
44 Answered no but made the comment: "but on consultants' committee. " 
46 Answered no but made the comment: "but we have to prescribe 
responsibly within evidence based guidelines. " 
50 I'm involved in the Hospital Pharmacy Committee and the High Cost 
Drug Committee. 
164 
Table A4.3.16 
Comments on the questionnaire as articulated by respondents 
Respondent Comment 
I Interesting. 
3 Only that I'm curious to see what endpoint. For me it's been a useful 
introduction to conjoint analysis from a leaming point of view. 
4 Certain of them not comparing like with like. 
5 Didn't ask how often the patient needed treatment or the type i. e. 
whether it was tablet or iv. If iv then how often. The interval between 
treatments by this method is very important to the patient. 
9 1 found it more difficult to do Showcard, 1 because there was no 
information on the number of patients in the trials. 
10 The questionnaire could have been clearer in certain aspects. Each 
showcard has too much information in order to come up with a choice. 
11 1 was interested in some of the things being compared in that they 
don't seem really comparable. 
13 It's a concept I hadn't actually appreciated. 
16 First lot of questions not that easy- too much information to take in- 
surgeons are a bit thick! However, it was good 
-I think it's very 
important trying to get across what's important in clinical trials. 
17 You seem to have covered everything. 
19 No 
- 
it was quite interesting. I'm interested in bisphosphonates. 
21 1 found it a bit difficult with some of the choices reconciling them in 
my mind. 
23 No but 10 minutes is unrealistic. 
24 There were two problems for me: 
1) We were asked to decide prevention strategy for all stages yet a 
lot of the data was only for Stage 3. 
2) 1 wouldn't make a decision on a single set of data given like 
this. 
It was a very false way of looking at scientific data and I was very 
unhappy with it. 
I would be very happy for him to contact me to discuss this further. 
27 The analysis of the data 
- 
it's the first time I've come across this type 
of vehicle at Showcard 1.1 found it quite a useful exercise. 
28 Only that on Showcard 2 we don't use this terminology (Stage I etc) 
- 
it's American but it didn't bother me unduly. 
30 1. There is one important factor in the decision to use bisphosphonates 
which is not featured anywhere: the need for the stafflng and 
infrastructure to give the treatments, especially if it is being done 
intravenously. 
2. The way Showcard I was devised, I feel sure I have contradicted 
myself at times. 
31 Some of the options in Showcards 1-16 don't look very feasible. 
Some of the scenarios are a bit difficult to understand how a trial can 
be designed this way. I can't get my head round why they've been 
written this way. 
Willing to participate in the next phase. 
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Table A4.3.16 (continued) 
Respondent Comment 
32 1 was ýTtrigued by the format. I understand the research was about 
conjoint analysis but it seemed to be about the use of bisphosphonates 
which is a pretty controversial subject at the moment. 
35 1 didn't know what conjoint analysis was-I looked it up on the web. 
I found assigning values to the different characteristics listed was 
difficult. 
36 Quite an interesting one. 
37 1 thought it was very well designed. 
38 Some of the cost differences are very large-some had zero! 
It was fully comprehensive but the issue of patients alive without 
disease recurrence and patients without metastatic bone disease made 
it difficult to way up when you've got different endpoints. 
40 1 just found it difficult on the 1- 16 choices, to make sure I'd noted the 
differences on each one. It was the number of choices. 
41 It's a lot of fun. Quite challenging. Half the choice questions were 
very easy and half I didn't feel either option was acceptable but came 
down on one for the purpose of this exercise. 
1) You know what % of stage III patients will be alive at a particular 
time point and that will naturally affect the way you look at it but 
you're told not to have any other information. 
2) How desirable is the outcome? How Rely is the outcome? Do you 
think your intervention is going to count on the outcome? 
42 I've not done anything like this before. I found it very interesting. 
44 It is not easy really. I have to think about the formulation of the 
questions and I can't come up with any bright ideas. 
45 It took longer than 20 minutes. I was told it would take 10 minutes. 
46 Good questionnaire. Have done this before. 
50 Respondent wished to point out that 90% of breast cancer patients are 
treated by clinical oncologists and if they are called radiotherapists it 
could upset a lot of people. The situation is politically very sensitive. 
The economic analysis needs to be good. 
Table A4.3.17 
Missing decision makers or influences as articulated by respondents 
Respondent Comment 
I Pathologists. 
2 Nurse specialist and the patient. 
3 Nurse specialists or research nurses. 
5 Patient. 
6 Medical endocrinologist. 
7 1. Clinical nurse specialists. 2. Pathologists. 
8 Pathologist. 
9 Breast nurse. 
10 Breast care nurses. 
11 Clinical nurse specialist 
- 
has some influence. 
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Table A4.3.17 (continued) 
13 Breast care nurse. 
17 Trust manager. 
19 The respondent had originally indicated NICE but then deleted and 
changed the answer to no important decision-makers missing. 
20 Palliative care people. 
21 Orthopaedic surgeon. 
23 Breast reconstruction surgeon. 
24 Policy makers = managers. 
25 Patient and relatives. 
26 Breast care nurse. 
27 The patient. 
31 Pathologist. 
34 1. Palliative medicine consultant. 2. Hospice consultant. 
36 1. Patient support groups (some influence). 
2. NICE (high degree of influence). 
38 1. Plastic surgeon. 2. Palliative care consultants. 
3. Breast care nurses/MacMillan nurses. 
39 1. Breast care nurse. 2. Palliative care team i. e. MacMillan nurse. 
3. Orthopaedic surgeon. 
40 Patients. 
41 1. The patient. 2. The media. 3. Specialist nurse. 
42 Breast care sister. 
43 NICE. 
44 Breast care nurses. 
46 Primary care Trusts as they have to fund increased costs. 
47 The patient. 
48 1. The patient. 2. The patient's relatives. 3. The breast care nurses. 
49 1. Clinical chemist. 2. Rheumatologist 
50 Answered no but made the comment: "You need to reframe 
radiotherapist as a clinical oncologist. " 
Table A4.3.18 
Missing endpoints as articulated by respondents 
_Respondent 
Conunent 
8 I. Serum calcium levels. 
2. Number of pathological bone fractures. 
31 1. Quality adjusted life-years 
2. Cost per QALY 
41 1. % of patients with spinal cord compression - this can go undetected. 
2. Nothing about disability or time spent in hospital. 
48 1. Health economics assessment. 
2. Bone density assessment. 
49 Cost of patient management without bisphosphonates. 
50 1. Some management can reduce costs. 
2. Endpoint 5 (cost): "Is this overall management cost? It's unclear. " 
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APPENDIX 4.4 
TECHNICAL APPENDIX 
The purpose of this Technical Appendix is to set out the assumptions, equations and 
sources of data used for the illustrative analyses and results reported in section 4.7, 
"Using discrete choice model results in RCT desigif'. Example calculations are 
provided. Although the examples draw on published data pertaining to a recently 
reported bisphosphonate tria F69, the calculations are illustrative and do not purport to 
solve an oPtimisation problem in this context. 
1. Interpolation of effectiveness outcomes 
In order to perforra the illustrative calculations presented in this paper, effectiveness 
and uncertainty outcomes were interpolated, for three time points, from the survival 
curves reported in Powles et al (2002) 
. 
269 These are presented in Table A4.4.1 below. 
Table A4.4.1 
Clodronatel P lacebo' Difference 2 Lower Upper Prlor4 
95% C13 95% C13 
% Patients without 
metastatic bone disease 
Year 2 96.20 93.30 2.90 0.23 5.57 1-6 
Year 5 89.00 84.50 4.50 0.45 8.55 1-9 
Year 8 83.00 80.00 3.00 
-1.65 7.65 1-8 
% Patients alive5 
Year 2 92.70 92.40 0.30 
-2.85 3.45 1-4 
Year 5 82.90 79.30 3.60 
-1.09 8.29 1-8 
Year 8 78.00 72.00 6.00 0.82 11.18 1-11 
1. Data points were interpolated from the survival curves reported in Powles d &1 (2002). 266 
2. Clodronate % minus placebo %. 
3. Confidence intervals for the differences in % effectiveness were calculated using the formula provided by Armitage & 
Berry (1995) pp 128-130.170 
4. The prior expectations for each outcome were assumed to be given by a uniform distribution in the range 1% to the 
upper limit of the 93% confidence interval (rounded up or down to the nearest whole number). Therefore, in the 
calculations, each value within the range is assumed to have an equal chance of representing the true difference in 
effectiveness. 
5. Powles et al (2002) did not report disease free survival rates. '" I lowevcr. for the illustrative analyses performed in 
this chapter, the overall survival rates reported were used as if they were the disease free survival rates. 
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2. Choice of baseline design 
It is important to note that the values of the predicted probabilities calculated for 
different trial designs depend upon the baseline values against which a new design is 
compared. Thus, such calculations require a 'baseline design' to be chosen. The 
calculations used to generate the results presented in Table 4.8 and Figures 4.2 to 4.4 
are based on the following baseline design: 
Table A4.4.2 
Attribute Baseline product evidence Justification 
Endpoint Patients without metastatic bone The primary endpoint in th 
disease Powles et al 
- 
(2002) trial269 
Effectiveness 2.90% 'Ibc statistically significant 
difference observed in the 
Powles et al (2002) study at the 
end of the treatment period (2 
years). 269 
Uncertainty 0.23% to 5.57% The confidence interval was 
[0.92] computed using the formula 
provided by Am itage & Be" 
(1995) pp 128-130 170 
Duration 2 years The period (medication period) 
over which the statistically 
significant difference in the 
above measure of effectiveness 
was observed. 
Population Patients with Stages I to III The Powles et al (2002) trial 
disease at diagnosis enrolled patients with primary 
operable breast cancer 
regardless of the stage of 
disease at diagnosis. 269 
Cost L450,000 Ibis level reflects the 
approximate cost of treating 
patients with oral clodronate for 
a2 year period as allowed for in 
the Powles et al (200? ) trial 
dosing regimen. 2*7 
This is the baseline design presented in column (1) Table 4.8. It is important to note 
that, despite being based on the Powles et al (2002) trial, the choice of this baseline is 
purely illustrative. 
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3. Example calculation of predicted probabilities of product adoption presented 
in Section 4.7.1, Table 4.8 and Figure 4.2 
Consider the comparison between the baseline design and "New product RCT Design 
7" shown respectively in columns (1) and (8) of Table 4.8. By substituting the 
regression coefficients from the full sample model (Table 4.7) and the differences in 
the values of the two RCT design attributes into Equation (8) we derive: 
A VAB 
= 
[(0.2787 *1)+ (0.0457 * 37.10)+ (-0.6210 * 
-0.91)+ .=2.9876 
. (0.0255 * 8)+ (0.2419 * 0)+ (-5.43e 
-07 * -450000)_ 
Substituting the above utility value into Equation (7) gives the predicted probability of 
preferring RCT Design 7 (A) to the baseline design (B): 
Pr(A I J) 
= (D (A VAB) = (D(2.9876) = 0.9986, and 
Pr(B I J) 
=I- (D(AVAB) =I-0.9986 = 0.0014. 
All the results presented in Table 4.8 and Figure 4.2 were calculated in this way. 
4. Example calculation of expected predicted probabilities of product adoption 
presented in Section 4.7.2, Figure 4.3 
For the illustrative calculations used to produce Figure 4.3, it is assumed that trial 
sponsors would only consider studies of 2,5 or 8 years duration and that they would 
only accept a study population which included subjects with all stages of primary 
operable breast cancer at diagnosis. It is further assumed that the new bisphosphonatc 
treatment would be priced at parity with the existing treatment (equivalcnt to 
E450,000 per 100 patients treated) and that a total sample size above 5000 subjects 
would not be contemplated. These assumptions are made in order to limit the 
computational effort involved. 
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As an example calculation, consider the comparison between a design which differs 
from the above baseline only in terms of the period of follow-up (5 years instead of 2 
years). The calculations are illustrated for a hypothetical trial which enrols a total of 
1500 subjects (750 per arm). The calculation involves the following steps: 
4.1. Calculation of expected effectiveness 
For each sample size, n, we first need to calculate the expected values for the 
effectiveness attribute. Utilising an approach previously described by Backhouse 
(1998) 203 and Detsky (1985,1990) 152; 154 
, 
the expected effectiveness, E. (A X) likely 
to be demonstrated by a trial of sample size n, is given by the following formula: 
ÖD 
where Pr(DO = AXIAX) is the conditional probability that a difference of AX will be 
established in a trial with significance level ý if that difference is in fact there (the 
power of a trial), and where Pr(AX) is the prior probability of a true difference of 
Ax. 
For this illustrative calculation, E.. 1500 
(A X) = 
(0.0781 0.1111 (85.5%-84.5%) + 
(0.1948 0.1111 (86.5%-84.5%) + 
(0.3874 0.1111 (87.5%-84.5%) + 
(0.6207 0.1111 (88.5%-84.5%) + 
(0.8216 0.1111 (89.5%-84.5%) + 
(0.9406 0.1111 (90.5%-84.5%) + 
(0.9869 0.1111 (91.5%-84.5%) + 
(0.9982 0.1111 (92.5%-84.5%) + 
(0-9999 0.1111 (93.5%-84.5%) = 4.19530/o. 
In the above calculation, the first number in each row is the power of the trial which is 
calculated using the formula described in Machin et al (1997) p19.195 A two tailed 
test with significance level ý= 5% was assumed for all calculations. The second 
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number in each row is the prior probability of the difference in effectiveness shown as 
the last number in each row. Thus, from Table MA 1, the assumed prior expectation 
of difference in effectiveness is 1% to 9% with each value in that range assumed to 
have an equal prior probability: 1/9 = 0.1111. 
4. Z Calculation of expected uncertainty 
To calculate the expected uncertainty, 95% confidence intervals for the expected 
effectiveness outcome were computed using the formula provided by Armitage & 
Berry (1995) pp 128-130 referred to in the footnote to Table A4.4.2 above. 170 Based 
on this formula, the expected 95% confidence interval is: 0.7537% to 7.6369% 
(4.1953% ± 3.4416%). The expected uncertainty attribute value for this particular 
trial is therefore given by: 
E1500 
= 
[(7.6369 
- 
0.7537)/4.1953]/ 2=0.8203. 
This is the uncertainty value which enters the calculation below. 
4.3. Calculation of expectedpredictedprobability 
By substituting the regression coefficients from the full sample model and the 
differences in the values of the two RCT design attributes into Equation (8) we derive: 
(0 2787 * 0) + (0.0457 1.2953) + (- 0.6210 * 
-0.0997) + Euoo (A VAg 
[(Oo* 1=0.1976 
. 
0255 * 3) + (0.2419 0) + (- 5.43e 
- 
07 * 
-0) 
Substituting the above utility value into Equation (7) gives the expected predicted 
probability of preferring the RCT design as described above (A) to the baseline design 
(B): 
E1500 Pr(A I J) 
= (D(E, 500 (A VAg)) = (D(O. 1976) = 0.5783. 
172 
This value was used to plot, in Figure 4.3, the expected predicted probability for a 
trial of 5 years duration with total sample size of 1500 and the percentage of patients 
without metastatic bone disease as the primary endpoint. Similar calculations were 
repeated across a large range of sample sizes and designs to produce Figure 4.3. 
5. Example calculation of expected net present values presented in Section 4.7.3, 
Figure 4.4 
Backhouse (1998) has shown how the net present value (NPV) for a trial can be 
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calculated and used to determine optimal (NPV maximising) designs. This is the 
approach adopted here. The example below builds on the example presented above. 
5.1 Calculation of cost 
In order to estimate the discounted cost of performing the trials PTC., the following 
simple cost function was assumed: 
H F, + Vn + FU,. n, PTC" 
= 
E. 
-- 
tttt 
t=O (1 + r) 
where F, denotes the fixed cost of perforniing the trial, V, denotes the variable cost 
per subject enrolled, FU, denotes the follow-up cost per patient per year, n, denotes 
the total trial sample size and t denotes the year in which the costs are incurred. In all 
calculations, the following assumptions are made: 
F= E1,000,000, incurred in the first year Q= 0) I 
V, 
= 
E3,000, incurred in the first year (t = 0) 
FUI 
= 
E1,000 incurred for each year of follow-up (t =I to 5) 
H= IS years, the time horizon for the NPV calculations 
r=0.15, the discount rate. 
Based on the above assumptions, the cost calculation for the 5- year trial illustrated 
in section 4 above is shown below in Table A4.4.3. 
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Table A4.4.3 
Year t n F, Vt. n, FUt. n, TC, PTC, 
1 0 1500 ; C1,000,000 E4,500,000 ; E5,500,000 E5,500,006-- 
2 1 1500 E1,500,000 EI, 500,000 fl, 304,348 
3 2 1500 E1,500,000 _ E1,500,000 f: 1,134,216 
4 3 1500 E1,500,000 fl, 500,000 E 986,274 
5 4 1500 E1,500,000 E1,500,000 E 857,630 
6 5 1500 fl, 500,000 E1,500,000 E 745,765 
Total PTC.. 1500 
I ; E10,528,233 
It should be emphasised that the assumed values used here are purely illustrative. 
They do not necessarily reflect the actual costs of perforniing such a trial. 
5.2 Calculation of revenue 
In order to estimate the discounted revenue associated with performing the trials, the 
following simple demand function was assumed: 
E. Prt (A I J) Mt 
where M, denotes the annual number of newly diagnosed cases of breast cancer 
assumed to be currently treated with the baseline product. The discounted revenue 
associated with a trial of given design and sample size, PTR, , is given by: 
H (A I J) M,. P, PTR. E,, Pr, 
t=O (I+rf 
where P, denotes the cost per year per patient treated and all other variables are as 
described above. 
In all calculations, the following variable values were assumed: 
Mt = 15,000, assumed to be constant for the time horizon of this illustrative 
calculation and represents the number of patients assumed to be currently 
treated with the baseline product. 
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P= E2 250 per patient per year for a two year course of treatment (treatment t 
cost= E4,500 per patient). 
H= 15 years, the time horizon for the NPV calculations 
0.15, the discount rate. 
Based on the above assumptions, the expected revenue calculations for the 5- year 
trial illustrated in section 4 above is shown in Table A4.4.4 below. 
S. 3 Calculation of expected NP V 
Finally, the expected net present value of a trial of given design and sample size, 
NPV., is given by: 
NP V,, 
= 
PTRn 
- 
PTCn 
which in this case equals E68,392,368 
- 
E10,528,233 = E57,864,135. This value was 
used to plot, in Figure 4.4, the expected NPV for a trial of 5 years duration with total 
sample size of 1500 and the percentage of patients without metastatic bone disease as 
the primary endpoint. Similar calculations were repeated across a large range of 
sample sizes and designs to produce Figure 4.4. 
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CHAPTER 5: DISCUSSION AND CONCLUSION 
Randomised controlled trials (RCTs) play a fundamental role in the development and 
marketing activities of pharmaceutical companies. They are costly to perform and 
their design and results are a major determinant of the sales of a product. The 
contribution of RCTs to the performance of pharmaceutical companies emphasizes 
the importance of considering the application of techniques by which the value of 
trials may be assessed. Yet a review of the literature pertaining to economic analysis 
and clinical trials performed in the course of this research revealed that a private 
sector investment appraisal approach to RCT design has not hitherto been proposed 
nor has its potential application previously been explored. Therefore the purpose of 
this thesis has been to begin to fill that gap by setting out how methods of investment 
appraisal might be applied to RCT design decision-making and by exploring aspects 
surrounding the practicalities of application. Each individual chapter presents 
conclusions and directions for future research so they will not be repeated in detail 
here. Rather the purpose of this chapter is to briefly surnmarise the A-ey conclusions 
and contributions of this thesis and to present an agenda of research topics that could 
be pursued to further develop the application of investment appraisal approaches to 
trial design. 
5.1 SUMMARY OF CONCLUSIONS AND CONTRIBUTIONS 
In the field of economic analysis and RCTs, this thesis makes original contributions of 
both a conceptual and applied nature. The main conclusions and contributions of this 
thesis are summarised below. 
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The main contributions based on Chapter 2 are two fold. Firstly, a potential role for 
private sector investment appraisal techniques in the design of RCTs was identified 
and proposed for the first time. Secondly, a general model was described setting out 
the key components of the approach. An illustration of the application of the NPV 
method of investment appraisal was presented using a hypothetical trial design 
problem facing a pharmaceutical company. It was shown how profit criteria could be 
applied to decide whether a particular RCT is worth conducting, to determine an 
optimal (NPV maximising) design, and to rank RCTs in terms of their expected 
NPVs. The latter would enable a company to select a portfolio of studies which 
maximises the return on a given development or trial budget. 
One of the strengths of this technique lies in the fact that it requires a health care 
decision maker focused approach to the planning and design of RCTs. It explicitly 
recognizes that the nature and extent of product adoption (and ultimately profit) is 
linked to the strength and relevance of the evidence that trials produce for decision 
makers. This has not been built in to the methods previously proposed for use by 
companies to assess the value of research and development projects. Therefore the 
importance of being able to estimate the demand for a product contingent upon RCT 
design and expected trial outcomes was highlighted and the potential use of discrete 
choice analysis for that purpose was proposed for the first time. 
The work in Chapter 3 was conducted at a time when the pharmaceutical industry 
started to express its concerns about the potential impact, on development times and 
costs, of decision makers' requiring cost-effectiveness evidence generated by RCTs. 
The work set out to explore how such a requirement might impact the major 
deten-ninants of RCT costs, namely sample size and study duration. The 
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applied investigation utilized data from a previously conducted clinical evaluation and 
published formulae to calculate sample sizes for testing cost-effectiveness hypotheses 
for a number of hypothetical study designs. The designs were chosen to portray 
different preferences for cost-effectiveness evidence characterized by various design 
components of an RCT. 
The main contributions based on Chapter 3 are two fold. Firstly, the analyses 
conducted demonstrate, for the first time, that the impact on RCT costs depends upon 
the speciji'c nature of the cost-effectiveness evidence requirements. In so doing, the 
work draws attention to one of the practical implications of the findings: such studies 
cannot be adequately designed without detailed prior information about decision- 
makers' preferences for evidence defined in terms of RCT design attributes. 
Secondly, the analyses conducted also demonstrate that circumstances can be such 
that a requirement to produce evidence of cost-effectiveness based wholly on RCTs 
can significantly increase product development costs and times above that which 
would be required to test hypotheses only on clinical endpoints. The direction and 
magnitude of any impact will always depend upon the specific requirements and 
circumstances surrounding a product. 
Empirical demand analysis is a key component of an investment appraisal approach to 
RCT design. Specifically, the technique cannot be operationalised, without estimating 
the demand for a product contingent on the design and results of RCTs. Therefore 
Chapter 4 focused on this critical component of the investment appraisal approach. 
The purpose of the work presented in Chapter 4 was to explore how DCA could be 
used as a means of incorporating decision makers' preferences into the design of 
RCTs. Specifically, a primary goal was to explore the use of DCA as a method 
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for estimating the probabilities of product adoption contingent upon different RCT 
designs and expected results in order to operationalise the investment appraisal 
approach to trial design. 
In Chapter 4, a discrete choice model of drug demand was presented in general form. 
This was followed by an overview of the key elements to be considered in the design 
of a stated preference survey to estimate the parameters of a discrete choice model. 
The approach was then illustrated through the design and application of a stated 
preference survey to elicit clinician preferences for RCT evidence pertaining to the 
use of bisphosphonates in the management of patients with primary operable breast 
cancer. The data collected in the survey were used to estimate the parameters of a 
discrete choice model. It was shown how those results could be used to derive 
predicted probabilities of product adoption which, in turn, can be used to detennine 
optimal RCT designs within an investment appraisal framework. 
The main contributions of the work presented in Chapter 4 are as follows. Firstly, the 
use of DCA as a method for incorporating decision-maker preferences for evidence 
into the design of RCTs has not hitherto been proposed. In Chapter 4, the potential 
use of DCA for that purpose has been identified and described. Secondly, the first 
application of DCA to RCT design was presented. The empirical case-study provides 
evidence that the method is practical and theoretically valid in that context. Finally, 
and in contrast to other health economics applications of DCA, the research has 
focused on the use of the predicted choice probabilities that can be derived from 
discrete choice models. Specifically, the research has shown for the first time how 
these can be used to determine preference maximizing or profit maximizing trial 
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designs. 
5.2 AN AGENDA FOR FURTHER RESEARCH 
This thesis has begun to explore how pharmaceutical companies might apply 
investment appraisal techniques to assist with RCT design decision-making. In this 
section, some major directions for further research into the application of investment 
appraisal techniques to RCT design are briefly highlighted. 
The application of investment appraisal to RCT design was illustrated using the NPV 
method of investment appraisal. This was chosen because of its known superiority 
over rival orthodox methods and because of its widespread use by pharmaceutical 
companies to appraise project investment decisions. However, future research should 
consider how the conclusions reached through the NPV method compare with those 
reached by alternatives such as decision-analytic methods and value of information 
analysiS277; 278 and the real options approach to investment decisions . 
279; 280 
Further research should also be directed at gaining experience with the application of 
investment appraisal methods to various investment decisions involving the design of 
RCTs. Specifically, it would be worthwhile focusing on applying investment 
appraisal techniques to determine an optimal programme of trials to meet the evidence 
needs of both the regulatory agencies and pricing and reimbursement authorities. Any 
application will require a company to be able to estimate both the costs and the 
revenues contingent upon different RCT designs and results. It is the estimation of 
the product adoption and revenues that will pose the greatest challenge to successful 
application of the approach 
181 
Empirical work presented in this thesis has shown that discrete choice analysis is a 
potentially promising technique for incorporating decision-makers preferences for 
evidence into the design of trials generally and for operationalising an investment 
appraisal approach to RCT design in particular. Further research into the application 
of DCA will need to address how the technique can be successfully applied to 
decision-makers other than clinicians and to more complex treatment choice situations 
than those illustrated here. Furthennore, future research will need to address how 
product diffusion can reliably be modeled based on the findings of stated preference 
surveys204 or other techniques. 281 
182 
REFERENCES 
1. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials, 
Second ed. Littleton, MA: PSG Publishing Company; 1985. 
2. Bulpitt CJ. Randomised. controlled clinical trials, First ed. The Hague: 
Martinus Nijhoff; 1983. 
3. Meinert CL. Clinical trials: design, conduct and analysis, First ed. Oxford 
University Press; 1986. 
4. Spilker B. Guide to clinical trials. New York: Raven Press; 1991. 
S. Pocock SJ. Clinical trials: a practical approach. John Wiley & Sons; 1991. 
6. US Food and Drug Administration (FDA): http: //www. fda. go 
7. European Medicines Evaluation Agency (EMEA): http: //www. emea. eu. int/. 
8. Clark T. A guide to the international pharmaceutical industry, 2005 ed. New 
Orleans: VOI Consulting Inc; 2005. 
9. Caspari M, DeFazio L, Geanotes A, Gerlach E, Hampton R, Harper C et al. 
Pharmaceutical pricing and reimbursement, 2003 ed. Cambridge, UK.: PPR 
Communications Ltd.; 2003. 
10. Drummond MF, Dubois D, Garattini L, Horisberger B, Jonsson B, Kristiansen 
IS et aL Current trends in the use of pharmacoeconomics and outcomes 
research in Europe. Value in Health 1999; 2: 323-32. 
183 
11. Drummond, M. F. The use of health economic information by reimbursement 
authorities. Rheumatology 42(Suppl 3), 60-63.2003. 
12. Taylor, R. S., Drummond, M. F., Salkeld, G., and Sullivan, S. D. Inclusion of 
cost effectiveness in licensing requirements of new drugs: the fourth hurdle. 
British Medical Journal 23(329), 972-975.2004. 
13. Tam, T. Y. H. and Dix Smith, M. Pharmacoeconomic guidelines around the 
world. ISPOR Connections 10(4), 5-15.2004. 
14. National Institute for Clinical Excellence. Guide to the methods of technology 
appraisal, April 2004 ed. London: NICE; 2004. 
15. National Institute for Health and Clinical Excellence (NICE). NICE. 2005. 
16. Williams H. New treatments for atopic dermatitis: good news, but when and 
how to use them is a muddle. British Medical Joumal 2002; 324: 1533-34. 
17. Williams H. Another vehicle-controlled study of 1% pfinecrolimus in atopic 
dermatitis: how does it help clinicians and patients and is it ethically sound? 
Archives of Dermatology 2002; 138: 1602-03. 
18. Grabowski H, Vernon J. Returns to R&D on new drug introductions in the 
1980s. Joumal of Health Economics 1994; 13: 3 83-406. 
19. Grabowski H. The effect of pharmaco economics on company research and 
development decisions. PharmacoEconornics 1997; 11: 389-97. 
184 
20. El Feki,, S. Prescription for change: a survey of pharmaceuticals. The 
Economist (June 18-24), 3-17.18-6-2005. 
21. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the 
economic evaluation of health care programmes, 2nd ed. Oxford: Oxford 
University Press; 1997. 
22. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health 
and medicine. Oxford: Oxford University Press; 1996. 
23. Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis 
in randomized control trials. Medical Care 1992; 30: 231-43. 
24. Culyer AJ, Wiseman J, Walker A. An annotated bibliography of health 
economics. London: Martin Robinson; 1977. 
25. Drummond MF, Ludbrook A, Lowson KV, Steele A. Studies in economic 
appraisal in health care, vol. 2. Oxford: Oxford University Press; 1986. 
26. Elixhauser A, Luce BF, Taylor WP, Reblando J. Health care cost-benefit and 
cost-effectiveness analysis from 1979 to 1990: a bibliography. Medical Care 
1993; 31: JSI-JS150. 
27. Elixhauser A. Health care cost-benefit and cost-effectiveness analysis: an 
update. Medical Care 199 8; 3 6: MS I 
-MS 147. 
28. Ganiats TG, Wong AF. Evaluation of cost 
-effectiveness research: a survey of 
recent publications. Family Medicine 1991; 23: 457-62. 
29. Udvarhelyi IS, Colditz GA, Rai A. Epstein AM. Cost-effectiveness and 
185 
cost-benefit analyses in the medical literature: are the methods being used 
correctly? Annals of Internal Medicine 1992; l 16: 238-44. 
30. Backhouse ME, Backhouse RJ, Edey SA. Economic evaluation bibliography. 
Health Economics 1992; 1: 1-236. 
31. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and 
significance: issues in the design and analysis of stochastic cost-effectiveness 
studies in health care. Medical Care 1994; 32: 150-63. 
32. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on 
medical decision analysis: Part I- getting staited. Medical Decision Making 
1997; 17: 123-25. 
33. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on 
medical decision analysis: Part 2- building a tree. Medical Decision Making 
1997; 17: 126-35. 
34. Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on 
medical decision analysis: Part 3- estimating probabilities and utilities. 
Medical Decision Making 1997; 17: 136-41. 
35. Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS. Primer on 
medical decision analysis: Part 4- analyzing the model and interpreting the 
results. Medical Decision Making 1997; 17: 142-5 1. 
36. Drummond MF. Economic analysis alongside controlled trials. London: 
Department of Health; 1994. 
186 
37. Drummond MF, Stoddart GL. Economic analysis and clinical trials. 
Controlled Clinical Trials 1984; 5: 115-28. 
38. Drummond MF. Experimental versus observational data in the economic 
evaluation of pharmaceuticals. Medical Decision Making 1998; 18: SI2-SI8. 
39. Buxton M, Drummond MF, VanHout BA, Prince RL, Sheldon TA, Szucs T et 
aL Modelling in economic evaluation: an unavoidable fact of life. Health 
Economics 1997; 6: 217-27. 
40. Holly N. A call for randomized controlled cost-effectiveness analysis of 
percutaneous translunfinal coronary angioplasty. International Journal of 
Technology Assessment in Health Care 1988; 4: 497-5 10. 
41. Schoenbaum SC. Cost/effectiveness considerations in clinical trials. Triangle 
1980; 19: 103-06. 
42. Copley-Merriman C, Egbuonu-Davis L, Kotsanos JG, Conforti P, Franson T, 
Gordon G. Clinical economics: a method for prospective health resource data 
collection. PharmacoEconornics 1992; 1: 370-76. 
43. Mauskopf J, Schulman KA, Bell L, Glick H. A strategy for collecting 
pharmacoeconomic data during phase II/IlI clinical trials. 
PharmacoEconomics 1996; 9: 264-77. 
187 
44. Backhouse, M. E., Gnanasakthy, A., Schuhnan, K- A., Akehurst, R. A., and 
Glick, H. The development of standard economic datasets for use in the 
economic evaluation of medicines. Drug Infon-nation Journal 34,1273-1291. 
2000. 
45. Briggs A. A Bayesian approach to stochastic cost-effectiveness analysis. 
Health Economics 1999; 8: 257-61. 
46. Briggs A, Mooney CZ, Wonderling D. Constructing confidence intervals for 
cost-effectiveness ratios: an evaluation of parametric and non-parametric 
techniques using Monte Carlo simulation. Statistics in Medicine 
1999; 18: 3245-62. 
47. Briggs A, Gray A. Handling uncertainty in economic evaluations of healthcare 
interventions. British Medical Journal 1999; 319: 635-3 8. 
48. Gardiner J, Holmes-Rovner M, Goddeeris J, Rovner D, Kupersmith J. 
Covariate-adjusted cost-effectiveness ratios. Journal of Statistical Planning 
and Inference 1999; 75: 291-304. 
49. Laska EM, Meisner M, Siegel CS. Power and sample size in cost-effectiveness 
analysis. Medical Decision Making 1999; 19: 339-43. 
50. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost- 
effectiveness ratios from clinical trials. Health Economics 1999; 8: 191-201. 
51. Obenchain, R. L. Resampling and multiplicity in cost-effectiveness inference. 
188 
Joumal of Biophannaceutical Statistics 9,563-582.1999. 
52. Rittenhouse BE, Dulisse B, Stinnett AA. At what price significance? The 
effect of price estimates on statistical inference in economic evaluation. Health 
Economics 1999; 8: 213-19. 
53. Torgerson D, Campbell MK- Cost effectiveness calculations and sample size. 
British Medical Journal 2000; 321: 697. 
54. Gardiner JC, Huebner M, Jetton J, Bradley CJ. Power and sample size 
assessments for tests of hypotheses on cost-effectiveness ratios. Health 
Economics 2000; 9: 227-34. 
55. Raikou M, Briggs A, Gray A, McGuire A. Centre-specific or average unit 
costs in multi-centre studies? Some theory and simulation. Health Economics 
2000; 9: 191-98. 
56. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness 
acceptability curve and cost-effectiveness ratio. PharmacoEconomics 
2000; 17: 339-49. 
57. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost- 
effectiveness acceptability curves. Health Econornics 2000; 9: 623-30. 
58. Al, M. J. and VanHout, B. A. A Bayesian approach to econornic analyses of 
clinical trials: the case of stenting versus balloon angioplasty. Health 
Economics 9,599-609.2000. 
189 
59. Cook, I R. and Heyse, J. F. Use of an angular transformation for ratio 
estimation in cost-effectiveness analysis. Statistics in Medicine 19,2989-3003. 
2000. 
60. Heitjan, D. F. Fieller's method and net health benefits. Health Economics 9, 
327-335.2000. 
61. Briggs A, O'Brien BJ. The death of cost-minimisation analysis? Health 
Economics 2000; 4. 
62. McIntosh MW, Ramsey SD, Berry K, Urban N. Parameter solicitation for 
planning cost effectiveness studies with dichotomous outcomes. Health 
Economics 2001; 10: 53-66. 
63. Tambour M. Zethraeus N, Johannesson M. A note on confidence intervals in 
cost-effectiveness analysis. International Journal of Technology Assessment in 
Health Care 1998; 14: 467-71. 
64. Tambour M, Zethraeus N. Bootstrap confidence intervals for cost- 
effectiveness ratios: some simulation results. Health Economics 1998; 7: 143- 
47. 
65. Al MJ, VanHout BA, Michel BC, Rutten FFH. Sample size calculation in 
economic evaluations. Health Economics 1998; 7: 327-35. 
66. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis 
of uncertainty in cost-effectiveness analysis. Medical Decision Making 
1998; 18: S68-S80. 
190 
67. Willke RJ, Glick HA, Polsky D, Schulman KA. Estimating country-specific 
cost-effectiveness from multinational clinical trials. Health Economics 
1998; 7: 481-93. 
68. Briggs A, Gray A. Power and sample size calculations for stochastic cost 
- 
effectiveness analysis. Medical Decision Making 1998; 1 8: S8 I 
-S92. 
69. Briggs A, Gray A. The distribution of health care costs and their statistical 
analysis for economic evaluation. Journal of Health Services Research and 
Policy 1998; 3: 233-45. 
70. Briggs A, Tambour M. The design and analysis of stochastic cost- 
effectiveness studies for the evaluation of health care interventions. Stockhohn 
School of Economics Working Paper Series in Economics and Finance 
1998; 234: 1-22. 
71. Heitjan DF, Moskowitz AJ, Whang W. Problems with interval estimates of the 
incremental cost-effectiveness ratio. Medical Decision Making 1999; 19: 9-15. 
72. Willan AR, O'Brien BJ. Sample size and power issues in estimating 
incremental cost-effectiveness ratios from clinical trials data. Health 
Economics 1999; 8: 203-11. 
73. Lord J, Asante MA. Estimating uncertainty ranges for costs by the bootstrap 
procedure combined with probabilistic sensitivity analysis. Health Economics 
1999; 8: 323-33. 
74. Severens JL, De Boo TM, Konst EM. Uncertainty of incremental cost- 
effectiveness ratios. International Journal of Technology Assessment in 
191 
Health Care 1999; 15: 608-14. 
75. WImg W, Sisk JE, Heitjan DF, Moskowitz AJ. Probabilistic sensitivity 
analysis. International Journal of Technology Assessment in Health Care 
1999; 15: 563-72. 
76. Etzioni R, Feuer E, Sullivan S, Lin D, Chengcheng H, Randall A. On the use 
of survival analysis techniques to estimate medical care costs. Journal of 
Health Economics 1999; 18: 365-80. 
77. Liu G, Zhao Z. Stochastic cost-effectiveness analysis. Value in Health 
1999; 2: 420-28. 
78. Bala M, Mauskopf J. The estimation and use of confidence intervals in 
economic analysis. Drug Information Journal 1999; 33: 841-48. 
79. Cook J, Drummond MF, Glick H, Heyse JF. Analyzing data from 
multinational clinical trials. HESG 1997. 
80. Laska EM, Meisner M, Siegel C. Statistical inference for cost 
- 
effectiveness 
ratios. Health Economics 1997; 6: 229-42. 
81. Lin D, Feuer E, Etzioni R, Wax Y. Estimating medical costs from incomplete 
follow-up data: when the cost histories are not recorded. Biometrics 
1997; 53: 419-34. 
82. Polsky D, Glick H, Willke P, Schulman KA. Confidence intervals for cost- 
effectiveness ratios: a comparison of four methods. Health Economics 
1997; 6: 243-52. 
192 
83. Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: 
the mean ratio versus the ratio of means. Medical Decision Making 
1997; 17: 483-89. 
84. Briggs A, Fenn P. Trying to do better than average: a commentary on 
'statistical inference for cost-effectiveness ratios'. Health Economics 
1997; 6: 491-95. 
85. Laska EM, Meisner M, Siegel C. The usefulness of average cost-effective 
ratios. Health Economics 1997; 6: 497-504. 
86. Fenn P, McGuire A, Phillips V, Backhouse ME, Jones DA. The analYSis of 
censored treatment cost data in economic evaluation. Medical Care 
1995; 33: 851-63. 
87. Gardiner J, Hogan A, H61mes-Rovner M, Rovner D, Griffith L, Kupersmith J. 
Confidence intervals for cost-effectiveness ratios. Medical Decision Making 
1995; 15: 254-63. 
88. Sacristan JA, Day SJ, Navarro 0, Ramos J, Hernandez JM. Use of confidence 
intervals and sample size calculations in health economic studies. The Annals 
of Phannacotherapy 1995; 29: 719-25. 
89. Wakker P, Klaasen MP. Confidence intervals for cost/effectiveness ratios. 
Health Economics 1995; 4: 373-81. 
90. Torgerson D, Ryan M, Ratcliffe J. Economics in sample size determination for 
clinical trials. Quarterly Journal of Medicine 1995; 88: 517-21. 
193 
91. Briggs A, Wonderling D. Pulling cost-effectiveness analysis up by its 
bootstraps: a non-parametric approach to confidence interval estimation. 
Health Economics 1997; 6: 327-40. 
92. Chaudhary MA, Steams SC. Estirnating confidence intervals for cost- 
effectiveness ratios: an example from a randomized trial. Statistics in 
Medicine 1996; 15: 1447-58. 
93. Coyle D. Statistical analysis in pharmaco economic studies: a review of current 
issues and standards. PharmacoEconomics 1996; 9: 506-16. 
94. Fenn P, McGuire A, Backhouse ME, Jones DA. Modelling programme costs 
in econornic evaluation. Journal of Health Econon-&s 1996; 15: 115-25. 
95. Lin D, Etzioni F_ Estimating medical costs from incomplete follow-up 
data: when the cost histories are recorded. Department of Biostatistics 
Technical Report, University of Washington 1996; 13 8. 
96. Sacristan JA. Use of confidence intervals in health economic studies. 
PharmacoEconomics 1996; 10: 432-33. 
97. Siegel C, Laska EM, Meisner M. Statistical methods for cost 
- 
effectiveness 
analysis. Controlled Clinical trials 1996; 17: 387-406. 
98. Willan A, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an 
application of Fieller's theorem. Health Economics 1996; 5: 297-305. 
99. Gray A, Marshall M, Lockwood A, Morris J. Problems in conducting 
economic evaluations alongside clinical trials: lessons from a study of case 
194 
managcment for people with mental disorders. British Journal of Psychiatry 
1997; 170: 47-52. 
100. Drummond MF, OBrien BJ. Clinical importance, statistical significance and 
the assessment of economic and quality-of-life outcomes. Health Economics 
1993; 2: 205-12. 
101. O'Brien BJ, Drummond ME Statistical versus quantitative significance in the 
socioeconomic evaluation of medicines. PharmacoEconornics 1994; 5: 389-98. 
102. VanHout BA, Al MJ, Gordon JS, Rutten FFH. Costs, effects and C/E 
- 
ratios 
alongside a clinical trial. Health Economics 1994; 3: 309-19. 
103. Rutten-van Molken MPMH, VanDoorslaer EKA, VanVliet RCJA. Statistical 
analysis of cost outcomes in a randomized controlled clinical trial. Health 
Economics 1994; 3: 333-45. 
104. Roland M, Torgerson D. Understanding controlled trials: what outcomes 
should be measured? British Medical Journal 1998; 317: 1975. 
105. Schulman KA, Burke J, Drummond MF, Davies L, Carlsson P, Gruger J et al. 
Resource costing for multinational neurologic clinical trials: methods and 
results. Health Economics 1998; 7: 629-38. 
106. Baker, A. M., Arnold, P. J., and Kaniecki, D. J. Economic analysis in clinical 
trials: practical considerations. Drug Information Journal 33,1053-1060.2000. 
107. Karnon J, Qizilbash N. Economic evaluation alongside n- of 
-I trials: getting 
closer to the margin. Health Economics 2001; 10: 79-82. 
195 
108. Dowie I Clinical trials and econon* evaluations? No, there are only 
evaluations. Health Economics 1997; 6: 87-89. 
109. OBrien BJ. Economic evaluation of pharmaceuticals: Frankenstein's monster 
or vampire of trials? Medical Care 1996; 34: DS99-DS 108. 
110. Freemantle N, Drununond MF. Should clinical trials with concurrent 
economic analyses be blinded. JAMA 1997; 277: 63-64. 
I 11. Rittenhouse BE. Exorcising protocol 
- 
induced spirits: making the clinical trial 
relevant for economics. Medical Decision Making 1997; 17: 331-39. 
112. Haycox A, Drummond MF, Walley T. Pharmacoeconomics: integrating 
economic evaluation into clinical trials. British Journal of Clinical 
Pharmacology 1997; 43: 559-62. 
113. Coyle D, Davies L, Drummond ME Trials and tribulations: emerging issues in 
designing economic evaluations alongside clinical trials. International Journal 
of Technology Assessment in Health Care 1998; 14: 135-44. 
114. Hillman BJ, Kahan JP, Neu CR, Hammons GT. Clinical trials to evaluate cost 
- 
cffectiveness. Investigative Radiology 1989; 24: 167-71. 
115. Drummond MF, Davies L. Economic analysis alongside clinical trials: 
revisiting the methodological issues. International Journal of Technology 
Assessment in Health Care 1991; 7: 561-73. 
116. Bonsel GJ, Rutten FFH, Uyl-de Groot CA. Economic evaluation alongside 
cancer trials: methodological and Practical aspects. European Journal of 
196 
Cancer 1993; 29A: SIO-Sl4. 
117. Bennett CL, Armitage JL, Buchner D, Gulati S. Economic analysis in phase 
III cancer trials. Cancer Investigation 1994; 12: 336-42. 
118. Coyle, D., Davies, L., and Drummond, M. F. Trials and tribulations: 
conducting economic evaluations alongside clinical trials. 1994. 
119. Hillis A. Cost containment: death knell or new opportunity for randomized 
trials? Archives of Ophthalmology 1994; 112: 174-75. 
120. Baker AM, Goldberg ARJ, Kaniecki DJ. Considerations in measuring resource 
use in clinical trials. Drug Information Journal 1995; 29: 1421-28. 
121. Berger ML. Design of prospective cost-effectiveness clinical trials: the critical 
role of the comparator group. Drug Information Journal 1995; 29: 1415-20. 
122. Drummond MF. Economic analysis alongside clinical trials: problems and 
potentiaL Joumal of Rheumatology 1995; 22: 1403-07. 
123. Drummond MF, O'Brien BJ. Economic analysis alongside clinical trials: 
practical considerations. The Journal of RheurnatologY 1995; 22: 1418-19. 
124. Glick H. Strategies for economic assessment during the development of new 
drugs. Drug Inforrmtion Journal 1995; 29: 1391-403. 
125. Powe NR, Griffiths RI. The clinical-economic trial: promise, problems and 
challenges. Controlled Clinical trials 1995; 16: 3 77-94. 
126. Rittenhouse BE. The relevance of searching for effects under a clinical trial 
197 
lamppost: a key issue. Medical Decision Making 1995; 15: 348-57. 
127. Schulman KA, Yabroff KR, Glick H. A health services approach for the 
evaluation of innovative pharmaceutical and biothechnology products. Drug 
Information Journal 1995; 29: 1405-14. 
128. Donaldson C, Hundley V, McIntosh E. Using economics alongside clinical 
trials: why we cannot choose the evaluation technique in advance. Health 
Economics 1996; 5: 267-69. 
129. Ellwein LB, Drummond MF. Economic analysis alongside clinical trials: bias 
in the assessment of economic outcomes. International Journal of Technology 
Assessment in Health Care 1996; 12: 691-97. 
130. Guess HA, Rudnick SA. Use of cost-effectiveness analysis in planning cancer 
chemoprophylaxis trials. Controlled Clinical trials 1983; 4: 89-100. 
131. Levy RI, Sondik EJ. Large scale clinical trials: are they worth the cost? Annals 
of the New York Academy of Sciences 1982; 411-22. 
132. Levy RI. Clinical trials: are the benefits worth the costs? Clinical Research 
1982; 116-22. 
133. Levy RI, Sondik EJ. Decision-making in planning large-scale comparative 
studies. Annals of the New York Academy of Sciences 1978; 304: 441-57. 
134. Schechtman KB, Gordon ME. A comprehensive algorithm for determining 
whether a run-in strategy will be a cost-effective design modification in a 
randomized clinical trial. Statistics in Medicine 1993; 12: 111-28. 
198 
135. McKinlay SM. Cost-efficient designs of cluster unit trials. Prev Med 
1994; 23: 606-11. 
136. Allison DB. When is it worth measuring a covariate in a randomized clinical 
trial? Journal of Consulting and Clinical Psychology 1995; 63: 339-43. 
137. Silverblatt FJ. Clinical trials and statistical rigovare the benefits necessarily 
worth the cost? feditorial]. Journal of Infectious Diseases 1987; 155: 168-69. 
138. Eliasziw M, Donner A. A cost 
- 
function approach to the design of reliability 
studies. Statistics in Medicine 1987; 6: 647-55. 
139. Bloch DA. Sample size requirements and the cost of a randomized clinical 
trial with repeated measurements. Stat Med 1986; 5: 663-67. 
140. Thomquist MD, Urban N, Tseng A, Edelstein C, Lund B, Omenn GS. 
Research cost analyses to aid in decision making in the conduct of a large 
prevention trial, CARET. Carotene and Retinol Efficacy Trial. Control Clin 
Trials 1993; 14: 325-39. 
141. Ciampi A, Till JE. Null results in clinical trials: the need for a decision-theory 
approach. Br J Cancer 1980; 41: 618-29. 
142. Baker SG, Heidenberger K Choosing sample sizes to maximize expected 
health benefits subject to a constraint on total trial costs. Medical Decision 
making 1989; 9: 14-25. 
143. Mosteller F, Weinstein MC. Toward evaluating the cost-effectiveness of 
medical and social experiments, In: Hausman JA, Wise SA, editors. Social 
199 
experimentation. Chicago: University of Chicago Press; 1985. p. 221-49. 
144. Weinstein MC. Cost-effective priorities for cancer prevention. Science 
1983; 221: 17-23. 
145. Mendoza G, Iglewicz B. An extension of Colton's model for comparing two 
medical treatments. Journal of the American Statistical Association 
1978; 73: 646-49. 
146. Bcgg CB, Mehta CR. Sequential analysis of comparative clinical trials. 
Biometrika 1979; 66: 97-103. 
147. Mehta CFL Sequential comparison of two exponential distributions with 
censored survival data. Biometrika 1981; 68: 669-75. 
148. Hamburg M. Statistical analysis for decision making. New York: Harcourt 
- 
Brace; 1977. 
149. Thompson MS. Decision-analytic determination of study size: the case of 
electronic fetal monitoring. Medical Decision Making 198 1; 1: 165-79. 
150. Thompson MS, Cohen AB. Decision analysis of electronic fetal monitoring, 
in: Wortman P, editor. Methods for evaluating health services. Beverly Hills: 
Sage; 1981. p. 109-40. 
151. Thompson MS. Evaluation for decision in social programmes. Westmead: 
Saxon House; 1975. 
152. Detsky AS. Using economic analysis to determine the resource consequences 
200 
of choices made in planning clinical trials. Journal of Chronic Diseases 
1985; 38: 753-65. 
153. Detsky AS. Are clinical trials a cost-effective investment? JAMA 
1989; 262: 1795-800. 
154. Detsky AS. Using cost-effectiveness analysis to improve the efficiency of 
allocating funds to clinical trials. Statistics in Medicine 1990; 9: 173-84. 
155. Claxton K, Posnett J. An economic approach to clinical trial design and 
research priority setting. Health Economics 1996; 5: 513-24. 
156. Claxton Y- Bayesian approaches to the value of information: implications for 
the regulation of new pharmaceuticals. Health Economics 1999; 8: 269-74. 
157. Claxton K. The irrelevance of inference: a decision making approach to the 
stochastic evaluation of health care technologies. Journal of Health Economics 
1999; 18: 341-64. 
158. Claxton, K., Neumann, P. J., ArakL S., and Weinstein, M. C. Bayesian value- 
of-information analysis. An application to a policy model of Alzheimer's 
disease. International Journal of Technology Assessment in Health Care 17(l), 
38-55.2001. 
159. Claxton I-C, Thompson KM. A dynamic programming approach to the efficient 
design of clinical trials. Journal of Health Economics 2001; 20: 797-822. 
160. Claxton, K, Ginnelly, L., Sculpher, M., Phillips, Z., and Palmer, S. A pilot 
study on the use of decision theory and value of information analysis as part of 
201 
the NHS Health Technology Assessment programme. Health Technology 
Assessment 8(31), 1-103.2004. 
161. Ades, A. E., Lu, G., and Claxton, K Expected value of sample information 
calculations in medical decision modelling. Medical Decision Making 24(2), 
207-227.2004. 
162. Claxton, V-, Eggington, S., Ginnelly, L., Griffin, S., McCabe, C., Philips, Z., 
Tappenden, P., and Wailoo, A. A pilot study of value of information analysis 
to support research recommendations. CHE Research Paper 4.2005. The 
University of York, Centre for Health Economics. 
163. Bergman S, Gittins J. Statistical method for pharmaceutical research planning. 
New York: Dekker; 1985. p. 167-246. 
164. Serm S. Some statistical issues in project prioritization in the pharmaceutical 
industry. Statistics in Medicine 1996; 15: 2669-702. 
165. Senn S. Further statistical issues in project prioritisation in the pharmaceutical 
industry. Drug Information Journal 1998; 32: 253-59. 
166. Hawkins CJ, Pearce DW. Capital investment appraisal. London: Macmillan; 
1979. 
167. Brealey RA, Myers SC. Principles of corporate finance, Fifth ed. New York: 
McGraw-Hill; 1996. 
168. Bierman H, Smidt S. The capital budgeting decision: economic analysis of 
investment projects, Eighth ed. New York: Macmillan; 1993. 
202 
169. Machin DM, Campbell MJ. Statistical tables for the design of clinical trials. 
Oxford: Blackwell Scientific Publications; 1987. 
170. Armitage P, Berry G. Statistical methods in medical research, Third ed. 
Oxford: Blackwell Science; 1995. 
171. Myers SC, Shyam-Sunder L. Measuring pharmaceutical industry risk and the 
cost of capital, In: Helms RB, editor. Competitive strategies in the 
pharmaceutical industry. Washington DC: American Enterprise Institute; 
1996. p. 208-37. 
172. DataEdge LLC. PICAS database. DataEdge Information (UK), 1998. 
173. Koutsoyiannis A. Modem micro economics, I st ed. London: Macmillan; 1978. 
174. Dent THS, Hawke S. Too soon to market. British Medical Journal 
1997; 315: 1248-49. 
175. Greenhalgh T. More convincing evidence of efficacy needs to be cited. British 
Medical Joumal 1997; 315: 1623. 
176. Stein K, Milne R, Best L. BMJ should require advertisements to detail actual 
state of evidence. British Medical Journal 1997; 315: 1623-24. 
177. Hooper P, Whitehead AM. Drug company's reply. British Medical Journal 
1997; 315: 1624. 
178. Wilkinson D, et A Review of drug in Drug and Therapeutics Bulletin is 
uninformed. British Medical Journal 1997; 315: 1625. 
203 
179. Ryan M. Using consumer preferences in health care decision making: the 
application of conjoint analysis. London: Office of Health Economics; 1996. 
180. Cattin P, Wittink DF. Commercial use of conjoint analysis: a survey. Journal 
of Marketing 1982; 46: 44-53. 
181. Mahajan, V, Muller E, Bass FM. New product diffusion models in marketing: 
a review and directions for research. Journal of Marketing 1990; 54: 1-26. 
182. Mahajan V, Peterson RA. Models for innovation diffusion, vol. 48. Sage; 
1985. 
183. Sultan F, Farley JU, Lehmann DR. A meta-analysis of applications of 
diffusion models. Journal of Marketing Research 1990; 27: 70-77. 
184. Battista RN. Innovation and diffusion of health-related technologies. 
International Journal of Technology Assessment in Health Care 1989; 5: 227- 
48. 
185. Greer AL. The state of the art versus the state of the science: the diffusion of 
new medical technologies into practice. International Journal of Technology 
Assessment in Health Care 1988; 4: 5-26. 
186. Sloan FA, Valvona J, Perrin JM, Adamache KW. Diffusion of surgical 
technology* an exploratory study. Journal of Health Economics 1986; 5: 31-61. 
187. Lilien GL, Rao AG, Kalish S. Bayesian estimation and control of detailing 
effort in a repeat purchase diffusion environment. Management Science 
1981; 27: 493-506. 
204 
188. Becker DM. Decision to adopt new medical technology: a case study of 
thrombolytic therapy. Social Science and Medicine 1985; 21: 291-98. 
189. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to 
randomised trials. Journal of the Royal Statistical Society 1994; 157: 357-416. 
190. ICH. Statistical principles for clinical trials. Harmonised, Tripartite Guideline 
1997; E9. 
191. National Institute for Clinical Excellence. Technical guidance for 
manufacturers and sponsors on making a submission to a technology 
appraisal. March 2001. National Institute for Clinical Excellence. 
192. O'Sullivan, A. K, Thompson, D., and Drummond, M. F. Collection of health- 
economic data alongside clinical trials: is there a future for piggyback 
evaluations? Value in Health 8(l), 67-79.2005. 
193. Cook, J., Drummond, M. F., and Heyse, J. F. Economic endpoints in clinical 
trials. Statistical Methods in Medical Research 13(2), 157-176.2004. 
194. Ramsey, S., Willke, R., Briggs, A., Brown, R., Buxton, M., Chawla, A., Cook, 
J., Glick, H., LiIjas, B., Petittiý D., and Reed, S. Good research practices for 
cost-effectiveness analysis alongside clinical trials: the ISPOR task force 
report. Value in Health 8(5), 521-533.2005. 
195. Machin DM, Campbell MJ, Fayers PM, Pinol APY. Sample size tables for 
clinical studies, Second ed. Oxford: Blackwell Science Ltd; 1997. 
196. Rosner B. Fundamentals of biostatistics, 5th ed. Pacific Grove, CA: Duxbury 
205 
Press; 2000. 
197. Briggs, A. and Tambour, M. The design and analysis of stochastic cost- 
effectiveness studies for the evaluation of health care interventions. Drug 
Infonmtion Joumal 35,1455-1468.2001. 
198. Briggs, A., O'Brien, B. J., and Blackhouse, G. Thinking outside the box: 
recent advances in the analysis and presentation of uncertainty in cost- 
effectiveness studies. Annual Review of Public Health 23,377-401.2002. 
199. Zethraeus, N., Johannesson, M., Jonsson, B., and Lothgren, M. Advantages of 
using the net-benefit approach for analysing uncertainty in economic 
evaluation studies. PharmacoEconomics 21(l), 39-48.2003. 
200. NHS Management Executive. The New NHS Reference Costs. Leeds: 
Department of Health; 1999. 
201. Smith DH, Gravelle H. The practice of discounting in economic evaluations of 
healthcare interventions. International Journal of Technology Assessment in 
Health Care 2001; 17: 236-43. 
202. Backhouse ME, Mauskopf J. Formal requirements for economic analysis of 
medicines: the potential implications of the UK NICE requirements for global 
product development, vol. April 3, Spectrum ed. Boston, MA: Decision 
Resources; 2000. p. 6.1-6.14. 
203. Backhouse ME. An investment appraisal approach to clinical trial design. 
Health Econon-dcs 1998; 7: 605-19. 
206 
204. Ben-Akiva M, Lerman SFL Discrete choice analysis. London: The MIT Press; 
1986. 
205. Hair JF, Anderson RE, Tatham RL, Black WC. Conjoint analysis, Multivariate 
data analysis, Fifth ed. New Jersey: Prentice Hall; 1998. p. 387-441. 
206. Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and 
application. Cambridge: Cambridge University Press; 2000. 
207. Wittink DR, Cattin P. Commercial use of conjoint analysis: an update. Journal 
of Marketing 1989; 53: 91-96. 
208. Wittink DR, Vriens M, Burhenne W. Commercial use of conjoint analysis in 
Europe: results and critical reflections. International Journal of Research in 
Marketing 1994; 11: 41-52. 
209. Bingham MF, Johnson FR, Miller D. Modeling choice behaviour for new 
pharmaceutical products. Value in Health 2001; 4: 32-44. 
210. Bryan S, Buxton M, Sheldon R, Grant A. Magnetic resonance imaging for the 
investigation of knee injuries: an investigation of preferences. Health 
Economics 1998; 7: 595-603. 
211. Bryan, S., Gold, L, Sheldon, R., and Buxton, M. Preference measurement 
using conjoint methods: an empirical investigation of reliability. Health 
Economics 9,3 85-3 95.2000. 
212. Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients' 
preferences for the management of non-metastatic prostate cancer: discrete 
207 
choice experiment. British Medical Journal 2004; 328: 382. 
213. Bryan S, Parry D. Structural reliability of conjoint measurement in healthcare: 
an empirical investigation. Applied Economics 2001; 1: 561-67. 
214. Bunch WH, Chapman RG. Patient preferences in surgery for scoliosis. J Bone 
Joint Surg [Arn] 1985; 67: 794-99. 
215. Carroll NV, Gagnon JP. Consumer demand for patient-oriented pharmacy 
services. Am J Public Health 1984; 74: 609-11. 
216. Chakraborty G, Gaeth G, Cunningham M. Understanding consumers 
preferences for dental service. Journal of Health Care Marketing 1993; 21: 48- 
58. 
217. Chakraborty G, Ettcnson R, Gaeth G. How consumers choose health 
insurance. Journal of Health Care Marketing 1994; 14: 21-33. 
218. Farrar S, Ryan M, Ross D, Ludbrook A. Using discrete choice modelling in 
priority setting: an application to clinical service developments. Social Science 
and Medicme 2000; 50: 63-75. 
219. Garb HN. A conjoint measurement analysis of clinical predictions. J Clin 
Psychol 1983; 39: 295-301. 
220. Graf MA, Tanner DD, Swinyard WR. Optimizing the delivery of patient and 
physician satisfaction: a conjoint analysis approach. Health Care Manage Rev 
1993; 18: 34-43. 
221. Hakim Z, Pathak D. Modelling the EuroQoI data: a comparison of 
208 
discrete choice conjoint and conditional preference modelling. Health 
Economics 1999; 8: 103-16. 
222. Harrison DD, Cooke CW. An elucidation of factors influencing physicians, 
willingness to perform elective female sterilization. Obstet Gynecol 
1988; 72: 565-70. 
223. Harwood RH, Rogers A, Dickinson E, Ebrahim S. Measuring handicap: the 
London handicap scale, a new outcome measure for chronic disease. Quality 
in Health Care 1994; 3: 11-16. 
224. Hershey JC, Kunreuther H, Schwartz JS, Williams SV. Health insurance under 
competition: would people choose what is expected? Inquiry 1984; 21: 349-60. 
225. Holtgave DF, Weber EU. Dimensions of risk perception for financial and 
health risks. Risk Anal 1993; 13: 553-58. 
226. Lee A, Lum ME, Beehan SJ, Hillman KM. Interhospital transfers: decision- 
making in critical care areas. Crit Care Med 1996; 24: 618-22. 
227. Maas A, Stalpers L. Assessing utilities by means of conjoint measurement: an 
application in medical decision analysis. Medical Decision Making 
1992; 12: 288-97. 
228. Verhoef CG, Maas A, Stalpers LJA, Verbeek ALM, Wobbes T, van Daal 
WAJ. The feasibility of additive conjoint measurement in measuring utilities 
in breast cancer patients. Health Policy 1991; 17: 39-50. 
229. Magat WA, Viscusi WK, Huber J. Paired comparison and contingent 
valuation approaches to morbidity risk valuation. Journal of Environmental 
Economics and Management 1988; 15: 395-411. 
230. Malhotra NK, Jain AK- A conjoint analysis approach to health care marketing 
and planning. Journal of Health Care Marketing 1982; 2: 35-44. 
231. McClain JO, Rao VR. Trade-offs and conflicts in evaluation of health system 
alternatives: methodology for analysis. Health Services Research 1974; 9: 35- 
52. 
232. Nickerson CA, McClelland GH, Petersen DM. Measuring contraceptive 
values: an altemative approack J Behav Med 1991; 14: 241-66. 
233. Parker BR, Srinivasan V. A consumer preference approach to the planning of 
rural primary health-care facilities. Operations Research 1976; 24: 991-1025. 
234. Propper C. Contingent valuation of time spent on NHS waiting lists. The 
Economic Journal 1991; 100: 193-99. 
235. Propper C. The disutility of time spent on the United Kingdonfs National 
Health Service waiting lists. The Journal of Human Resources 1995; 30: 677- 
700. 
236. Ratcliffe J, Buxton M. Patient's preferences regarding the process and 
outcomes of life-saving technology: an application of conjoint analysis to liver 
transplantation. International Journal of Technology Assessment in Health 
Care 1999; 15: 340-51. 
237. Ratcliffe J. The use of conjoint analysis to elicit willingness-to-pay values. 
210 
Proceed with caution? International Journal of Technology Assessment in 
Health Care 2000; 16: 270-90. 
238. Ratcliffe J. Public preferences for the allocation of donor liver grafts for 
transplantation. Health Economics 2000; 9: 137-48. 
239. Ratcliffe J, Van Haselen R, Buxton M, Hardy K, Colehan J, Partridge M. 
Assessing patients' preferences for characteristics associated with homeopathic 
and conventional treatment of asthma: a conjoint analysis study. Thorax 
2001; Submitted. 
240. Reardon G, Pathak DS. Segmenting the antihistamine market: an investigation 
of consumer preferences. Journal of Health Care Marketing 1990; 10: 23-33. 
241. Reed Johnson F, Desvousges WIH, Ruby MC, Stieb D, De Civita P. Eliciting 
stated health preferences: an application to willingness to pay for longevity. 
Medical Decision Making 1998; 1 8: SS7-S67. 
242. Johnson FF, Banzhaf MR, Desvousges WH. Willingness to pay for improved 
respiratory and cardiovascular health: a multiple- fonnat, stated-preference 
approach. Health Economics 2000; 9: 295-317. 
243. Rosko MD, Walker LIZ, McKenna W, DeVita M. Measuring consumer 
preferences for ambulatory medical care arrangements. J Med Syst 
1983; 7: 545-54. 
244. Rosko MD, DeVita M, McKenna WF, Walker LR. Strategic marketing 
applications of conjoint analysis: an HMO perspective. Journal of Health Care 
211 
Marketing 1985; 5: 27-38. 
245. Ryan M, Hughes J. Using conjoint analysis to assess women's preferences for 
miscarriage management. Health Economics 1997; 6: 261-73. 
246. Ryan M, McIntosh E, Shackley P. Using conjoint analysis to assess consumer 
preferences in primary care: an application to the primary health card. Health 
Expectations 1998; 1: 117-29. 
247. Ryan M, McIntosh E, Shackley P. Methodological issues in the application of 
conjoint analysis in health care. Health Economics 1998; 7: 373-78. 
248. Ryan M, et al. Framing effects: a methodological issue in conjoint analysis. 
Health Economics 1999. 
249. Ryan M. Using conjoint analysis to go beyond health outcomes: an application 
to in vitro fertilisation. Social Science and Medicine 1999; 8: 535-46. 
250. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. 
British Medical Joumal 2000; 320: 1530-33. 
251. Ryan M, McIntosh E, Dean T, Old P. Trade-offs between location and waiting 
tilnes in the provision of health care: the case of elective surgery on the Isle of 
Wight. Journal of Public Health Medicine 2000; 22: 202-10. 
252. San Miguel F, Ryan M, McIntosh E. Demonstrating the use of conjoint 
analysis in health economics: an application to menoffhagia. Applied 
Economics 2000; 32: 823-33. 
253. Vick S, Scott A. Agency in health care. Examining patients' 
212 
preferences for attributes of the doctor-patient relationship. Journal of Health 
Economics 1998. 
254. Scott A. Eliciting GPs' preferences for pecuniary and non-pecuniary job 
characteristics. Journal of Health Economics 2001; 20: 329-47. 
255. Singh J, Cuttler L, Shin M, Silvers JB, Neuhauser D. Medical decision-making 
and the patient: understanding preference patterns for growth hormone therapy 
using conjoint analysis. Medical Care 1998; 36: AS3 I 
-AS45. 
256. Spoth R. Simulating smokers' acceptance of modifications in a cessation 
program Public Health Rep 1992; 107: 81-92. 
257. Spoth R, Redmond C. ldentifýing program preferences through conjoint 
analysis: illustrative results from a parent sample. American Journal of Health 
Promotion 1993; 8: 124-33. 
258. Szeinback SL, Mason HL. Variables affecting pharmacists' willingness to 
accept third-party prescription contracts: a conjoint analysis. Journal of Health 
Care Marketing 1990; 10: 45-50. 
259. van der Pol M, Cairns J. Establishing patient preferences for blood transfusion 
support: an application of conjoint analysis. Journal of Health Services 
Research and Policy 1998; 3: 70-76. 
260. Wigton RS, Hoellerich VL, Patil. KD. How physicians use clinical information 
in diagnosing pulmonary embolism: an application of conjoint analysis. Med 
Decis Making 1986; 6: 2-11. 
213 
261. Bradley M. Stated preference experiment editor and designer (SPEED) user 
manual. Hague Consulting Group; 1991. 
262. Stata Corporation. Stata reference manual release 7., vol. Volume 2 H-P. 
College Station, Texas: Stata Press; 2001. p. 580-94. 
263. Ryan A Establishing arguments in the infertile person! s utility function using 
the economic instrument of conjoint analysis. HERU Discussion Paper 
1995; 8. 
264. Ryan M. A role for conjoint analysis in technology assessment in health care? 
International Journal of Technology Assessment in Health Care 1999; 15: 443- 
57. 
265. Jones A. Applied econometrics. London: Office of Health Economics; 2001. 
266. National Institute for Clinical Excellence. Guidance on cancer services: 
improving outcomes in breast cancer. London: National Institute for Clinical 
Excellence; 2002. 
267. Monthly Index of Medical Specialities, vol. January. London: Haymarket 
Medical Limited; 2002. 
268. Diel IJ, Sol0mayer E, Costa SD, Gollan C, Goemer R, et al. Reduction in new 
metastases in breast cancer with adjuvant clodronate treatment. New England 
Journal of Medicine 1998; 339: 357-63. 
269. powles T, Paterson S, 
Kanis JA, McCloskey E, Ashley S, et al. Randomized, 
placebo-COntrOlled trial of clodronate in patients with primary operable 
breast 
214 
cancer. Journal of Clinical Oncolgy 2002; 20: 3219-24. 
270. NSABP protocol B-34. http: //www. nsabp. pitt. edu/B34 Information. htrrL Last 
accessed 9-10-2002. 
271. The Medical Directory. FT Business Ltd; 1999. 
272. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its 
value judgements. British Medical Journal 2004; 329: 224-27. 
273. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what 
other factors influence its decisions? A binary choice analysis. Health 
Economics 2004; 13: 437-52. 
274. Ryan, A and Gerard, K. Using discrete choice experiments to value health 
care programmes: current practice and future research reflections. Applied 
Health Economics and Health Policy 2(l), 1-10.2003. 
275. Ryan, M. and Skatun, D. Modelling non-demanders in choice experiments. 
Health Economics 13,397-402.2004. 
276. Kontoleon, A. and Yabe, M. Assessing the impacts of 'opt-out' fon-nats in 
choice experiment studies: consumer preferences for genetically modified 
content and production information in food. Journal of Agricultural Policy 
Research (5), 1-43.2003. 
277. Raiffa H, Schlaifer R. Probability and statistics for business decisions. New 
York: McGraw-Hill; 1959. 
278. Raiffa H. Decision analysis: introductory lectures on choices under 
ýN 
RITV k- ým 
uncertainty. Reading: Addison-Wesley, 1968. 
279. Dixit AK, Pindyck RS. Investment under uncertainty. Princeton: Princeton 
University Press; 1994. 
280. Dixit Mr, Pindyck RS. The options approach to capital investment. Harvard 
Business Review 1995; 73: 105-15. 
281. Mahajan V, Muller E, Bass FM. New product diffusion models, In: Eliashberg 
J, Lilien GL, editors. Handbooks in OR & MS, vol. 5. Elsevier Science 
Publishers; 1998. p. 349-408. 
216 
